Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease):an attempted network meta-analysis by Buzzetti, Elena et al.
Syddansk Universitet
Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease)
Buzzetti, Elena; Kalafateli, Maria; Thorburn, Douglas; Davidson, Brian R; Thiele, Maja ;
Gluud, Lise Lotte; Del Giovane, Cinzia; Askgaard, Gro; Krag, Aleksander; Tsochatzis,
Emmanuel; Gurusamy, Kurinchi Selvan
Published in:
Cochrane Database of Systematic Reviews
DOI:
10.1002/14651858.CD011646.pub2
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-SA
Citation for pulished version (APA):
Buzzetti, E., Kalafateli, M., Thorburn, D., Davidson, B. R., Thiele, M., Gluud, L. L., ... Gurusamy, K. S. (2017).
Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network
meta-analysis. Cochrane Database of Systematic Reviews, 2017(3), [CD011646]. DOI:
10.1002/14651858.CD011646.pub2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. aug.. 2017
Cochrane Database of Systematic Reviews
Pharmacological interventions for alcoholic liver disease
(alcohol-related liver disease) (Review)
Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Gluud LL, Del Giovane C, Askgaard G,
Krag A, Tsochatzis E, Gurusamy KS
Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Gluud LL, Del Giovane C, Askgaard G, Krag A, Tsochatzis E, Gurusamy KS.
Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease).
Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD011646.
DOI: 10.1002/14651858.CD011646.pub2.
www.cochranelibrary.com
Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
31ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
52DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
64CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
164DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
178WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
179CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
179DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
179SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
180DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
180NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iPharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Pharmacological interventions for alcoholic liver disease
(alcohol-related liver disease)
Elena Buzzetti1, Maria Kalafateli1, Douglas Thorburn1 , Brian R Davidson2 , Maja Thiele3, Lise Lotte Gluud4, Cinzia Del Giovane5,
Gro Askgaard6, Aleksander Krag7, Emmanuel Tsochatzis1 , Kurinchi Selvan Gurusamy2
1Sheila Sherlock Liver Centre, Royal Free Hospital and the UCL Institute of Liver and Digestive Health, London, UK. 2Department
of Surgery, Royal Free Campus, UCL Medical School, London, UK. 3Department of Gastroenterology and Hepatology, Odense Uni-
versity Hospital, Odense, Denmark. 4Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
5Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Mod-
ena, Italy. 6Department of Hepatology, Rigshospitalet, København Ø, Denmark. 7Department of Gastroenterology and Hepatology,
Odense University Hospital, Odense C, Denmark
Contact address: Kurinchi Selvan Gurusamy, Department of Surgery, Royal Free Campus, UCLMedical School, Pond Street, London,
NW3 2QG, UK. k.gurusamy@ucl.ac.uk.
Editorial group: Cochrane Hepato-Biliary Group.
Publication status and date: Edited (no change to conclusions), published in Issue 4, 2017.
Citation: Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Gluud LL, Del Giovane C, Askgaard G, Krag A, Tsochatzis
E, GurusamyKS. Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease).Cochrane Database of Systematic
Reviews 2017, Issue 3. Art. No.: CD011646. DOI: 10.1002/14651858.CD011646.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Alcohol-related liver disease is due to excessive alcohol consumption. It includes a spectrum of liver diseases such as alcohol-related fatty
liver, alcoholic hepatitis, and alcoholic cirrhosis. Mortality associated with alcoholic hepatitis is high. The optimal pharmacological
treatment of alcoholic hepatitis and other alcohol-related liver disease remains controversial.
Objectives
To assess the comparative benefits and harms of different pharmacological interventions in the management of alcohol-related liver
disease through a network meta-analysis and to generate rankings of the available pharmacological interventions according to their
safety and efficacy in order to identify potential treatments. However, even in the subgroup of participants when the potential effect
modifiers appeared reasonably similar across comparisons, there was evidence of inconsistency by one or more methods of assessment
of inconsistency. Therefore, we did not report the results of the network meta-analysis and reported the comparative benefits and harms
of different interventions using standard Cochrane methodology.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded,
World Health Organization International Clinical Trials Registry Platform and randomised controlled trials registers until February
2017 to identify randomised clinical trials on pharmacological treatments for alcohol-related liver diseases.
Selection criteria
Randomised clinical trials (irrespective of language, blinding, or publication status) including participants with alcohol-related liver
disease. We excluded trials that included participants who had previously undergone liver transplantation and those with co-existing
chronic viral diseases. We considered any of the various pharmacological interventions compared with each other or with placebo or
no intervention.
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Data collection and analysis
Two review authors independently identified trials and independently extracted data. We calculated the odds ratio (OR) and rate ratio
with 95% confidence intervals (CIs) using both fixed-effect and random-effects models based on available-participant analysis with
Review Manager. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and
assessed the quality of the evidence using GRADE.
Main results
We identified a total of 81 randomised clinical trials. All the trials were at high risk of bias, and the overall quality of the evidence was
low or very low for all outcomes.
Alcoholic hepatitis
Fifty randomised clinical trials included 4484 participants with alcoholic hepatitis. The period of follow-up ranged from one to
12 months. Because of concerns about transitivity assumption, we did not perform the network meta-analysis. None of the active
interventions showed any improvement in any of the clinical outcomes reported in the trials, which includes mortality (at various time
points), cirrhosis, decompensated cirrhosis, liver transplantation. None of the trials reported health-related quality of life or incidence
of hepatocellular carcinoma.
Severe alcoholic hepatitis
Of the trials on alcoholic hepatitis, 19 trials (2545 participants) included exclusively participants with severe alcoholic hepatitis (Maddrey
Discriminat Function > 32). The period of follow-up ranged from one to 12 months. There was no alteration in the conclusions when
only people with severe alcoholic hepatitis were included in the analysis.
Source of funding: Eleven trials were funded by parties with vested interest in the results. Sixteen trials were funded by parties without
vested interest in the results. The source of funding was not reported in 23 trials.
Other alcohol-related liver diseases
Thirty-one randomised clinical trials included 3695 participants with other alcohol-related liver diseases (with a wide spectrum of
alcohol-related liver diseases). The period of follow-up ranged from one to 48 months. The mortality at maximal follow-up was lower
in the propylthiouracil group versus the no intervention group (OR 0.45, 95% CI 0.26 to 0.78; 423 participants; 2 trials; low-quality
evidence). However, this result is based on two small trials at high risk of bias and further confirmation in larger trials of low risk of bias is
necessary to recommend propylthiouracil routinely in people with other alcohol-related liver diseases. The mortality at maximal follow-
up was higher in the ursodeoxycholic acid group versus the no intervention group (OR 2.09, 95% CI 1.12 to 3.90; 226 participants;
1 trial; low-quality evidence).
Source of funding: Twelve trials were funded by parties with vested interest in the results. Three trials were funded by parties without
vested interest in the results. The source of funding was not reported in 16 trials.
Authors’ conclusions
Because of very low-quality evidence, there is uncertainty in the effectiveness of any pharmacological intervention versus no intervention
in people with alcoholic hepatitis or severe alcoholic hepatitis. Based on low-quality evidence, propylthiouracil may decrease mortality
in people with other alcohol-related liver diseases. However, these results must be confirmed by adequately powered trials with low risk
of bias before propylthiouracil can be considered effective.
Future randomised clinical trials should be conducted with approximately 200 participants in each group and follow-up of one to two
years in order to compare the benefits and harms of different treatments in people with alcoholic hepatitis. Randomised clinical trials
should include health-related quality of life and report serious adverse events separately from adverse events. Future randomised clinical
trials should have a low risk of bias and low risk of random errors.
P L A I N L A N G U A G E S U M M A R Y
Medical treatment of alcohol-related liver disease
Background
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Alcohol-related liver disease or alcoholic liver disease is liver disease related to excessive alcohol consumption. It includes a spectrum
of liver diseases that includes alcoholic steatosis (simple fatty liver or simple steatosis or accumulation of fat in liver cells), alcoholic
hepatitis (inflammation of liver cells), and alcoholic cirrhosis (destruction of liver cells and replacement with scar tissue). This can
cause major health problems such as excessive tiredness, and liver failure leading to vomiting blood, confusion, and death. A number
of medical treatments have been used to treat alcohol-related liver disease. The best way to treat alcohol-related liver disease is not clear.
We sought to resolve this issue by searching for existing studies on the topic. We included all randomised clinical trials whose results
were reported until February 2017. We included only studies in which participants had not undergone liver transplantation previously
and those who did not have liver disease due to other causes such as viral infections. Apart from using standard Cochrane methods
which allow comparison of only two treatments at a time (direct comparison), we planned to use an advanced method which allows
comparison of the many different treatments that are individually compared in the trials (network meta-analysis). However, because
of the nature of the information available, we could not determine whether the network meta-analysis results were reliable. Therefore,
we used standard Cochrane methodology.
Study characteristics
We identified 81 trials which were eligible for our review. We have presented the results for people with differing spectrum of alcohol-
related liver disease separately.
Key results
Alcoholic hepatitis
Fifty randomised clinical trials included 4484 participants with alcoholic hepatitis. The period of follow-up ranged from one to 12
months. Because of the nature of the information available, we used methods similar to Cochrane methodology. None of the active
interventions showed any improvement in any of the clinical outcomes reported in the trials, which includes deaths (at various time
points), cirrhosis, liver failure or liver transplantation. None of the trials reported health-related quality of life or incidence of primary
liver cancer.
Severe alcoholic hepatitis
Of the trials on alcoholic hepatitis, 19 trials (2545 participants) included exclusively participants with severe alcoholic hepatitis. The
period of follow-up ranged from one to 12 months. There was no alteration in the conclusions when only people with severe alcoholic
hepatitis were included in the analysis.
Source of funding: Eleven trials were funded by parties with vested interest in the results. Sixteen trials were funded by parties without
vested interest in the results. The source of funding was not reported in 23 trials.
Other alcohol-related liver diseases
Thirty-one randomised clinical trials included 3695 participants with other alcohol-related liver diseases (with a wide spectrum of
alcohol-related liver diseases). The period of follow-up ranged fromone to 48months. The risk of deathswas lower in the propylthiouracil
group than in the no intervention group and higher in the ursodeoxycholic acid group than in the no intervention group. However,
these results are based on trials with methodological deficiencies that make the results unreliable. As a result, trials of low risk of bias
of sufficient sample size are required before propylthiouracil can be recommended routinely. There was no evidence of improvement
in any of the remaining clinical outcomes by any of the interventions compared with no intervention.
Source of funding: Twelve trials were funded by parties with vested interest in the results. Three trials were funded by parties without
vested interest in the results. The source of funding was not reported in 16 trials.
Quality of the evidence
The overall quality of the evidence was very low and all the trials were at unclear or high risk of bias, which means that there is possibility
of making wrong conclusions overestimating benefits or underestimating harms of one treatment or the other because of the way that
the studies were conducted. Further high-quality randomised clinical trials are necessary.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)
Patient or population: part icipants with alcoholic hepat it is (all severity)
Settings: secondary or tert iary care
Intervention: glucocort icosteroids
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Glucocorticosteroids
M ortality at maximal fol-
low-up
Follow-up: 1 to 12 months
348 per 1000 353 per 1000
(301 to 409)
OR 0.85
(0.67 to 1.08)
1147
(12 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
217 per 1000 391 per 1000
(313 to 472)
OR 1.00
(0.71 to 1.39)
672
(4 trials)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 12 months
390 per 1000 467 per 1000
(385 to 552)
OR 1.37
(0.98 to 1.93)
546
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded by one level)
2Imprecision: small sample size (downgraded by one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded by one level).
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B A C K G R O U N D
Description of the condition
Alcohol-related liver disease or alcoholic liver disease is liver dis-
ease related to excessive alcohol consumption (BLT 2014; NCBI
2014a; NHS 2014). It includes a spectrum of liver diseases that
includes alcoholic steatosis (simple fatty liver (simple steatosis)),
overt alcoholic hepatitis, and alcoholic cirrhosis (Gao 2011;NCBI
2014a). Fatty liver, which indicates accumulation of fat in the liver
parenchymal cells (NCBI 2014b), is usually the earliest manifesta-
tion of alcohol-related liver disease and develops in about 90% to
95% of people who consume large quantities of alcohol (O’Shea
2010; Gao 2011). About 10% to 40% of people with fatty liver
develop liver fibrosis (O’Shea 2010; Gao 2011). One fifth of peo-
ple who develop liver fibrosis develop alcoholic liver cirrhosis (ad-
vanced liver fibrosis) (Gao 2011). About 10% to 35% of people
who consume large quantities of alcohol may also develop alco-
holic hepatitis (Gao 2011). Alcoholic hepatitis is characterised by
liver parenchymal necrosis and inflammation (Gao 2011; NCBI
2014c), and presents clinically as jaundice and liver failure that
usually occur after several decades of consumption of large quan-
tities of alcohol (Lucey 2009). About 18% of people with alco-
holic hepatitis progress to cirrhosis (O’Shea 2010). A significant
proportion of people may develop alcoholic cirrhosis without de-
veloping alcoholic hepatitis (O’Shea 2010).
Alcohol increases the fats that reach the liver from the intestine,
increases fatty acid synthesis (lipogenesis), and decreases the break-
down of fatty acids (by decreasing beta-oxidation of fatty acids)
resulting in accumulation of fat in liver cells (Lucey 2009; Gao
2011). The process of alcohol metabolism results in generation
of reactive oxygen species, lipid peroxidation, mitochondrial glu-
tathione depletion, and S-adenosylmethionine depletion (Lucey
2009; Gao 2011). This sensitises liver cells to injury (Gao 2011).
Acetate, a breakdown product of alcohol, causes inflammation
(Gao 2011). In addition, alcohol increases gut permeability and
translocation of bacteria from the bowel resulting in increased bac-
terial lipopolysaccharides, which in turn cause inflammation by
activation of Kupffer cells (Lucey 2009; Gao 2011). Thus, alcohol
can cause alcoholic hepatitis (Lucey 2009; Gao 2011). Alcohol
may also inhibit proliferation of liver cells, thereby decreasing liver
regeneration in response to injury (Gao 2011). Acetaldehyde, an-
other breakdown product of alcohol, activates hepatic stellate cells
(Gao 2011). Activation of Kupffer cells also promotes fibrogenesis
by activating the hepatic stellate cells (Gao 2011). In addition to
activation of Kupffer cells, increased lipopolysaccharides due to
translocation of bacteria from the bowel also promotes fibrogene-
sis directly by activating hepatic stellate cells (Gao 2011). Natural
killer cells destroy activated hepatic stellate cells and produce in-
terferon-gamma (Gao 2011). Alcohol inhibits natural killer cells
and so promotes fibrosis (Gao 2011).
The true prevalence of alcohol-related liver disease is difficult to
estimate. Overall, alcohol causes 38 deaths per 100,000 men and
28 deaths per 100,000 women every year in Europe due to liver
cirrhosis, alcoholic hepatitis, alcohol-related injuries, and cancers
attributable to alcohol consumption (WHO 2013). Worldwide,
of every 100 deaths, alcohol causes 5.9 deaths (7.6 deaths per 100
deaths in men and four deaths per 100 deaths in women) (WHO
2014). About 30% of people with alcoholic hepatitis die within
three months of hospital admission (Whitfield 2009). Alcohol
is the most common cause of liver cirrhosis in Europe (Blachier
2013). Cirrhosis has two phases - an asymptomatic ’compen-
sated cirrhosis’ phase and a symptomatic ’decompensated cirrho-
sis’ phase characterised by clinical symptoms such as upper gas-
trointestinal bleeding from varices, ascites, encephalopathy, jaun-
dice, or renal failure (D’Amico 2006). The median survival after
compensated liver disease can be more than 10 years, while that
of decompensated liver disease is less than two years (D’Amico
2006). The only definitive treatment for decompensated liver cir-
rhosis is liver transplantation. Alcoholic cirrhosis is the second
most common cause of liver transplantation in the USA (SRTR
2012). The median survival after liver transplantation is in excess
of 10 years (Duffy 2010; SRTR 2012; Schoening 2013). There
is also improvement in the health-related quality of life of people
with chronic liver disease after liver transplantation (Yang 2014).
Description of the intervention
Alcohol abstinence is the main form of preventing and limiting
the damage due to alcohol-related liver disease (O’Shea 2010; Gao
2011). Disulfiram, frequently prescribed to promote alcohol ab-
stinence, is not recommended in people with alcohol-related liver
disease because of its liver toxicity (Gao 2011). Various interven-
tions have been used for the treatment of alcohol-related liver dis-
ease. These include pharmacological interventions such as gluco-
corticosteroids, anabolic-androgenic steroids, pentoxifylline, anti-
tumour necrosis factor (infliximab and etanercept), colchicine, S-
adenosylmethionine, N-acetyl cysteine, propylthiouracil, vitamin
E and other antioxidants, and milk thistle (silymarin or Silybum
marianum extract); nutritional supplement, for example, protein
and vitamin supplementation; and psychotherapy for alcohol ab-
stinence (Ferri 2006; Rambaldi 2006; Rambaldi 2015; Stewart
2007; Lucey 2009;Whitfield 2009;O’Shea2010; Fede 2011;Gao
2011;Nguyen-Khac 2011;Mathurin 2013). Glucocorticoidsmay
be combined with other treatments (Stewart 2007; O’Shea 2010;
Nguyen-Khac 2011; Mathurin 2013).
How the intervention might work
Glucocorticosteroids, pentoxifylline, and anti-tumour necrosis
factor are aimed at decreasing the inflammation (Lucey 2009;
Gao 2011; Mathurin 2013). In addition to its action on tumour
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necrosis factor (TNF) (and hence its effect on inflammation),
pentoxifylline might prevent hepatorenal syndrome by maintain-
ing kidney function (Lucey 2009; Mathurin 2013). S-adenosyl-
methionine (SAMe), N-acetyl cysteine (NAC), propylthiouracil,
Vitamin E and other antioxidants, and milk thistle (silymarin)
are aimed at decreasing the oxidative damage to liver cells (Hicks
1992; Stewart 2007; Lucey 2009; Abenavoli 2010; Gao 2011;
Nguyen-Khac 2011; Anstee 2012). Anabolic-androgenic steroids
have been evaluated in alcohol-related liver disease because of their
anabolic (muscle building) effect (Lucey 2009), and direct effects
on liver metabolism (Gluud 1988). Colchicine has been evaluated
in alcohol-related liver disease because of its anti-inflammatory
and anti-fibrogenic properties (O’Shea 2010).
Why it is important to do this review
We included only pharmacological therapies used in the treatment
of alcoholic liver disease with the aim of reducing liver injury. The
current guidelines on management of alcohol-related liver disease
by the European Association for the Study of Liver (EASL) and
American Association for the Study of Liver Diseases (AASLD)
are similar in terms of recommending glucocorticoids for severe
alcoholic hepatitis unless there are contraindications, inwhich case
pentoxifylline is recommended (O’Shea 2010; EASL2012). EASL
guidelines also suggest that N-acetyl cysteinemay be useful in peo-
ple with severe alcoholic fatty liver disease receiving corticosteroids
(EASL 2012). The role of the other pharmacological agents, the
benefit of combination therapies, and the relative ranking of these
different interventions is not clear from these guidelines. Network
meta-analyses allow combination of the direct evidence and in-
direct evidence, and allow ranking of different interventions in
terms of the different outcomes (Salanti 2011; Salanti 2012). This
systematic review and attempted network meta-analysis aimed to
provide the best level of evidence for the role of different pharma-
cological interventions in the treatment of people with alcohol-
related liver disease.
O B J E C T I V E S
To assess the comparative benefits and harms of different pharma-
cological interventions in the management of alcohol-related liver
disease through a network meta-analysis and to generate rank-
ings of the available pharmacological interventions according to
their safety and efficacy in order to identify potential treatments.
However, even in the subgroup of participants when the potential
effect modifiers appeared reasonably similar across comparisons,
there was evidence of inconsistency by one or more methods of
assessment of inconsistency. Therefore, we assessed the compara-
tive benefits and harms of different interventions using standard
Cochrane methodology. However, we have presented the methods
of the network meta-analysis for one of the subgroups where the
potential effect modifiers appeared reasonably similar across com-
parisons; the data used for network meta-analysis and the results
in Appendix 1; Appendix 2; Appendix 3; Appendix 4; Appendix
5; Appendix 6. Once new data appear allowing the conduct of a
network meta-analysis which is reliable, we will perform a revised
analysis, and then, we will move it back into the Methods section
and Results section of the Cochrane review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Weconsidered only randomised clinical trials for thismeta-analysis
irrespective of language, publication status, or date of publication.
We excluded studies of other design because of the risk of bias in
such studies. We are all aware that such exclusions make us focus
much more on potential benefits and not fully assess the risks of
serious adverse events as well as risks of adverse events.
Types of participants
We included randomised clinical trials involving participants with
alcohol-related liver disease irrespective of the method of diag-
nosis of the disease and severity of alcohol-related liver disease.
We excluded randomised clinical trials in which participants had
undergone liver transplantation previously. We also excluded ran-
domised clinical trials in which participants had other causes of
chronic liver disease such as hepatitis C virus, hepatitis B virus,
and hepatitis delta virus infections along with alcohol-related liver
disease, or non-alcohol-related liver disease.
Types of interventions
We included any of the following pharmacological interventions
that are possible treatments for alcohol-related liver disease (i.e.
alcoholic fatty liver, alcoholic hepatitis, alcoholic cirrhosis), and
which can be compared with each other either alone or in combi-
nation or with placebo or no intervention.
The interventions that we considered a priori included:
• glucocorticosteroids;
• anabolic-androgenic steroids;
• pentoxifylline;
• anti-tumour necrosis factor (infliximab and etanercept);
• colchicine;
• S-adenosylmethionine;
• N-acetyl cysteine;
• propylthiouracil;
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• antioxidants (including vitamin E);
• milk thistle (silymarin).
We included anti-tumour necrosis factor (anti-TNF), granulo-
cyte stimulation factor (GSF), rifaximin, and ursodeoxycholic acid
(UDCA), used either alone or in a combination of the above in-
terventions after searching the references. We have reported the
findings for these interventions in the Results and Discussion sec-
tions of the review.
In this systematic review, we included only pharmacological inter-
ventions where the target of treatment is the liver, i.e. we did not
include nutritional, psychotherapy, and other supportive therapy
required tomanage complications such as infections, portal hyper-
tension, or alcohol withdrawal syndrome, or therapies targeted at
promoting alcohol abstinence or decreasing alcohol dependence.
Types of outcome measures
We assessed the comparative benefits and harms (and report the
relative ranking) of available pharmacological interventions aimed
at reducing liver injury with alcohol-related liver disease for the
following outcomes.
Primary outcomes
• Mortality at maximal follow-up.
• Early mortality (up to three months).
• Adverse events. Depending on the availability of data, we
planned to classify adverse events as serious or non-serious. We
defined a non-serious adverse event as any untoward medical
occurrence not necessarily having a causal relationship with the
intervention but resulting in a dose reduction or discontinuation
of treatment (any time after commencement of treatment)
(ICH-GCP 1997). We defined a serious adverse event as any
event that would increase mortality; is life-threatening; requires
hospitalisation; results in persistent or significant disability; is a
congenital anomaly/birth defect; or any important medical event
that might jeopardise the person or require intervention to
prevent it (ICH-GCP 1997). We used the definition used by
study authors for non-serious and serious adverse events:
◦ proportion of participants with serious adverse events;
◦ number of serious adverse events.
• Health-related quality of life as defined in the included
trials using a validated scale such as EQ-5D or 36-item Short
Form (SF-36) (EuroQol 2014; Ware 2014):
◦ short term (up to one year);
◦ medium term (one to five years);
◦ long term (beyond five years).
We planned to consider long-term health-related quality of life
more important than short-term or medium-term health-related
quality of life, although short-term and medium-term health-re-
lated quality of life are also important primary outcomes.
Secondary outcomes
• Liver transplantation (maximal follow-up):
◦ proportion of participants with liver transplantation;
◦ time to liver transplantation.
• Decompensated liver disease (maximal follow-up):
◦ proportion of participants with decompensated liver
disease;
◦ time to liver decompensation.
We had to calculate the decompensated liver disease rate rather
than proportion since it was not always clear whether these
episodes of decompensation occurred in the same participant or
different participants.
• Cirrhosis (maximal follow-up) (in participants without
cirrhosis):
◦ proportion of participants with cirrhosis;
◦ time to cirrhosis.
• Proportion of participants with hepatocellular carcinoma
(maximal follow-up).
• Any adverse events:
◦ proportion of participants with any type of adverse
event;
◦ number of any type of adverse event.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, and Science Citation Index
Expanded (Royle 2003) from inception to February 2017 for ran-
domised clinical trials comparing two or more of the above inter-
ventions (including placebo or no intervention) without applying
any language restrictions.We searched for all possible comparisons
formed by the interventions of interest. To identify further ongo-
ing or completed trials, we also searched the World Health Orga-
nization International Clinical Trials Registry Platform search por-
tal (www.who.int/ictrp/en/), which searches various trial registers,
including ISRCTN and ClinicalTrials.gov. Appendix 7 shows the
search strategies that we used.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane reviews on alcohol-related liver disease to identify addi-
tional trials for inclusion.
Data collection and analysis
Selection of studies
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Two review authors (EB and MK) independently identified trials
for inclusion by screening the titles and abstracts. We sought full-
text articles for any references that at least one of the review authors
identified for potential inclusion. We selected trials for inclusion
based on the full-text articles, or, if no full text existed, then the
abstracts of the trial.We listed the excluded full-text referenceswith
reasons for their exclusion in the ’Characteristics of excluded trials’
table.We also listed any ongoing trials identified primarily through
the search of the clinical trial registers for further follow-up. We
resolved discrepancies through discussion and by arbitration with
KG, DT, and ET.
Data extraction and management
Two review authors (EB and MK) independently extracted the
following data.
• Outcome data (for each outcome and for each intervention
group whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcome, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and the
number of participants with events and the mean follow-up
period for time-to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex, co-
morbidities, and proportion of participants with severe alcoholic
hepatitis;
◦ details of the intervention and control (including dose,
frequency, and duration);
◦ risk of bias (assessment of risk of bias in included
trials).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
Data were not available separately for different severities of alco-
holic hepatitis. Therefore, the subgroup analysis of severe alcoholic
hepatitis was based on a study level. We sought unclear or missing
information by contacting the trial authors. If there was any doubt
whether trials shared the same participants, completely or partially
(by identifying common authors and centres), we attempted to
contact the trial authors to clarify whether the trial report was du-
plicated. We resolved any differences in opinion through discus-
sion.
Assessment of risk of bias in included studies
We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) and described
in the Cochrane Hepato-Biliary Group Module (Gluud 2016) to
assess the risk of bias in included studies. Specifically, we assessed
the risk of bias in included trials for the following domains using
the methods below (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We planned to only include such studies for assessment
of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We
planned to only include such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
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Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: (e.g. at least one of the long-term outcomes related to
the disease process, namely, mortality, decompensated liver
disease, or requirement for transplantation along with treatment-
related adverse events). If the original trial protocol was available,
the outcomes should have been those called for in that protocol.
If the trial protocol was obtained from a trial registry (e.g.
www.clinicaltrials.gov), the outcomes sought should have been
those enumerated in the original protocol if the trial protocol
was registered before or at the time that the trial was begun. If
the trial protocol was registered after the trial was begun, those
outcomes were not considered to be reliable.
• Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial.
• Uncertain risk of bias: the trial may or may not have been
free of for-profit bias as no information on clinical trial support
or sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control, baseline differences, early stopping)
that could put it at risk of bias.
• Uncertain risk of bias: the trial may or may not have been
free of other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. baseline differences, early
stopping).
We considered a trial at low risk of bias if we assessed the trial to
be at low risk of bias across all domains. Otherwise, we considered
trials to be at high risk of bias.
Measures of treatment effect
For dichotomous variables (e.g. short-term and medium-term
mortality or liver transplantation, proportion of participants with
adverse events, decompensated liver disease, cirrhosis, or hepato-
cellular carcinoma), we calculated the odds ratio (OR) with 95%
confidence intervals (CIs). For continuous variables (e.g. health-
related quality of life reported on the same scale), we planned to
calculate the mean difference (MD) with 95% CI. We planned to
use standardised mean difference (SMD) values with 95% CI for
health-related quality of life if included trials used different scales.
For count outcomes (e.g. number of adverse events), we calculated
the rate ratio with 95% CI. For time-to-event data (e.g. mortal-
ity at maximal follow-up or requirement for liver transplantation,
time to liver decompensation, and time to cirrhosis), we planned
to use the hazard ratio (HR) with 95% confidence intervals. How-
ever, because of the nature of the data available, we calculated the
odds ratio with 95% CI for these outcomes also. We also calcu-
lated Trial Sequential Analysis-adjusted CI to control random er-
rors (Thorlund 2011).
Unit of analysis issues
The unit of analysis were people with alcohol-related liver disease
according to the intervention group to which they were randomly
assigned.
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Cluster-randomised clinical trials
As expected, we did find cluster-randomised clinical trials. How-
ever, had we found any such trials, we planned to include them
provided that the effect estimate adjusted for cluster correlation is
available.
Cross-over randomised clinical trials
We included the outcomes after the period of first intervention
since alcohol-related liver disease is a chronic unstable disease and
the treatments could potentially have a residual effect. On the
other hand, alcoholic hepatitis is an acute illness and the interven-
tion given initially can influence the outcome of the patients with
alcoholic disease.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the
inclusion criteria. The codes for analysis, that we used, accounts
for the correlation between the effect sizes from studies with more
than two groups.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used the data that were available
to us (e.g. a trial might have reported only per-protocol analysis
results). As such per-protocol analyses may be biased, we planned
to conduct best-worst case scenario analyses (good outcome in
intervention group and bad outcome in control group) and worst-
best case scenario analyses (bad outcome in intervention group and
good outcome in control group) as sensitivity analyses whenever
possible. However, we did not perform these analyses because of
lack of sufficient information.
For continuous outcomes, we planned to impute the standard de-
viation from P values according to guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If the data were likely to be normally distributed, we planned to
use the median for meta-analysis when the mean was not avail-
able. If it was not possible to calculate the standard deviation from
the P value or the confidence intervals, we planned to impute the
standard deviation using the largest standard deviation in other
trials for that outcome. This form of imputation may decrease the
weight of the study for calculation of mean differences and may
bias the effect estimate to no effect for calculation of standardised
mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. Dif-
ferent study designs and risk of bias may contribute to method-
ological heterogeneity. We used the I2 test and Chi2 test for het-
erogeneity, and overlapping of CIs to assess heterogeneity.
Assessment of reporting biases
We used visual asymmetry on a funnel plot to explore reporting
bias in the presence of at least 10 trials that could be included for
a comparison (Egger 1997; Macaskill 2001). In the presence of
heterogeneity that could be explained by subgroup analysis, we
planned to produce a funnel plot for each subgroup in the presence
of an adequate number of trials (at least 10 trials). We used the
linear regression approach described by Egger 1997 to determine
funnel plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of Cochrane (Higgins 2011), using the software package Re-
viewManager 5 (RevMan 2014).We used a random-effects model
(DerSimonian 1986) and a fixed-effect model (DeMets 1987). In
the case of a discrepancy between the two models, we reported the
more conservative results; otherwise, we reported only the results
from the fixed-effect model.
We performed the direct comparisons using the same codes and
the same technical details.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix
8. We performed Trial Sequential Analysis to control the risk
of random errors (Wetterslev 2008; Thorlund 2011; TSA 2011;
Wetterslev 2017) when there were at least two trials included for
the comparisons involving an active intervention versus no inter-
vention for the following outcomes: mortality at maximal follow-
up, serious adverse events (proportion), and health-related quality
of life. These are outcomes that determine whether an interven-
tion should be used. We used an alpha error as per guidance of
Jakobsen 2014, power of 90% (beta error of 10%), a relative risk
reduction of 20%, a control group proportion observed in the tri-
als, and the diversity observed in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
• Trials with low risk of bias compared to trials with high risk
of bias.
• Biopsy-confirmed alcohol-related liver disease.
• Different severity of alcoholic hepatitis.
• Different regimens of pharmacological interventions. For
example, different doses and different durations.
Weplanned touse theChi2 test for subgroupdifferences to identify
subgroup differences.
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Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned to
re-analyse the results using the best-worst scenario and worst-best
case scenario analyses as sensitivity analyses whenever possible.
Presentation of results
We presented the results in a ’Summary of findings’ table for-
mat, downgrading the quality of the evidence for risk of bias, in-
consistency, indirectness, imprecision, and publication bias using
GRADE (Guyatt 2011). We presented the ’Summary of findings’
tables for primary outcomes comparing active interventions versus
no interventions when there were at least two trials for at least one
of the primary outcomes.
R E S U L T S
Description of studies
Results of the search
We identified 11,178 references through electronic searches of
CENTRAL (Wiley) (n = 1406),MEDLINE (OvidSP) (n = 5901),
Embase (OvidSP) (n = 1830), Science Citation Index expanded
(n = 1942), ClinicalTrials.gov (n = 51) and WHO Trials register
(n = 48). After removing duplicate references, there were 8021
references.We excluded 7866 clearly irrelevant references through
reading titles and abstracts. We identified two references by refer-
ence searching. We retrieved a total of 157 full text references for
further assessment in detail. We excluded 29 references (27 trials)
for the reasons stated in the Characteristics of excluded studies.
Thus, we included a total of 81 trials described in 128 references
(Characteristics of included studies). The reference flow is shown
in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Of the 81 trials included in the review, 50 trials were conducted
exclusively in people with acute alcoholic hepatitis (Helman 1971;
Porter 1971; Campra 1973; Resnick 1974; Blitzer 1977;Maddrey
1978; Shumaker 1978; Depew 1980; Baker 1981; Serrano-
Cancino 1981; Halle 1982; Mirouze 1982; Theodossi 1982;
Radvan 1983;Mendenhall 1984; Carithers 1989; Trinchet 1989a;
Trinchet 1989b; Akriviadis 1990; Bird 1991; McHutchinson
1991; Ramond 1992; Trinchet 1992; Richardet 1993; Bird
1998; Akriviadis 2000; Spahr 2002; Mezey 2004; Naveau 2004;
Stigliano 2005; Paladugu 2006; Phillips 2006; Stewart 2007;
Boetticher 2008; De 2009; Popescu 2009; Lebrec 2010; Moreno
2010; Nguyen-Khac 2011; Garrido Garcia 2012; Sidhu 2012a;
Sidhu 2012b; Mathurin 2013; De 2014; Park 2014; Singh 2014;
Basu 2015; Higuera de la Tijera 2015; Thursz 2015; Tkachenko
2016), while 31 trials were conducted in people with different
alcoholic disorders (fatty liver, alcoholic hepatitis, and cirrho-
sis) (Fenster 1966; Geminiani 1979; Orrego 1979; Pierri 1985;
Salvagnini 1985; Gluud 1986; Bories 1987; Orrego 1987; Feher
1989; Takase 1989; Plevris 1991; Sainz 1992; Keiding 1994; De
la Maza 1995; Lotterer 1995; Diaz Belmont 1996; Fleig 1997;
Velussi 1997; Caballeria 1998; Colman 1998; Pares 1998; Mato
1999; Stenner 2000; Cortez-Pinto 2002; Lucena 2002; De Silva
2003; Pelletier 2003; Morgan 2005; Fernandez-Rodriguez 2008;
Medici 2011; Kim 2012).
Acute alcoholic hepatitis
We included a total of 4484 participants in 50 trials on acute
alcoholic hepatitis (Helman 1971; Porter 1971; Campra 1973;
Resnick 1974; Blitzer 1977; Maddrey 1978; Shumaker 1978;
Depew 1980; Baker 1981; Serrano-Cancino 1981; Halle 1982;
Mirouze 1982; Theodossi 1982; Radvan 1983;Mendenhall 1984;
Carithers 1989; Trinchet 1989a; Trinchet 1989b; Akriviadis 1990;
Bird 1991; McHutchinson 1991; Ramond 1992; Trinchet 1992;
Richardet 1993; Bird 1998; Akriviadis 2000; Spahr 2002; Mezey
2004; Naveau 2004; Stigliano 2005; Paladugu 2006; Phillips
2006; Stewart 2007; Boetticher 2008; De 2009; Popescu 2009;
Lebrec 2010; Moreno 2010; Nguyen-Khac 2011; Garrido Garcia
2012; Sidhu 2012a; Sidhu 2012b;Mathurin 2013; De 2014; Park
2014; Singh 2014; Basu 2015; Higuera de la Tijera 2015; Thursz
2015; Tkachenko 2016). A total of 26 interventions (25 active and
one inactive interventions)were evaluated in the 50 trials.One trial
was a cross-over randomised clinical trial (Richardet 1993); and
the remaining trials were parallel-group design trials. Two trials
had three interventions (Mendenhall 1984; Basu 2015); two trials
had four interventions (Higuera de la Tijera 2015; Thursz 2015);
and the remaining trials had two interventions. A total of 48 trials
(4335 participants) contributed to one or more outcomes.
A total of 2545 participants included in 19 trials had severe acute
alcoholic hepatitis, defined as Maddrey Discriminant Function
(DF) > 32 (Ramond 1992; Akriviadis 2000; Spahr 2002; Naveau
2004; Paladugu 2006; De 2009; Moreno 2010; Nguyen-Khac
2011;GarridoGarcia 2012; Sidhu 2012a; Sidhu 2012b;Mathurin
2013; De 2014; Park 2014; Singh 2014; Basu 2015; Higuera
de la Tijera 2015; Thursz 2015; Tkachenko 2016). A total of
13 interventions (12 active and one inactive interventions) were
evaluated in the 19 trials. All the trials were parallel-group design
trials. One trial had three interventions (Basu 2015); two trials
had four interventions (Higuera de la Tijera 2015; Thursz 2015);
and the remaining trials had two interventions. A total of 18 trials
(2477 participants contributed to one or more outcomes).
Further details about the mean age in the participants, proportion
of females, inclusion and exclusion criteria, details of the interven-
tion, and the outcomes reported are available in theCharacteristics
of included studies.
Source of funding: Eleven trials were funded by parties with vested
interest in the results (Resnick 1974; Blitzer 1977; Shumaker
1978; Baker 1981; Trinchet 1989a; Trinchet 1989b; Bird 1991;
Akriviadis 2000; Spahr 2002; Naveau 2004;Mathurin 2013). Six-
teen trials were funded by parties without vested interest in the
results (Helman 1971; Porter 1971; Maddrey 1978; Halle 1982;
Carithers 1989; Akriviadis 1990; Ramond 1992; Trinchet 1992;
Bird 1998; Mezey 2004; Stewart 2007; Boetticher 2008; Sidhu
2012a; Park 2014; Higuera de la Tijera 2015; Thursz 2015). The
source of funding was not reported in the remaining trials.
Alcohol-related liver diseases (others)
We included a total of 3695 participants in 31 trials on alcohol-
related liver disease (Fenster 1966; Geminiani 1979;Orrego 1979;
Pierri 1985; Salvagnini 1985; Gluud 1986; Bories 1987; Orrego
1987; Feher 1989; Takase 1989; Plevris 1991; Sainz 1992; Keiding
1994; De la Maza 1995; Lotterer 1995; Diaz Belmont 1996; Fleig
1997; Velussi 1997; Caballeria 1998; Colman 1998; Pares 1998;
Mato 1999; Stenner 2000; Cortez-Pinto 2002; Lucena 2002; De
Silva 2003; Pelletier 2003; Morgan 2005; Fernandez-Rodriguez
2008; Medici 2011; Kim 2012). A total of 15 interventions (14
active and one inactive interventions) were evaluated in the 31
trials. One trial was a cross-over randomised clinical trial (Plevris
1991); the remaining trials were parallel-group design trials. All
the trials had only two interventions. A total of 26 trials (3212
participants contributed to one or more outcomes).
Further details about the mean age in the participants, proportion
of females, inclusion and exclusion criteria, details of the interven-
tion, and the outcomes reported are available in theCharacteristics
of included studies.
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Source of funding: Twelve trials were funded by parties with vested
interest in the results (Fenster 1966; Orrego 1979; Orrego 1987;
Keiding 1994; De la Maza 1995; Pares 1998; Mato 1999; Lucena
2002; De Silva 2003; Pelletier 2003; Fernandez-Rodriguez 2008;
Medici 2011). Three trials were funded by parties without vested
interest in the results (Gluud 1986; Cortez-Pinto 2002; Kim
2012). The source of funding was not reported in the remaining
trials.
Excluded studies
Twenty-seven studies were excluded because of the reasons listed in
theCharacteristics of excluded studies.While the reasons for exclu-
sion of 24 studies are clear and do not warrant further discussion,
exclusion of three studies warrants further discussion (Mathurin
1996; Spahr 2008; Kolasani 2016). Mathurin 1996 reported the
long-term follow-up of participants included in Ramond 1992;
however, at the end of the study period, all the participants were
administered the intervention, and the randomisation was lost.
Therefore, we did not include this study in our analysis (Ramond
1992). In Spahr 2008 and Kolasani 2016, the intervention and
control groups were allowed to take other drugs targeted at treat-
ment of alcoholic liver disease as per clinicians’ discretion. We ac-
cepted only when it was possible to know that the co-interventions
were administered equally in the intervention and control groups
of the trial; therefore, we excluded these two studies (Spahr 2008;
Kolasani 2016).
Risk of bias in included studies
The risk of bias in trials is summarised in Figure 2 and Figure 3.
As shown in these figures, none of the trials were at low risk of bias
in all the domains and were considered to be at high risk of bias.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Alcoholic hepatitis
Twenty-one trials were at low risk of bias due to random sequence
generation (Porter 1971; Baker 1981; Trinchet 1989b; Ramond
1992; Akriviadis 2000; Spahr 2002; Mezey 2004; Naveau 2004;
Phillips 2006; Stewart 2007; Boetticher 2008; De 2009; Lebrec
2010; Nguyen-Khac 2011; Sidhu 2012a; Mathurin 2013; De
2014; Park 2014; Singh 2014; Higuera de la Tijera 2015; Thursz
2015). The remaining trials were at unclear risk of bias.
Fourteen trials were at low risk of bias due allocation conceal-
ment (Blitzer 1977; Baker 1981; Theodossi 1982; Carithers 1989;
Trinchet 1989a; Trinchet 1989b; Akriviadis 1990; Bird 1991;
Akriviadis 2000; Mezey 2004; Sidhu 2012a; Sidhu 2012b; Singh
2014; Thursz 2015).The remaining trials were at unclear risk of
bias.
Overall, seven trials were at low risk of bias due to both random
sequence generation and allocation concealment and were con-
sidered to be at low risk of selection bias (Baker 1981; Trinchet
1989b; Akriviadis 2000; Mezey 2004; Sidhu 2012a; Singh 2014;
Thursz 2015).
Alcohol-related liver disease (others)
Sixteen trials were at low risk of bias due to random sequence
generation (Orrego 1979;Gluud1986; Bories 1987;Orrego1987;
Keiding 1994; Caballeria 1998; Pares 1998; Mato 1999; Cortez-
Pinto 2002; Lucena 2002; De Silva 2003; Pelletier 2003; Morgan
2005; Fernandez-Rodriguez 2008; Medici 2011; Kim 2012). The
remaining trials were at unclear risk of bias.
Nine trials were at low risk of bias due allocation concealment
(Gluud 1986; Keiding 1994; Pares 1998; Cortez-Pinto 2002;
Lucena 2002; Morgan 2005; Fernandez-Rodriguez 2008; Medici
2011; Kim 2012). The remaining trials were at unclear risk of bias.
Overall, nine trials were at low risk of bias due to both random
sequence generation and allocation concealment, and were con-
sidered to be at low risk of selection bias (Gluud 1986; Keiding
1994; Pares 1998; Cortez-Pinto 2002; Lucena 2002; Morgan
2005; Fernandez-Rodriguez 2008; Medici 2011; Kim 2012)
Blinding
Alcoholic hepatitis
Twenty-three trials were at low risk of performance bias (Helman
1971; Porter 1971; Blitzer 1977; Maddrey 1978; Shumaker
1978; Depew 1980; Baker 1981; Halle 1982; Mendenhall 1984;
Carithers 1989; Trinchet 1989a; Trinchet 1989b; Akriviadis 1990;
Ramond 1992; Akriviadis 2000; Spahr2002;Mezey2004;Naveau
2004; Stewart 2007; Boetticher 2008; Mathurin 2013; De 2014;
Thursz 2015). Twelve trials were at high risk of performance
bias (Campra 1973; Theodossi 1982; Phillips 2006; Popescu
2009; Nguyen-Khac 2011; Garrido Garcia 2012; Sidhu 2012a;
Park 2014; Singh 2014; Basu 2015; Higuera de la Tijera 2015;
Tkachenko 2016). The remaining trials were at unclear risk of
performance bias.
Fifteen trials were at low risk of detection bias (Maddrey 1978;
Carithers 1989; Trinchet 1989b; Akriviadis 1990; Ramond
1992; Akriviadis 2000; Spahr 2002; Mezey 2004; Stewart 2007;
Boetticher 2008; De 2009; Lebrec 2010; Sidhu 2012a; De 2014;
Thursz 2015). Seven trials were at high risk of detection bias
(Campra 1973;Nguyen-Khac 2011; Park 2014; Singh 2014; Basu
2015; Higuera de la Tijera 2015; Tkachenko 2016). The remain-
ing trials were at unclear risk of detection bias.
Overall, 12 trialswere at low risk of performance bias anddetection
bias (Maddrey 1978; Carithers 1989; Trinchet 1989b; Akriviadis
1990; Ramond 1992; Akriviadis 2000; Spahr 2002; Mezey 2004;
Stewart 2007; Boetticher 2008; De 2014; Thursz 2015).
Alcohol-related liver disease (others)
Ten trials were at low risk of performance bias (Orrego 1979;
Gluud 1986; Orrego 1987; Pares 1998; Cortez-Pinto 2002;
Lucena 2002;De Silva 2003;Morgan 2005; Fernandez-Rodriguez
2008; Medici 2011). Five trials were at high risk of performance
bias (Takase 1989; Plevris 1991; Sainz 1992; Velussi 1997; Kim
2012). The remaining trials were at unclear risk of performance
bias.
Ten trials were at low risk of detection bias (Pierri 1985; Gluud
1986;Orrego1987; Pares 1998;Cortez-Pinto 2002; Lucena 2002;
De Silva 2003;Morgan 2005; Fernandez-Rodriguez 2008;Medici
2011). Two trials were at high risk of detection bias (Plevris 1991;
Kim 2012). The remaining trials were at unclear risk of detection
bias.
Overall, nine trials were at low risk of performance bias and detec-
tion bias (Gluud 1986; Orrego 1987; Pares 1998; Cortez-Pinto
2002; Lucena 2002; De Silva 2003; Morgan 2005; Fernandez-
Rodriguez 2008; Medici 2011).
Incomplete outcome data
Alcoholic hepatitis
Thirteen trials were at low risk of attrition bias (Helman 1971;
Shumaker 1978; Depew 1980; Carithers 1989; Spahr 2002;
Phillips 2006; Boetticher 2008; Garrido Garcia 2012; Sidhu
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2012a; Sidhu 2012b; Singh 2014; Higuera de la Tijera 2015;
Tkachenko 2016). Sixteen trials were at high risk of attrition bias
(Porter 1971; Campra 1973; Resnick 1974; Blitzer 1977; Halle
1982; Theodossi 1982; Radvan 1983; Bird 1991; Trinchet 1992;
Naveau2004; Stewart 2007;Nguyen-Khac 2011;Mathurin 2013;
De 2014; Park 2014; Thursz 2015). The remaining trials were at
unclear risk of attrition bias.
Alcohol-related liver disease (others)
Nine trialswere at low risk of attritionbias (Geminiani 1979; Pierri
1985; Bories 1987; Takase 1989; Lotterer 1995; Diaz Belmont
1996; Velussi 1997; Morgan 2005; Fernandez-Rodriguez 2008).
Eleven trials were at high risk of attrition bias (Fenster 1966;
Orrego 1979; Orrego 1987; Plevris 1991; Keiding 1994; De la
Maza 1995; Caballeria 1998; Stenner 2000; Cortez-Pinto 2002;
Lucena 2002; De Silva 2003). The remaining trials were at unclear
risk of attrition bias.
Selective reporting
Alcoholic hepatitis
We could find a published protocol for only one trial (Thursz
2015). Forty-one trials were at low risk of selecting outcome
reporting bias as they reported the important clinical out-
comes (mortality and adverse events) (Helman 1971; Porter
1971; Resnick 1974; Blitzer 1977; Maddrey 1978; Depew 1980;
Baker 1981; Serrano-Cancino 1981; Halle 1982; Mirouze 1982;
Theodossi 1982; Radvan 1983; Mendenhall 1984; Trinchet
1989a; Trinchet 1989b; Akriviadis 1990; Bird 1991; Trinchet
1992; Bird 1998; Akriviadis 2000; Spahr 2002; Mezey 2004;
Naveau 2004; Phillips 2006; Stewart 2007; Boetticher 2008; De
2009; Popescu 2009; Lebrec 2010; Moreno 2010; Nguyen-Khac
2011;GarridoGarcia 2012; Sidhu 2012a; Sidhu 2012b;Mathurin
2013; De 2014; Park 2014; Singh 2014; Higuera de la Tijera
2015; Thursz 2015; Tkachenko 2016). The remaining trials were
considered to be at high risk of selective outcome reporting bias
because they did not report either mortality or adverse events or
both, outcomes expected to bemeasured in such clinical outcomes.
Alcohol-related liver disease (others)
Wewere unable to find a published protocol for any trial. Ten trials
were at low risk of due to selecting outcome reporting bias as they
reported the important clinical outcomes (mortality and adverse
events) (Orrego 1979; Orrego 1987; Keiding 1994; De la Maza
1995; Pares 1998; Mato 1999; Cortez-Pinto 2002; Pelletier 2003;
Morgan 2005; Fernandez-Rodriguez 2008). The remaining trials
were considered to be at high risk of selective outcome reporting
bias because they reported neithermortality nor adverse events nor
both and these are outcomes expected otherwise to be measured
in such clinical outcomes.
Other potential sources of bias
Alcoholic hepatitis
Sixteen trials were at low risk of for-profit bias (Helman 1971;
Porter 1971; Maddrey 1978; Halle 1982; Carithers 1989;
Akriviadis 1990; Ramond 1992; Trinchet 1992; Bird 1998;Mezey
2004; Stewart 2007; Boetticher 2008; Sidhu 2012a; Park 2014;
Higuera de la Tijera 2015; Thursz 2015). Eleven trials funded by
pharmaceutical industry were considered to be at high risk of for-
profit bias (Resnick 1974; Blitzer 1977; Shumaker 1978; Baker
1981; Trinchet 1989a; Trinchet 1989b; Bird 1991; Akriviadis
2000; Spahr 2002; Naveau 2004; Mathurin 2013). The remain-
ing trials were at unclear risk of for-profit bias.
All the trials were at low of other bias.
Alcohol-related liver disease (others)
Three trials were at low risk of for-profit bias (Gluud 1986; Cortez-
Pinto 2002; Kim 2012). Twelve trials funded by pharmaceutical
industry were considered to be at high risk of for-profit bias (
Fenster 1966; Orrego 1979; Orrego 1987; Keiding 1994; De la
Maza 1995; Pares 1998;Mato 1999; Lucena 2002; De Silva 2003;
Pelletier 2003; Fernandez-Rodriguez 2008; Medici 2011). The
remaining trials were at unclear risk of for-profit bias.
All the trials were at low risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison
Glucocorticosteroids compared with no intervention for alcoholic
hepatitis (all severity); Summary of findings 2 Pentoxifylline
compared with no intervention for alcoholic hepatitis (all
severity); Summary of findings 3 Colchicine compared with
no intervention for alcoholic hepatitis (all severity); Summary
of findings 4 Insulin plus glucagon compared with no
intervention for alcoholic hepatitis (all severity); Summary of
findings 5 Propylthiouracil compared with no intervention
for alcoholic hepatitis (all severity); Summary of findings 6
Glucocorticosteroids compared with no intervention for severe
alcoholic hepatitis; Summary of findings 7 Pentoxifylline
compared with no intervention for severe alcoholic hepatitis;
Summary of findings 8 Anabolic steroids compared with no
intervention for alcohol-related disorders (others); Summary of
findings 9 Antioxidants compared with no intervention for
alcohol-related disorders (others); Summary of findings 10
Colchicine compared with no intervention for alcohol-related
disorders (others); Summary of findings 11 Propylthiouracil
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compared with no intervention for alcohol-related disorders
(others)
Alcoholic hepatitis
Mortality at maximal follow-up
A total of 48 trials including 4337 participants reported mortality
at maximal follow-up (Helman 1971; Porter 1971; Campra 1973;
Resnick 1974; Blitzer 1977; Maddrey 1978; Shumaker 1978;
Depew 1980; Baker 1981; Serrano-Cancino 1981; Halle 1982;
Mirouze 1982; Theodossi 1982; Radvan 1983;Mendenhall 1984;
Carithers 1989; Trinchet 1989a; Trinchet 1989b; Akriviadis 1990;
Bird 1991; McHutchinson 1991; Ramond 1992; Trinchet 1992;
Bird 1998; Akriviadis 2000; Spahr 2002; Mezey 2004; Naveau
2004; Stigliano 2005; Paladugu 2006; Phillips 2006; Stewart
2007; Boetticher 2008; De 2009; Popescu 2009; Lebrec 2010;
Moreno 2010; Nguyen-Khac 2011; Garrido Garcia 2012; Sidhu
2012a; Sidhu 2012b;Mathurin 2013; De 2014; Park 2014; Singh
2014; Higuera de la Tijera 2015; Thursz 2015; Tkachenko 2016)
(Analysis 1.1). The period of follow-up ranged from one month
to 12 months. The risk of mortality at maximal follow-up was
higher in the anti-tumour necrosis factor (anti-TNF) group versus
the no intervention group (odds ratio (OR) 4.64, 95% confidence
interval (CI) 1.31 to 16.42; 48 participants; 1 trial). There was
no evidence of differences in any of the remaining comparisons
of active interventions versus no intervention. The results did not
change using the random-effects model.
Early mortality (up to three months)
Thirty-days mortality
A total of 38 trials including 3433 participants reported 30-
days mortality (Porter 1971; Blitzer 1977; Maddrey 1978;
Shumaker 1978; Depew 1980; Baker 1981; Serrano-Cancino
1981; Halle 1982; Mirouze 1982; Theodossi 1982; Radvan
1983; Carithers 1989; Trinchet 1989a; Akriviadis 1990; Bird
1991; McHutchinson 1991; Ramond 1992; Trinchet 1992; Bird
1998; Spahr 2002; Naveau 2004; Stigliano 2005; Paladugu 2006;
Phillips 2006; Boetticher 2008; De 2009; Popescu 2009; Moreno
2010; Nguyen-Khac 2011; Garrido Garcia 2012; Sidhu 2012a;
Sidhu 2012b;Mathurin 2013; De 2014; Park 2014; Higuera de la
Tijera 2015; Thursz 2015; Tkachenko 2016) (Analysis 1.2). The
more conservative random-effects model was used. There was no
evidence of any differences in 30-days mortality in any of the com-
parisons comparing active intervention versus no intervention.
Ninety-days mortality
A total of 14 trials including 2027 participants reported 90-days
mortality (Helman 1971; Blitzer 1977; Trinchet 1989a; Trinchet
1989b; Ramond 1992; Trinchet 1992; Spahr 2002; Mezey 2004;
De 2009; Nguyen-Khac 2011; De 2014; Singh 2014; Higuera de
laTijera 2015;Thursz 2015) (Analysis 1.3). Therewas no evidence
of any differences in 90-days mortality in any of the comparisons
comparing active intervention versus no intervention. The results
did not change using the random-effects model.
Serious adverse events
Two trials (1140 participants) reported serious adverse events (pro-
portion) (Boetticher 2008; Thursz 2015) (Analysis 1.4). There
was no evidence of any differences in serious adverse events (pro-
portion) in any of the comparisons. There was only one trial in-
cluded in each comparison. Therefore, random-effects model is
not applicable.
Two trials (73 participants) reported serious adverse events (num-
ber) (Boetticher 2008; Naveau 2004) (Analysis 1.5). The number
of serious adverse events was higher in the anti-TNF group versus
the no intervention group (rate ratio 1.86; 95% CI 1.01 to 3.43).
The number of serious adverse events was higher in the glucocor-
ticosteroids plus anti-TNF group versus the glucocorticosteroids
group (rate ratio 4.72; 95% CrI 1.37 to 16.31). There was only
one trial included in each comparison. Therefore, random-effects
model is not applicable.
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Liver transplantation
A total of three trials including 530 participants reported liver
transplantation (Bird 1991; Nguyen-Khac 2011;Mathurin 2013)
(Analysis 1.6). There was no evidence of differences in any of the
comparisons. There was only one trial included in each compari-
son. Therefore, random-effects model is not applicable.
Decompensated cirrhosis
A total of 17 trials including 2405 participants reported decom-
pensated cirrhosis (Shumaker 1978; Depew 1980; Halle 1982;
Trinchet 1989a; Akriviadis 1990; Akriviadis 2000; Naveau 2004;
Paladugu 2006; Boetticher 2008; De 2009; Nguyen-Khac 2011;
Garrido Garcia 2012; Sidhu 2012a; Mathurin 2013; De 2014;
Higuera de la Tijera 2015; Thursz 2015) (Analysis 1.7). There
was no evidence of any differences in decompensated cirrhosis in
any of the comparisons comparing active intervention versus no
intervention. The results did not change using the random-effects
model.
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Cirrhosis
One trial including 37 participants reported new onset cirrhosis
(Helman 1971) (Analysis 1.8). There was no evidence of differ-
ence in the proportion of people who developed cirrhosis between
glucocorticosteroids and no intervention groups (OR 1.32, 95%
CI 0.19 to 9.02).
Hepatocellular carcinoma
None of the trials reported hepatocellular carcinoma.
Any adverse events
A total of 21 trials including 1458 participants reported ad-
verse events (proportion) (Porter 1971; Blitzer 1977; Maddrey
1978; Baker 1981; Halle 1982; Theodossi 1982; Trinchet 1989a;
Trinchet 1989b; Bird 1991; Bird 1998; Akriviadis 2000; Spahr
2002; Naveau 2004; Phillips 2006; Stewart 2007; Boetticher
2008; Popescu 2009; Moreno 2010; Sidhu 2012b; Mathurin
2013; Singh 2014) (Analysis 1.9). The proportion of people with
any adverse events was higher in the glucocorticosteroids group
(OR 4.00, 95% CI 1.80 to 8.88; 159 participants; 4 trials) and in
the pentoxifylline group (OR2.21, 95%CI 1.10 to 4.46; 151 par-
ticipants = 151; 2 trials) versus the no intervention group. There
was no evidence of any differences in any adverse events (propor-
tion) in any of the remaining comparisons comparing active inter-
vention versus no intervention. The results did not change using
the random-effects model.
A total of 32 trials including 3221 participants reported ad-
verse events (number) (Porter 1971; Blitzer 1977; Maddrey
1978; Shumaker 1978; Depew 1980; Baker 1981; Halle 1982;
Theodossi 1982; Trinchet 1989a; Akriviadis 1990; Bird 1991;
Bird 1998; Akriviadis 2000; Spahr 2002; Naveau 2004; Phillips
2006; Stewart 2007; Boetticher 2008; De 2009; Popescu 2009;
Moreno 2010; Nguyen-Khac 2011; Garrido Garcia 2012; Sidhu
2012a; Sidhu 2012b;Mathurin 2013; De 2014; Park 2014; Singh
2014; Higuera de la Tijera 2015; Thursz 2015; Tkachenko 2016)
(Analysis 1.10). The more conservative random-effects model was
used. The number of any adverse events was higher in the anti-
TNF group versus the no intervention group (rate ratio 2.26, 95%
CI 1.05 to 4.85; 48 participants; 1 trial) and in the glucocorticos-
teroids group (rate ratio 1.43, 95% CI 1.10 to 1.87; 760 partici-
pants; 7 trials) versus the no intervention group (rate ratio 1.34;
95% CrI 1.02 to 1.76; 201 participants; 2 trials). There was no
evidence of any differences in any adverse events (number) in any
of the remaining comparisons comparing active intervention ver-
sus no intervention.
Subgroup analysis and sensitivity analysis
We did not perform any subgroup analysis other than performing
an analysis of a subset of trials including severe alcoholic hepatitis
exclusively, which we have presented below. We did not perform
the other subgroup analyses because all the trials were at high risk
of bias; separate data were not available in biopsy-confirmed al-
cohol-related liver disease in many trials, and because of the few
trials included in each comparison. We did not perform a sensi-
tivity analysis since the reasons for dropouts were not adequately
described in each intervention group to perform ameaningful sen-
sitivity analysis.
Reporting bias
As there was only comparison with more than 10 trials (glucocor-
ticosteroids versus no intervention), we explored reporting bias via
funnel plot for this comparison only. Although the Egger’s test did
not reveal any evidence of reporting bias (P = 0.11), visualisation
appears to suggest that there was reporting bias favouring gluco-
corticoids.
Sample size calculations and Trial Sequential Analysis
As shown in Figure 4, Figure 5, and Figure 6, the accrued sample
sizes were only small fractions of the diversity-adjusted required
information size (DARIS). The Z-curve did not cross any of the
trial sequential boundaries indicating that there was a high risk of
random errors. The Trial Sequential Analysis-adjusted CIs were as
follows.
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Figure 4. Trial Sequential Analysis of mortality at maximal follow-up (alcoholic hepatitis):
glucocorticosteroids versus no intervention and pentoxifylline versus no intervention.Based on an alpha error
of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion
observed in the trials (Pc = 34.8%), and diversity observed in the analyses (78% and 56%), the accrued sample
size (1147 participants for glucocorticosteroids versus no intervention and 881 participants for pentoxifylline
versus no intervention) was lower than the diversity-adjusted required information size (DARIS) (10,187
participants for glucocorticosteroids versus no intervention and 5232 participants for pentoxifylline versus no
intervention). The Z-curve (blue line) crosses the conventional boundaries (dotted green lines) favouring
glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional
boundaries after the large trial (Thursz 2015). The Z-curve does not cross any of trial sequential monitoring
boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these
comparisons.
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Figure 5. Trial Sequential Analysis of mortality at maximal follow-up (alcoholic hepatitis): colchicine versus
no intervention and insulin plus glucagon versus no intervention.Based on an alpha error of 2.5%, power of 90%
(beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials
(Pc = 34.8%), and diversity observed in the analyses (0% and 52%), the accrued sample size (139 participants for
colchicine versus no intervention and 265 participants for insulin plus glucagon versus no intervention) was
lower than the diversity-adjusted required information size (DARIS) (2205 participants for colchicine versus no
intervention and 4579 participants for insulin plus glucagon versus no intervention). The Z-curve (blue line)
does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries
(dotted red lines). This indicates that there is a high risk of random errors in both these comparisons.
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Figure 6. Trial Sequential Analysis of mortality at maximal follow-up (alcoholic hepatitis): propylthiouracil
versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk
reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed
in the analyses (0%), the accrued sample size (108 participants) was only a small proportion of the diversity-
adjusted required information size (DARIS) (2205 participants); therefore, the trial sequential monitoring
boundaries were not drawn.The Z-curve (blue line) does not cross the conventional boundaries (dotted green
lines). This indicates that there is a high risk of random errors in this comparison.
• Glucocorticosteroids versus no intervention: 0.66 (95% CI
0.07 to 6.05).
• Pentoxifylline versus no intervention: 0.77 (95% CI 0.25 to
2.39).
• Colchicine versus no intervention: 1.31 (95% CI 0.02 to
84.61).
• Insulin plus glucagon versus no intervention: 1.14 (95% CI
0.14 to 9.14).
• Propylthiouracil versus no intervention: not estimable (as
the accrued sample size was very small).
These wide confidence intervals indicate that there is high risk of
random error.
Quality of the evidence
The quality of the evidence was low or very low for all the out-
comes (Summary of findings for the main comparison; Summary
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of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5). The reasons for downgrading include:
high risk of bias in trials (downgraded by one level), heterogene-
ity in some comparisons as evidenced by differences in the effect
estimates obtained by the fixed-effect model and random-effects
model (downgraded by one level), imprecision (small sample size;
downgraded by one level), and imprecision (confidence intervals
overlapped a clinically significant increase or reduction and clini-
cally insignificant increase or reduction; downgraded by one level).
Subset of trials including severe alcoholic hepatitis
exclusively
Mortality at maximal follow-up
A total of 18 trials including 2477 participants reported mor-
tality at maximal follow-up (Ramond 1992; Akriviadis 2000;
Spahr 2002; Naveau 2004; Paladugu 2006; De 2009; Moreno
2010; Nguyen-Khac 2011; Garrido Garcia 2012; Sidhu 2012a;
Sidhu 2012b; Mathurin 2013; De 2014; Park 2014; Singh 2014;
Higuera de laTijera 2015;Thursz 2015;Tkachenko 2016) (Analy-
sis 2.1). The follow-up varied between one month and 12 months.
There was no evidence of any differences in mortality at maximal
follow-up in any of the comparisons comparing active interven-
tion versus no intervention. The results did not change using the
random-effects model.
Early mortality (up to three months)
Thirty-days mortality
A total of 16 trials including 2330 participants reported 30-days
mortality (Ramond 1992; Spahr 2002; Naveau 2004; Paladugu
2006; De 2009; Moreno 2010; Nguyen-Khac 2011; Garrido
Garcia 2012; Sidhu 2012a; Sidhu 2012b; Mathurin 2013; De
2014; Park 2014; Higuera de la Tijera 2015; Thursz 2015;
Tkachenko 2016) (Analysis 2.2). There was no evidence of any
differences in 30-days mortality in any of the comparisons com-
paring active intervention versus no intervention. The results did
not change using the random-effects model.
Ninety-days mortality
A total of eight trials including 1656 participants reported 90-days
mortality (Ramond 1992; Spahr 2002; De 2009; Nguyen-Khac
2011; De 2014; Singh 2014; Higuera de la Tijera 2015; Thursz
2015) (Analysis 2.3). There was no evidence of any differences
in 90-days mortality in any of the comparisons comparing active
intervention versus no intervention. The results did not change
using the random-effects model.
Serious adverse events
Only one trial (1092 participants; four interventions) reported se-
rious adverse events (proportion) (Thursz 2015) (Analysis 2.4).
There was no evidence of differences in any of the comparisons.
Only one trial (35 participants) reported serious adverse events
(number) (Naveau 2004) (Analysis 2.6). The number of serious
adverse events was higher in the glucocorticosteroids plus anti-
TNF group versus the glucocorticosteroids group (rate ratio 4.72;
95% CI 1.37 to 16.31). As there was only one trial in each com-
parison, the issue of random-effects model did not arise.
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Liver transplantation
A total of two trials including 444 participants reported liver trans-
plantation (Nguyen-Khac 2011; Mathurin 2013) (Analysis 2.6).
There was no evidence of differences in any of the comparisons. As
there was only one trial in each comparison, the issue of random-
effects model did not arise.
Decompensated cirrhosis
A total of 11 trials including 2095 participants reported decom-
pensated cirrhosis (Akriviadis 2000;Naveau2004; Paladugu 2006;
De 2009;Nguyen-Khac 2011;GarridoGarcia2012; Sidhu2012a;
Mathurin 2013; De 2014; Higuera de la Tijera 2015; Thursz
2015) (Analysis 2.7). There was no evidence of any differences
in decompensated cirrhosis in any of the comparisons compar-
ing active intervention versus no intervention. The results did not
change using the random-effects model.
Cirrhosis
None of the trials reported the proportionof peoplewhodeveloped
cirrhosis.
Hepatocellular carcinoma
None of the trials reported the proportionof peoplewhodeveloped
hepatocellular carcinoma.
Any adverse events
A total of four trials including 241 participants reported ad-
verse events (proportion) (Akriviadis 2000; Moreno 2010; Sidhu
2012b; Singh 2014) (Analysis 2.8). The proportion of people with
any adverse events was higher in the pentoxifylline group versus
the no intervention group (OR 2.21, 95% CI 1.10 to 4.46; 151
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participants = 151; 2 trials). There was no evidence of any differ-
ences in any adverse events (proportion) in any of the remaining
comparisons comparing active intervention versus no interven-
tion. The results did not change using the random-effects model.
A total of 16 trials including 2386 participants reported adverse
events (number) (Akriviadis 2000; Spahr 2002; Naveau 2004; De
2009; Moreno 2010; Nguyen-Khac 2011; Garrido Garcia 2012;
Sidhu 2012a; Sidhu 2012b;Mathurin 2013; De 2014; Park 2014;
Singh 2014; Higuera de la Tijera 2015; Thursz 2015; Tkachenko
2016) (Analysis 2.9). There was no evidence of any differences in
any adverse events (number) in any of the comparisons comparing
active intervention versus no intervention. The results did not
change using the random-effects model.
Subgroup analysis and sensitivity analysis
We did not perform any subgroup analysis because all the trials
were at high risk of bias; separate data were not available in biopsy-
confirmed alcohol-related liver disease in many trials, and because
of the few trials included in each comparison. We did not perform
a sensitivity analysis since the reasons for dropouts were not ade-
quately described in each intervention group to perform a mean-
ingful sensitivity analysis.
Reporting bias
As there was no comparison including more than 10 trials, we did
not explore reporting bias.
Sample size calculations and Trial Sequential Analysis
As shown in Figure 7, the accrued sample sizes were only
small fractions of the diversity-adjusted required information size
(DARIS).The Z-curve did not cross any of the trial sequential
boundaries indicating that there was a high risk of random errors.
The Trial Sequential Analysis-adjusted CIs were as follows.
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Figure 7. Trial Sequential Analysis of mortality at maximal follow-up (severe alcoholic hepatitis):
glucocorticosteroids versus no intervention and pentoxifylline versus no intervention.Based on an alpha error
of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion
observed in the trials (Pc = 40.9%), and diversity observed in the analyses (98% and 76%), the accrued sample
size (607 participants for glucocorticosteroids versus no intervention and 726 participants for pentoxifylline
versus no intervention) was lower than the diversity-adjusted required information size (DARIS) (72,755
participants for glucocorticosteroids versus no intervention and 7148 participants for pentoxifylline versus no
intervention). For glucocorticosteroids versus no intervention, the accrued sample size was so small that the
trial sequential monitoring boundaries were not drawn. The Z-curve (blue line) crosses the conventional
boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but
does not cross the conventional boundaries after the large trial (Thursz 2015). The Z-curve does not cross any
of trial sequential monitoring boundaries (dotted red lines) for pentoxifylline versus no intervention. This
indicates that there is a high risk of random errors in both these comparisons.
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• Glucocorticosteroids versus no intervention: not estimable
(as the accrued sample size was only a small fraction of required
information size).
• Pentoxifylline versus no intervention: 0.60 (95% CI 0.05 to
7.48).
These wide confidence intervals indicate that there is high risk of
random error.
Quality of the evidence
The quality of the evidence was low or very low for all the out-
comes (Summary of findings 6; Summary of findings 7). The rea-
sons for downgrading include: high risk of bias in trials (down-
graded by one level), imprecision (small sample size; downgraded
by one level), and imprecision (confidence intervals overlapped a
clinically significant increase or reduction and clinically insignifi-
cant increase or reduction; downgraded by one level).
Alcohol-related liver diseases (others)
Mortality at maximal follow-up
A total of 16 trials including 2727 participants reported mor-
tality at maximal follow-up (Fenster 1966; Geminiani 1979;
Orrego 1979; Pierri 1985; Gluud 1986; Bories 1987; Orrego
1987; Keiding 1994; De la Maza 1995; Fleig 1997; Caballeria
1998; Pares 1998; Mato 1999; Cortez-Pinto 2002; Pelletier 2003;
Morgan 2005) (Analysis 3.1). The period of follow-up ranged
from one month to 48 months. The risk of mortality at maximal
follow-up was lower in the propylthiouracil group versus the no
intervention group (OR 0.45, 95% CI 0.26 to 0.78; 423 partic-
ipants; 2 trials). The risk of mortality at maximal follow-up was
higher in the ursodeoxycholic acid group versus the no interven-
tion group (OR 2.09, 95% CI 1.12 to 3.90; 226 participants; 1
trial). There was no evidence of difference in any of the remaining
comparisons.
Early mortality (up to three months)
Thirty-days mortality
A total of six trials including 580 participants reported 30-days
mortality (Geminiani 1979; Orrego 1979; Pierri 1985; Bories
1987; Caballeria 1998; Pelletier 2003) (Analysis 3.2). There was
no evidence of difference in any of the comparisons. There was
only one trial included in each comparison. Therefore, random-
effects model was not applicable.
Ninety-days mortality
A total of three trials including 208 participants reported 90-days
mortality (Pierri 1985; Bories 1987; Mato 1999) (Analysis 3.3).
There was no evidence of difference in any of the comparisons.
There was only one trial included in each comparison. Therefore,
random-effects model was not applicable.
Serious adverse events
Only one trial (37 participants) reported serious adverse events
(proportion) (Medici 2011) (Analysis 3.4). There were no serious
adverse events in either SAMe or no intervention groups. None of
the trials reported serious adverse events (number).
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Liver transplantation
Only one trial including 123 participants reported liver transplan-
tation (Mato 1999) (Analysis 3.5). There was no evidence of dif-
ference between SAMe and no intervention (OR 0.32, 95% CI
0.03 to 3.13; 123 participants; 1 trial).
Decompensated cirrhosis
A total of three trials including 1182 participants reported decom-
pensated cirrhosis (Keiding 1994; Pelletier 2003; Morgan 2005)
(Analysis 3.6). There was no evidence of difference in any of the
comparisons. There was only one trial included in each compari-
son. Therefore, random-effects model was not applicable.
Cirrhosis
None of the trials reported the proportionof peoplewhodeveloped
cirrhosis.
Hepatocellular carcinoma
A total of two trials including 344 participants reported hepatocel-
lular carcinoma (Gluud 1986; Mato 1999) (Analysis 3.7). There
was no evidence of difference in any of the comparisons. There was
only one trial included in each comparison. Therefore, random-
effects model was not applicable.
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Any adverse events
A total of 18 trials including 2342 participants reported ad-
verse events (proportion) (Orrego 1979; Orrego 1987; Feher
1989; Takase 1989; Plevris 1991; Keiding 1994; Lotterer 1995;
Diaz Belmont 1996; Velussi 1997; Caballeria 1998; Pares 1998;
Mato 1999; Cortez-Pinto 2002; De Silva 2003; Morgan 2005;
Fernandez-Rodriguez 2008; Medici 2011; Kim 2012) (Analysis
3.8). There was no evidence of difference in any of the compar-
isons. Using the random-effects model, there was no alteration in
the results.
A total of 11 trials including 1965 participants reported ad-
verse events (number) (Caballeria 1998; Cortez-Pinto 2002;
Fernandez-Rodriguez 2008; Keiding 1994; Mato 1999; Medici
2011; Morgan 2005; Orrego 1979; Orrego 1987; Pares 1998;
Plevris 1991) (Analysis 3.9). There was no evidence of difference
in any of the comparisons. Changing the model from fixed-effect
model to random-effects model did not alter the conclusions.
Subgroup analysis and sensitivity analysis
We did not perform any subgroup analysis because all the trials
were at high risk of bias; separate data were not available in biopsy-
confirmed alcohol-related liver disease in many trials, and because
of the few trials included in each comparison. We did not perform
a sensitivity analysis because the reasons for dropouts were not ad-
equately described in each intervention group in order to perform
a meaningful sensitivity analysis.
Reporting bias
Since there was no comparison with more than 10 trials, we did
not explore reporting bias.
As shown in Figure 8 and Figure 9, the accrued sample sizes were
only small fractions of the diversity-adjusted required information
size (DARIS).The Z-curve did not cross any of the trial sequential
boundaries indicating that there was a high risk of random errors.
The Trial Sequential Analysis-adjusted CIs were as follows.
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Figure 8. Trial Sequential Analysis of mortality at maximal follow-up (alcohol-related disorders (others)):
anabolic steroids versus no intervention and antioxidants versus no intervention.Based on an alpha error of
2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion
observed in the trials (Pc = 25.2%), and diversity observed in the analyses (0% in the both the comparisons),
the accrued sample size (248 participants for anabolic steroids versus no intervention and 255 participants for
antioxidants versus no intervention) was lower than the diversity-adjusted required information size (DARIS)
(3428 participants for both comparisons). The Z-curve (blue line) does not cross the conventional boundaries
(dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there
is a high risk of random errors in both these comparisons.
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Figure 9. Trial Sequential Analysis of mortality at maximal follow-up (alcohol-related disorders (others)):
colchicine versus no intervention and propylthiouracil versus no intervention.Based on an alpha error of 2.5%,
power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed
in the trials (Pc = 25.2%), and diversity observed in the analyses (44% and 0%), the accrued sample size (604
participants for colchicine versus no intervention and 423 participants for propylthiouracil versus no
intervention) was lower than the diversity-adjusted required information size (DARIS) (6071 participants for
colchicine versus no intervention and 3428 participants for propylthiouracil versus no intervention). For the
comparison of colchicine versus no intervention, the Z-curve (blue line) does not cross the conventional
boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). For the
comparison, propylthiouracil versus no intervention, the Z-curve crosses the conventional boundaries while it
does not cross the trial sequential monitoring boundaries. This indicates that there is a high risk of random
errors in both these comparisons.
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• Anabolic steroids versus no intervention: 1.29 (95% CI
0.11 to 15.86).
• Antioxidants versus no intervention: 1.96 (95% CI 0.12 to
31.91).
• Colchicine versus no intervention: 1.11 (95% CI 0.30 to
4.15).
• Propylthiouracil versus no intervention: 0.45 (95% CI 0.05
to 4.13).
These wide confidence intervals indicate that there is high risk of
random error.
Quality of the evidence
The quality of the evidencewas lowor very low for all the outcomes
(Summary of findings 8; Summary of findings 9; Summary of
findings 10; Summary of findings 11). The reasons for downgrad-
ing include: high risk of bias in trials (downgraded by one level),
heterogeneity in some comparisons as evidenced by differences in
the effect estimates obtained by fixed-effect model and random-
effects model (downgraded by one level), imprecision (small sam-
ple size; downgraded by one level), and imprecision (confidence
intervals overlapped a clinically significant increase or reduction
and clinically insignificant increase or reduction; downgraded by
one level).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)
Patient or population: part icipants with alcoholic hepat it is (all severity)
Settings: secondary or tert iary care
Intervention: pentoxif ylline
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Pentoxifylline
M ortality at maximal fol-
low-up
Follow-up: 1 to 12 months
348 per 1000 331 per 1000
(271 to 396)
OR 0.77
(0.58 to 1.02)
881
(6 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
217 per 1000 431 per 1000
(342 to 528)
OR 1.18
(0.81 to 1.74)
545
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 12 months
390 per 1000 406 per 1000
(327 to 491)
OR 1.07
(0.76 to 1.51)
545
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Colchicine compared with no intervention for alcoholic hepatitis (all severity)
Patient or population: part icipants with alcoholic hepat it is (all severity)
Settings: secondary or tert iary care
Intervention: colchicine
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Colchicine
M ortality at maximal fol-
low-up
Follow-up: 3 to 4 months
348 per 1000 86 per 1000
(32 to 206)
OR 1.31
(0.47 to 3.64)
139
(2 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
217 per 1000 185 per 1000
(9 to 853)
OR 3.18
(0.13 to 81.01)
69
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)
Patient or population: part icipants with alcoholic hepat it is (all severity)
Settings: secondary or tert iary care
Intervention: insulin plus glucagon
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Insulin plus glucagon
M ortality at maximal fol-
low-up
Follow-up: 1 to 6 months
348 per 1000 423 per 1000
(307 to 550)
OR 1.14
(0.69 to 1.90)
265
(5 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
217 per 1000 623 per 1000
(371 to 821)
OR 2.57
(0.92 to 7.15)
72
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)
Patient or population: part icipants with alcoholic hepat it is (all severity)
Settings: secondary or tert iary care
Intervention: propylthiouracil
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Propylthiouracil
M ortality at maximal fol-
low-up
Follow-up: 1 to 2 months
348 per 1000 427 per 1000
(243 to 636)
OR 1.16
(0.50 to 2.72)
108
(2 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
None of the trials reported this outcome.
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis
Patient or population: part icipants with severe alcoholic hepat it is
Settings: secondary or tert iary care
Intervention: glucocort icosteroids
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Glucocorticosteroids
M ortality at maximal fol-
low-up
Follow-up: 2 to 12 months
409 per 1000 378 per 1000
(304 to 456)
OR 0.88
(0.63 to 1.21)
607
(2 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
272 per 1000 274 per 1000
(210 to 348)
OR 1.01
(0.71 to 1.43)
607
(2 trials)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 12 months
390 per 1000 467 per 1000
(385 to 552)
OR 1.37
(0.98 to 1.93)
546
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Pentoxifylline compared with no intervention for severe alcoholic hepatitis
Patient or population: part icipants with severe alcoholic hepat it is
Settings: secondary or tert iary care
Intervention: pentoxif ylline
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Pentoxifylline
M ortality at maximal fol-
low-up
Follow-up: 1 to 12 months
409 per 1000 356 per 1000
(290 to 425)
OR 0.80
(0.59 to 1.07)
726
(4 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
272 per 1000 306 per 1000
(232 to 394)
OR 1.18
(0.81 to 1.74)
545
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 12 months
390 per 1000 406 per 1000
(327 to 491)
OR 1.07
(0.76 to 1.51)
545
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Anabolic steroids compared with no intervention for alcohol- related disorders (others)
Patient or population: alcohol-related disorders (others)
Settings: secondary or tert iary care
Intervention: anabolic steroids
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Anabolic steroids
M ortality at maximal fol-
low-up
Follow-up: 6 to 28 months
252 per 1000 303 per 1000
(191 to 446)
OR 1.29
(0.70 to 2.39)
248
(2 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
None of the trials reported this outcome.
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Antioxidants compared with no intervention for alcohol- related disorders (others)
Patient or population: alcohol-related disorders (others)
Settings: secondary or tert iary care
Intervention: ant ioxidants
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Antioxidants
M ortality at maximal fol-
low-up
Follow-up: 12 to 24 months
252 per 1000 398 per 1000
(250 to 567)
OR 1.96
(0.99 to 3.89)
255
(2 trials)
⊕©©©
very low1,2,3,4
Early mortality (mortality
up to 90 days)
None of the trials reported this outcome.
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Colchicine compared with no intervention for alcohol- related disorders (others)
Patient or population: alcohol-related disorders (others)
Settings: secondary or tert iary care
Intervention: colchicine
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Colchicine
M ortality at maximal fol-
low-up
Follow-up: 41 to 48 months
252 per 1000 272 per 1000
(212 to 340)
OR 1.11
(0.80 to 1.53)
604
(2 trials)
⊕©©©
very low1,2,3
Early mortality (mortality
up to 90 days)
None of the trials reported this outcome.
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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Propylthiouracil compared with no intervention for alcohol- related disorders (others)
Patient or population: alcohol-related disorders (others)
Settings: secondary or tert iary care
Intervention: propylthiouracil
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Propylthiouracil
M ortality at maximal fol-
low-up
Follow-up: 1 to 24 months
252 per 1000 132 per 1000
(81 to 208)
OR 0.45
(0.26 to 0.78)
423
(2 trials)
⊕⊕©©
low1,2
Early mortality (mortality
up to 90 days)
None of the trials reported this outcome.
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
5
0
P
h
a
rm
a
c
o
lo
g
ic
a
l
in
te
r
v
e
n
tio
n
s
fo
r
a
lc
o
h
o
lic
liv
e
r
d
ise
a
se
(a
lc
o
h
o
l-re
la
te
d
liv
e
r
d
ise
a
se
)
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded one level)
2Imprecision: small sample size (downgraded one level)
3Imprecision: Conf idence intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (downgraded one level).
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D I S C U S S I O N
Summary of main results
Alcoholic hepatitis
A total of 50 trials (4484 participants with alcoholic hepatitis)
were included under this comparison. A total of 48 trials (4335
participants) contributed to one or more outcomes. The type of
participants included in the trials appeared to have different sever-
ity. Therefore, network meta-analysis was inappropriate because
of the possible violation of transitivity assumption. None of the
active interventions reduced mortality at any time point versus
no intervention. On the other hand, anti-tumour necrosis factor
(anti-TNF) may increase the complications and mortality. None
of the trials reported health-related quality of life. There was no
improvement in any of the clinical outcomes such as cirrhosis,
decompensated cirrhosis, liver transplantation by any active inter-
ventions compared with no intervention. None of the trials re-
ported the proportion of participants who developed hepatocel-
lular carcinoma. Overall, there does not appear to be any benefit
with any active intervention in participants with alcoholic hepati-
tis. However, it should be noted that the trials included were at
high risk of bias and quality of the evidence was low, as described
below. So, there is significant uncertainty in this.
Severe acute alcoholic hepatitis
A total of 19 trials (2545 participants with severe alcoholic hep-
atitis) were included under this comparison. A total of 18 trials
(2477 participants) contributed to one or more outcomes. Al-
though the type of participants included in the trials appeared to
be similar across comparisons (Appendix 4), there was evidence
of inconsistency by one or more methods in all the outcomes in
which it was possible to assess inconsistency. Therefore, we have
presented the results of networkmeta-analysis in the appendix and
have presented only the main comparisons. As for the participants
with alcoholic hepatitis of any severity, there was no evidence of
differences indicating any clinical benefit of any active interven-
tions versus no intervention. On the other hand, anti-TNF may
increase the complications.
Based on the network meta-analysis (which we have presented in
the appendix because of the uncertainty about the reliability of the
results), it appears that granulocyte stimulation factor (GSF) plus
pentoxifylline, glucocorticosteroids plus metadoxine, and pentox-
ifylline plus metadoxine may decrease mortality at maximal fol-
low-up compared with no intervention. However, it should be
noted that these estimates are based on indirect comparisons and
were based on single small trials. While these interventions war-
rant further investigation by direct comparisons in new trials, it is
not appropriate to recommend these interventions based on the
network meta-analysis results.
Alcohol-related liver disease (others)
A total of 31 trials (3695 participants with different phases of al-
cohol-related liver disease) were included under this comparison.
A total of 26 trials (3212 participants) contributed to one or more
outcomes. The risk of mortality at maximal follow-up was lower
in the propylthiouracil group versus the no intervention group
and higher in the ursodeoxycholic acid group versus the no in-
tervention group. However, the trials which were included in the
comparison between propylthiouracil and no intervention were
reported in 1979 and 1987. These were small trials of high risk of
bias. In addition, the risk of random errors was high as demon-
strated by Trial Sequential Analysis. As a result, trials of low risk of
bias of sufficient sample size are required before propylthiouracil
can be recommended routinely.
Health-related quality of life and the incidence of cirrhosis was
not reported in any of the trials. There was no evidence of any
clinical benefit in terms of decompensated cirrhosis or liver trans-
plantation. Therefore, there is nothing to suggest that any active
intervention improves clinical outcomes in people with any type
of alcohol-related liver disease.
Overall completeness and applicability of
evidence
In this review, we have included all the randomised clinical trials
on people with alcohol-related liver disease with and without ev-
idence of alcoholic hepatitis. However, the majority of the trials
excluded participants with infection or gastrointestinal bleeding.
This is likely to be because of the harmful effect of glucocorticos-
teroids, which were used in many of the trials either alone or in
combination. Therefore, the findings of the review are only appli-
cable in people with alcoholic hepatitis or other forms of alcoholic
liver disease who do not have infections or gastrointestinal bleed-
ing.
Quality of the evidence
The overall quality of the evidence was low or very low for all the
comparisons. The quality of the evidence was low or very low for
all the outcomes. The reasons for downgrading include: high risk
of bias in trials (downgraded by one level), imprecision (small sam-
ple size; downgraded by one level), and imprecision (confidence
intervals overlapped a clinically significant increase or reduction
and clinically insignificant increase or reduction; downgraded by
one level).
Potential biases in the review process
We selected a range of databases without any language restrictions.
We did not rely on the network meta-analysis results when we
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suspected the transitivity assumption may not be true or when the
evidence was based on small trials of high risk of bias. In addition,
we have performed the analysis using the fixed-effectmodel and the
random-effects model, and used the more conservative model. We
have also assessed the risk of random errors using Trial Sequential
Analysis. These are the strengths of the review process.
We have excluded studies which compared variations in duration
or dose in the different treatments. Hence this review does not
provide information on whether one variation is better than other.
Another major limitation of the review was the paucity of data.
There were few trials included under each comparison. In many
comparisons, there was only one trial included under the compar-
ison. This makes it difficult to assess whether the effect estimates
are reproducible. This paucity of data decreases the confidence in
the results.
We only included randomised clinical trials which are known to
focus mostly on benefits and do not collect and report harms in a
detailed manner. According to our choice of studies (i.e. only ran-
domised clinical trials), we might have missed a large number of
studies that address reporting of harms. Accordingly, this review is
biased towards benefits ignoring harms. We did not search for in-
terventions and trials registered at regulatory authorities (e.g. FDA
(US Food and Drug Administration); EMA (EuropeanMedicines
Agency), etc). This may have overlooked trials and as such trials
usually are unpublished, the lack of inclusion of such trials may
make our comparisons look more advantageous than they really
are.
Agreements and disagreements with other
studies or reviews
We identified one other network meta-analysis on severe alcoholic
hepatitis (Singh 2015). The authors concluded that in patients
with severe alcoholic hepatitis, pentoxifylline and corticosteroids
(alone and in combination with pentoxifylline or N-acetyl cys-
teine) can reduce 30-day mortality. No intervention decreases risk
of mortality between three months and 12 months. Our conclu-
sions differ because we did not rely on the results of the network
meta-analysis of uncertain reliability.
Our conclusions also differ from the Cochrane review on propy-
lthiouracil (Fede 2011). This was because we performed a sepa-
rate analysis of alcoholic hepatitis and other alcoholic liver disease.
Our review agrees with the findings of the Cochrane review on
pentoxifylline, which concluded that the evidence on the effect of
pentoxifylline was inconclusive (Whitfield 2009). The findings of
our review do not agree with the findings of a systematic review
onglucocorticosteroidswhich concluded that glucocorticosteroids
might be effective in people with severe alcoholic hepatitis and
that further randomised clinical trials were necessary (Rambaldi
2008). A large randomised clinical trial demonstrating no evidence
of effect of glucocorticosteroids or pentoxifylline, or their combi-
nation on people with severe alcoholic disease was published by
Thursz 2015, and whether this trial will change the conclusions
of the meta-analysis by Rambaldi 2008 or not may become ev-
ident when an update of this review is published by Pavlov and
colleagues later this year (Pavlov 2016).
We also disagree with EASL (European Association for the Study
of Liver) and AASLD (American Association for the Study of Liver
Diseases), which recommend glucocorticosteroids in people with
severe alcoholic hepatitis and pentoxifylline in people with con-
traindications to glucocorticosteroids (O’Shea 2010; EASL2012).
This again may be due to the recent publication of a large trial
(of more than 1000 participants) with at least 500 participants
included for each pairwise comparison between glucocorticos-
teroids, pentoxifylline, a combination of the above, and placebo.
In this trial, there was no evidence of any benefit of treatment, as
opposed to previous small trials, some of which showed benefits
and some of which did not show any evidence of benefit of these
drugs (Thursz 2015). This may also be because of improvement
in general medical care for these patients, which means that the
treatment effect might have reduced.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Because of very low-quality evidence, there is uncertainty in the
effectiveness of any pharmacological intervention versus no in-
tervention in people with alcoholic hepatitis or severe alcoholic
hepatitis. Based on low-quality evidence, propylthiouracil may de-
crease mortality in people with other alcohol-related liver diseases.
However, these have to be confirmed by adequately powered trials
with low risk of bias before propylthiouracil can be considered
effective.
Implications for research
Large randomised clinical trials should be conducted with approx-
imately 200 participants in each group to compare the benefits
and harms of different interventions in people with alcoholic hep-
atitis. The interventions compared should include no interven-
tion (placebo) as the one of the trial groups. They may also in-
clude glucocorticosteroids, pentoxifylline, and combinations in-
volving these drugs such as granulocyte stimulation factor (GSF)
plus pentoxifylline, pentoxifylline plus metadoxine, or glucocorti-
costeroids as one of the intervention groups as these combinations
appear to decreasemortality based on networkmeta-analysis. Such
trials should follow up participants for at least one to two years
and should include health-related quality of life and report serious
adverse events separately from adverse events. The trials should
be designed and reported using guidance from SPIRIT statement
(Chan 2013) and CONSORT statements (Schulz 2010).
53Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A C K N OW L E D G E M E N T S
We thank the Cochrane Comparing of Multiple Interventions
Methods Group and the CochraneHepato-Biliary Group for their
support and advice. We thank the copy-editors for their support.
Peer reviewers of the review:Theis Lange,Denmark; AdrianiNiko-
lakopolou, Greece.
Contact Editor: Christian Gluud, Denmark.
Sign-off Editor: Christian Gluud, Denmark.
Cochrane Review Group funding acknowledgement: The Danish
State is the largest single funder of the Cochrane Hepato-Biliary
Group through its investment in The Copenhagen Trial Unit,
Centre for Clinical Intervention Research, Rigshospitalet, Copen-
hagen University Hospital, Denmark. Disclaimer: The views and
opinions expressed in this review are those of the authors and do
not necessarily reflect those of the Danish State or The Copen-
hagen Trial Unit.
R E F E R E N C E S
References to studies included in this review
Akriviadis 1990 {published data only}
Akriviadis EA, Steindel H, Pinto PC, Fong TL, Kanel
G, Reynolds TB, et al. Failure of colchicine to improve
short-term survival in patients with alcoholic hepatitis.
Gastroenterology 1990;99:811–8.
Akriviadis 2000 {published data only}
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T,
Shakil O. Improved short-term survival with pentoxifylline
treatment in severe acute alcoholic hepatitis. Hepatology
1997;26(4 (Pt 2)):250a.
∗ Akriviadis E, Botla R, Briggs W, Han S, Reynolds T,
Shakil O. Pentoxifylline improves short-term survival in
severe acute alcoholic hepatitis: a double-blind, placebo-
controlled trial. Gastroenterology 2000;119:1637–48.
Baker 1981 {published data only}
∗ Baker AL, Jaspan JB, Haines NW. A randomized clinical
trial of insulin and glucagon infusion for treatment
of alcoholic hepatitis: progress report in 50 patients.
Gastroenterology 1981;80:1410–4.
Hatfield G, Haines N, Schneider J. Randomized clinical
trial of insulin and glucagon for alcoholic hepatitis.
Gastroenterology 1979;76:1284.
Basu 2015 {published data only}
Basu P, Shah NJ, Aloysius MM. Role of mycophenolate
mofetil (mmf) in steroid non responsive severe acute
alcoholic hepatitis: a randomized open label placebo control
prospective clinical pilot trial. HPB 2015;17:44.
Bird 1991 {published data only}
Bird G, Lau JY, Koskinas J, Wicks C, Williams R. Insulin
and glucagon infusion in acute alcoholic hepatitis: a
prospective randomized controlled trial. Hepatology 1991;
14:1097–101.
Bird 1998 {published data only}
Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR,
Danesh BJ. Randomised controlled double-blind trial of
the calcium channel antagonist amlodipine in the treatment
of acute alcoholic hepatitis. Journal of Hepatology 1998;28:
194–8.
Blitzer 1977 {published data only}
Blitzer BL, Mutchnic MG, Joshi PH, Phillips MM, Fessel
JM, Conn HO. Adrenocorticosteroid therapy in alcoholic
hepatitis - prospective, double-blind, randomized study.
Gastroenterology 1973;64(4):880.
∗ Blitzer BL, Mutchnick MG, Joshi PH.
Adrenocorticosteroid therapy in alcoholic hepatitis. A
prospective, double blind randomized study. American
Journal of Digestive Diseases 1977;22:477–84.
Boetticher 2008 {published data only}
Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel
B, et al. A randomized, double-blinded, placebo-controlled
multicenter trial of etanercept in the treatment of alcoholic
hepatitis. Gastroenterology 2008;135:1953–60.
Bories 1987 {published data only}
Bories P, Guedj JY, Mirouze D, Yousfi A, Michel H.
Treatment of acute alcoholic hepatitis with prednisolone.
45 patients. Presse Medicale 1987;16(16):769–72.
Caballeria 1998 {published data only}
Caballeria J. Metadoxine in the treatment of alcoholic fatty
liver a randomized multicenter trial. Hepatology 1996;24(4
(Pt 2)):444a.
∗ Caballeria J, Pares A, Bru C, Mercader J, Garcia Plaza
A, Caballeria L, et al. Metadoxine accelerates fatty liver
recovery in alcoholic patients: results of a randomized
double-blind, placebo-control trial. Spanish Group for the
Study of Alcoholic Fatty Liver. Journal of Hepatology 1998;
28:54–60.
Campra 1973 {published data only}
Campra JL, Hamlin EM Jr, Kirshbaum RJ, Olivier M,
Redeker AG, Reynolds TB. Prednisone therapy of acute
alcoholic hepatitis. Report of a controlled trial. Annals of
Internal Medicine 1973;79(5):625–31.
Carithers 1989 {published data only}
∗ Carithers RL Jr, Herlong F, Diehl AM, Shaw EW, Combes
B, Fallon HJ, et al. Methylprednisolone therapy in patients
with severe alcoholic hepatitis. A randomized multicenter
trial. Annals of Internal Medicine 1989;110(9):685–90.
Maddrey WC, Carithers RL, Herlong HF, Combes B, Diehl
AM, Shaw E, et al. Prednisolone therapy in patients with
54Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
severe alcoholic hepatitis: results of a multicenter trial.
Hepatology 1986;6:1202.
Colman 1998 {published data only}
Colman JC, Cromie SL, Cox JM, Roberts SK, Dudley E,
Dudley FJ. The natural history of alcoholic cirrhosis: effect
of colchicine. Hepatology 1998;28:510A.
Cortez-Pinto 2002 {published data only}
Cortez Pinto H, Alexandrino P, Camilo ME, Couveia-
Oliveira A, Santos PM, Alves MM, et al. Lack of effect of
colchicine in alcoholic cirrhosis: Final results of a double-
blind randomized trial. Hepatology 2000;32(4 (Pt 2)):423a.
Cortez Pinto H, Alexandrino P, Santos PM, Alves MM,
Camilo ME, Moura MC. Colchicine in alcoholic cirrhosis
- preliminary results of a double-blind randomized trial.
Hepatology 1992;16(2 (Pt 2)):229a.
∗ Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-
Oliveira A, Santos PM, Alves MM, et al. Lack of effect of
colchicine in alcoholic cirrhosis: final results of a double
blind randomized trial. European Journal of Gastroenterology
& Hepatology 2002;14:377–81.
De 2009 {published data only}
De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A,
Ghosh P. Pentoxifylline versus prednisolone for severe
alcoholic hepatitis: a randomized controlled trial. World
Journal of Gastroenterology 2009;15(13):1613–9.
De 2014 {published data only}
De B, Mandal S, Sau D, Mani S, Chatterjee S, Mondal S,
et al. Pentoxifylline plus prednisolone versus pentoxifylline
only for severe alcoholic hepatitis: a randomized controlled
clinical trial. Annals of Medical and Health Sciences Research
2014;4(5):810–6.
De la Maza 1995 {published data only}
De la Maza MP, Petermann M, Bunout D, Hirsch S.
Effects of long-term vitamin E supplementation in alcoholic
cirrhotics. Journal of the American College of Nutrition 1995;
14:192–6.
Depew 1980 {published data only}
∗ Depew W, Boyer T, Omata M. Double-blind controlled
trial of prednisolone therapy in patients with severe acute
alcoholic hepatitis and spontaneous encephalopathy.
Gastroenterology 1980;78:524–9.
Depew WT, Boyer TD, Omata M, Redeker AG, Reynolds
TB. Double-blind controlled trial of corticosteroid-therapy
in severe alcoholic hepatitis with encephalopathy. Clinical
Research 1978;26(2):A150.
De Silva 2003 {published data only}
de Silva HA, Saparamadu PA, Thabrew MI, Pathmeswaran
A, Fonseka MM, de Silva HJ. Liv.52 in alcoholic
liver disease: a prospective, controlled trial. Journal of
Ethnopharmacology 2003;84:47–50.
Diaz Belmont 1996 {published data only}
Diaz Belmont A, Dominguez Henkel R, Uribe Ancira F.
Parenteral S-adenosylmethionine compared to placebos in
the treatment of alcoholic liver diseases. Anales de Medicina
Interna 1996;13:9–15.
Feher 1989 {published data only}
Feher J, Deak G, Muzes G, Lang I, Niederland V, Nekam K,
et al. Liver-protective action of silymarin therapy in chronic
alcoholic liver diseases. Orvosi Hetilap 1989;130:2723–7.
Fenster 1966 {published data only}
Fenster LF. The non efficacy of short-term anabolic steroid
therapy in alcoholic liver disease. Annals of Internal Medicine
1966;65:738–44.
Fernandez-Rodriguez 2008 {published data only}
∗ Fernandez-Rodriguez CM, Lledo JL, Lopez-Serrano P,
Gutierrez ML, Alonso S, Perez-Fernandez MT, et al. Effect
of pentoxifylline on survival, cardiac function and both
portal and systemic hemodynamics in advanced alcoholic
cirrhosis-a randomized double-blind placebo-controlled
trial. Revista Espanola de Enfermedades Digestivas 2008;100:
481–9.
Fernandez-Rodriguez CM, Lledó JL, Lopez Serrano P,
Alonso S, Cerro J, Sanz-Mayordomo P. Pentoxifylline
ameliorates vasodilation and left ventricular function in
alcoholic cirrhosis. Journal of Hepatology 2005;42(Suppl 2):
80.
Fleig 1997 {published data only}
Fleig WE, Morgan MY, Holzer MA. The ayurvedic
medicine LIV.52 in alcoholic cirrhosis of the liver: Results
of a prospective, randomised, double-blind, placebo-
controlled, clinical study. Zeitschrift fur Gastroenterologie
1998;36:100.
∗ Fleig WE, Morgan MY, Hölzer MA. The ayurvedic
drug Liv52 in patients with alcoholic cirrhosis results of a
prospective, randomized, doubleblind, placebo-controlled
clinical trial. Journal of Hepatology 1997;26(Suppl 1):S127.
Garrido Garcia 2012 {published data only}
Garrido Garcia JR, Sánchez HG, Melchor LA, Elizalde
BCI, Sánchez VL. Pentoxifylline versus steroid in short-
term survival in severe acute alcoholic hepatitis. Medicina
Interna de México 2012;28(3):227–33.
Geminiani 1979 {published data only}
Geminiani S, Mazella G, Aldini R, Bazzoli F, Morselli A M,
Rossi R, et al. Effect of cycloxilic acid administration on
ethanol-induced hepatic steatosis. Controlled clinical trial.
Farmaco - Edizione Pratica 1979;34:449–55.
Gluud 1986 {published data only}
Gluud C. Effect of testosterone treatment in men with
alcoholic cirrhosis. Journal of Hepatology 1985;1(Suppl 1):
S59.
∗ The Copenhagen Study Group for Liver Diseases.
Testosterone treatment of men with alcoholic cirrhosis: a
double-blind study. The Copenhagen Study Group for
Liver Diseases. Hepatology 1986;6(5):807–13.
Halle 1982 {published data only}
∗ Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, Reynolds
TB. Double-blind, controlled trial of propylthiouracil
55Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in patients with severe acute alcoholic hepatitis.
Gastroenterology 1982;82:925–31.
Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, Reynolds
TB. Propylthiouracil therapy in severe acute alcoholic
hepatitis. Gastroenterology 1980;79(5 (Pt 2)):1024.
Helman 1971 {published data only}
Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic
hepatitis. Natural history and evaluation of prednisolone
therapy. Annals of Internal Medicine 1971;74:311–21.
Higuera de la Tijera 2015 {published data only}
∗ Higuera-de la Tijera F, Servin-Caamano AI, Cruz-Herrera
J, Serralde-Zuniga AE, Abdo-Francis JM, Gutierrez-Reyes
G, et al. Treatment with metadoxine and its impact on early
mortality in patients with severe alcoholic hepatitis. Annals
of Hepatology 2014;13:343–52.
Higuera-de la Tijera F, Servin-Caamano AI, Serralde-Zuniga
AE, Cruz-Herrera J, Perez-Torres E, Abdo-Francis JM, et
al. Metadoxine improves the three- and six-month survival
rates in patients with severe alcoholic hepatitis. World
Journal of Gastroenterology 2015;21(16):4975–85.
Keiding 1994 {published data only}
∗ Keiding S, Badsberg JH, Becker U, Bentsen KD, Bonnevie
O, Caballeria J, et al. The prognosis of patients with
alcoholic liver disease. An international randomized,
placebo-controlled trial on the effect of malotilate on
survival. Journal of Hepatology 1994;20:454–60.
Keiding S, Bendtsen K, Becker U, Bonnevie O, Hardt
F, Juhl E, et al. Malotilate in alcoholic liver disease a
randomized, double-blind, international trial of the effect
of long-term treatment on survival. Hepatology 1990;12(2):
419.
Kim 2012 {published data only}
Kim MY, Baik SK, Jang YO, Yea CJ, Won CS, Byun JW,
et al. The beneficial effect of angiotensin-blocking agent
on liver fibrosis in patients with alcoholic liver disease: a
randomized controlled trial. Hepatology 2009;50:812A–3A.
∗ Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang
YO, et al. Beneficial effects of candesartan, an angiotensin-
blocking agent, on compensated alcoholic liver fibrosis - a
randomized open-label controlled study. Liver International
2012;32:977–87.
Lebrec 2010 {published data only}
Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B,
Barraud H, et al. Pentoxifylline (PTX) reduces the risk of
complications in patients with advanced cirrhosis. Analysis
of the results of a pivotal phase 3 trial. Journal of Hepatology
2009;50:S378.
∗ Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B,
Barraud H, et al. Pentoxifylline does not decrease short-term
mortality but does reduce complications in patients with
advanced cirrhosis. Gastroenterology 2010;138:1755–U40.
Lotterer 1995 {published data only}
Lotterer E, Etzel R. LIV. 52 in patients with alcoholic
liver cirrhosis - pilot study of a controlled clinical trial.
Forschende Komplementärmedizin 1995;2:12–4.
Lucena 2002 {published data only}
Lucena MI, Andrade RJ, Cruz JP, Rodriguez-Mendizabal
M, Blanco E, Sanchez de la Cuesta F. Effects of silymarin
MZ-80 on oxidative stress in patients with alcoholic
cirrhosis. International Journal of Clinical Pharmacology &
Therapeutics 2002;40:2–8.
Maddrey 1978 {published data only}
Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr,
Mezey E, White RI Jr. Corticosteroid therapy of alcoholic
hepatitis. Gastroenterology 1978;75:193–9.
Mathurin 2013 {published data only}
Louvet A, Dao TM, Nahon P, Diaz E, Carbonell N,
Boursier J, et al. Pentoxifylline does not improve short-term
survival in severe alcoholic hepatitis in combination with
corticosteroids: results of a randomized controlled trial.
Journal of Hepatology 2012;56:S533–4.
∗ Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N,
Boursier J, et al. Prednisolone with vs without pentoxifylline
and survival of patients with severe alcoholic hepatitis: a
randomized clinical trial. JAMA 2013;310:1033–41.
Mato 1999 {published data only}
∗ Mato JM, Camara J, Fernandez de Paz J, Caballeria L, Coll
S, Caballero A, et al. S-adenosylmethionine in alcoholic
liver cirrhosis: a randomized, placebo-controlled, double-
blind, multicenter clinical trial. Journal of Hepatology 1999;
30:1081–9.
Mato JM, Camara J, Ortiz P, Rodes J. S-adenosylmethionine
in the treatment of alcoholic liver cirrhosis: Results from a
multicentric placebo-controlled, randomized, double-blind
clinical trial. Hepatology 1997;26(4 (Pt 2)):251a.
McHutchinson 1991 {published data only}
McHutchinson JG, Runyon BA, Draguesku JQ, Cominelli
F, Person JL, Castracane J. Pentoxyfylline may prevent
renal impairment (hepatorenal syndrome) in severe acute
alcoholic hepatitis. Hepatology 1991;14(Suppl S4):96A.
Medici 2011 {published data only}
Medici V, Virata MC, Peerson JM, Stabler SP, French
SW, Gregory JF 3rd, et al. S-adenosyl-L-methionine
treatment for alcoholic liver disease: a double-blinded,
randomized, placebo-controlled trial. Alcoholism, Clinical
and Experimental Research 2011;35:1960–5.
Mendenhall 1984 {published data only}
Mendenhall C. Survival after steroid treatment (T) for
alcoholic hepatitis (AH). Hepatology 1983;3(5):850.
Mendenhall C, Goldberg S. Risk factors and therapy in
alcoholic hepatitis (AH). Gastroenterology 1977;72(5):A–77.
∗ Mendenhall CL, Anderson S, Garcia-Pont P. Short-term
and long-term survival in patients with alcoholic hepatitis
treated with oxandrolone and prednisolone. New England
Journal of Medicine 1984;311:1464–70.
Mezey 2004 {published data only}
∗ Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J,
Pares A. A randomized placebo controlled trial of vitamin E
for alcoholic hepatitis. Journal of Hepatology 2004;40:40–6.
Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares
A. A randomized placebo controlled trial of vitamin E in
56Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
alcoholic hepatitis. Hepatology 2003;38(4):264A.
Mirouze 1982 {published data only}
Mirouze D, Redeker A, Reynolds T, Michel H. A
randomized clinical trial of insulin and glucagon infusion
for treatment of severe acute alcoholic hepatitis: Report in
26 patients. Scandinavian Journal of Gastroenterology 1982;
17:36.
Moreno 2010 {published data only}
Moreno C, Langlet P, Hittelet A, Evrard S, Lasser L, Colle I.
Enteral nutrition with or without N-acetylcysteine in the
treatment of severe acute alcoholic hepatitis: a randomized,
multicenter, controlled trial. Journal of Hepatology 2009;50:
S366.
∗ Moreno C, Langlet P, Hittelet A, Lasser L, Degre D,
Evrard S, et al. Enteral nutrition with or without N-
acetylcysteine in the treatment of severe acute alcoholic
hepatitis: a randomized multicenter controlled trial. Journal
of Hepatology 2010;53(6):1117–22.
Morgan 2005 {published data only}
Morgan TR, Nemchausky B, Schiff E, Anand BS, Bloor J,
Kidao J, et al. Colchicine does not prolong life in patients
with advanced alcoholic cirrhosis: Results of a prospective,
randomized, placebo-controlled, multicenter VA trial (CSP
352). Gastroenterology 2002;122(4):A641.
∗ Morgan TR, Weiss DG, Nemchausky B, Schiff ER,
Anand B, Simon F, et al. Colchicine treatment of alcoholic
cirrhosis: a randomized, placebo-controlled clinical trial of
patient survival. Gastroenterology 2005;128:882–90.
Naveau 2004 {published data only}
Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet
P, Piquet MA, et al. A double blind randomized controlled
trial of infliximab associated with prednisolone in acute
alcoholic hepatitis. Gastroenterology 2004;126(4):A692.
∗ Naveau S, Chollet-Martin S, Dharancy S, Mathurin P,
Jouet P, Piquet MA, et al. A double-blind randomized
controlled trial of infliximab associated with prednisolone in
acute alcoholic hepatitis. Hepatology 2004;39(5):1390–7.
Nguyen-Khac 2011 {published data only}
Nguyen-Khac E, Thevenot T, Piquet M, Benferhat S,
Goria O, Chatelain D. Treatment of severe acute alcoholic
hepatitis (AAH) with corticoids plus N-acetyl cysteine
(C+NAC) versus corticoids alone (C): a multicentre,
randomized, controlled trial. Hepatology 2009;50(4
(Suppl)):346a–7a.
∗ Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S,
Goria O, Chatelain D, et al. Glucocorticoids plus N-
acetylcysteine in severe alcoholic hepatitis. New England
Journal of Medicine 2011;365:1781–9.
Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat
S, Goria O, Chatelain D, et al. Treatment of severe
acute alcoholic hepatitis (AAH) with corticoids plus N-
acetyl cysteine (C+NAC) versus corticoids alone (C):
a multicentre, randomized, controlled trial. Journal of
Hepatology 2010;52:S38.
Orrego 1979 {published data only}
Orrego H, Kalant H, Israel Y, Blake J, Medline A, Rankin
JG, et al. Effect of short-term therapy with propylthiouracil
in patients with alcoholic liver disease. Gastroenterology
1979;76:105–15.
Orrego 1987 {published data only}
Orrego H, Blake JE, Blendis LM, Compton KV, Israel
Y. Long-term treatment of alcoholic liver disease with
propylthiouracil. Lancet 1988;1(8590):892.
∗ Orrego H, Blake JE, Blendis LM, Compton KV, Israel
Y. Long-term treatment of alcoholic liver disease with
propylthiouracil. New England Journal of Medicine 1987;
317:1421–7.
Orrego H, Blake JE, Blendis LM, Compton KV, Volpe R,
Israel Y. Long-term treatment of alcoholic liver disease with
propylthiouracil. Part 2: influence of drop-out rates and of
continued alcohol consumption in a clinical trial. Journal of
Hepatology 1994;20(3):343–9.
Paladugu 2006 {published data only}
Paladugu H, Sawant P, Dalvi L, Kudalkar J. Role of
pentoxifylline in treatment of severe acute alcoholic hepatitis
- a randomized controlled trial. Journal of Gastroenterology
and Hepatology 2006;21:A459.
Pares 1998 {published data only}
Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero
D, et al. Effects of silymarin in alcoholic patients with
cirrhosis of the liver: results of a controlled, double-blind,
randomized and multicenter trial. Journal of Hepatology
1998;28:615–21.
Park 2014 {published data only}
Kim DJ, Suk KT, Park SH, Tak WY, Yim HJ, Um SH, et
al. Short-term survival in patients with severe alcoholic
hepatitis treated with pentoxifylline vs. corticosteroid:
a non-inferiority trial - a preliminary report. Journal of
Hepatology 2013;58:S219–20.
∗ Park SH, Kim DJ, Kim YS, Yim HJ, Tak WY, Lee HJ, et
al. Pentoxifylline vs. corticosteroid to treat severe alcoholic
hepatitis: a randomised, non-inferiority, open trial. Journal
of Hepatology 2014;61:792–8.
Pelletier 2003 {published data only}
Pelletier G, Roulot D, Davion T, Masliah C, Causse
X, Oberti F, et al. A randomized controlled trial of
ursodeoxycholic acid in patients with alcohol-induced
cirrhosis and jaundice. Hepatology 2003;37:887–92.
Phillips 2006 {published data only}
∗ Phillips M, Curtis H, Portmann B, Donaldson N,
Bomford A, O’Grady J. Antioxidants versus corticosteroids
in the treatment of severe alcoholic hepatitis-a randomised
clinical trial. Journal of Hepatology 2006;44:784–90.
Phillips M, Curtis H, Portmann B, Donaldson N, Bomford
A, O’Grady J. Antioxidants versus corticosteroids in the
treatment of severe alcoholic hepatitis: a randomized trial.
Hepatology 2001;34(4):250A.
Pierri 1985 {published data only}
Pierri G, Giorgio A, Amoroso P, Fico P, Finelli L. Epomediol
treatment of fatty liver in alcohol abuse. A controlled
57Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
clinical double-blind study. Clinica Terapeutica 1985;112:
527–35.
Plevris 1991 {published data only}
∗ Plevris JN, Hayes PC, Bouchier IAD. Ursodeoxycholic
acid in the treatment of alcoholic liver-disease. European
Journal of Gastroenterology & Hepatology 1991;3:653–6.
Plevris JN, Jones AL, Dawkes R, Howie AF, Bouchier
IAD, Hayes PC. Ursodeoxycholic acid in the treatment of
alcoholic liver disease. Gut 1993;34(4):S7.
Popescu 2009 {published data only}
Popescu A, Voiculescu M. Improved survival in patients
with advanced alcoholic hepatitis (AAH) with a combined
treatment associating a non-absorbable antibiotic rifaximin
to corticoids plus ursodeoxicholic acid (UDCA). Journal of
Hepatology 2009;50:S369.
Porter 1971 {published data only}
Porter HP, Simon FR, Pope CE, Volwiler W, Fenster LF.
Corticosteroid therapy in severe alcoholic hepatitis - double-
blind drug trial. New England Journal of Medicine 1971;
284:1350–5.
Radvan 1983 {published data only}
Radvan G, Kanel G, Redeker A. Management of acute
alcoholic hepatitis with insulin and glucagon infusion.
Australian and New Zealand Journal of Medicine 1983;13:
322.
Ramond 1992 {published data only}
Ramond MJ, Poynard T, Rueff B, Mathurin P, Chaput JC,
Benhamou JP. [corticotherapy improves short-term survival
in patients with severe acute alcoholic hepatitis. A bicenter
double-blind randomized study]. Gastroenterologie Clinique
Et Biologique 1991;15(2 bis):A4.
∗ Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore
C, Chaput JC, et al. A randomized trial of prednisolone
in patients with severe alcoholic hepatitis. New England
Journal of Medicine 1992;326:507–12.
Ramond MJ, Poynard T, Rueff B, Theodore C, Matthurin
P, Chaput JC, et al. Prednisolone markedly improves short-
term survival of patients with severe biopsy-proven alcoholic
hepatitis a double blind randomized bicenter trial. Journal
of Hepatology 1991;13(Suppl 2):S63.
Resnick 1974 {published data only}
Resnick RH, Boitnott J, Iber FL, Makopour H, Cerda
JJ. Preliminary observations of d-penicillamine therapy in
acute alcoholic liver disease. Digestion 1974;11:257–65.
Richardet 1993 {published data only}
Mal F, Pham Huu T, Richardet JP, Roulot D, Labadie H,
Pol S, et al. Corticosteroids (Cs) does not influence plasma
tumor necrosis factor-alpha (pTNF) and interleukin 6
(pIl6) concentrations in severe alcoholic hepatitis (AH): a
cross over study. Hepatology 1992;16(2 (Pt 2)):234a.
∗ Richardet JP, Dehoux M, Mal F, Roulot D, Labadie H,
Pol S, et al. Influence of corticosteroids (Cs) on plasma
cytokines concentrations in patients with severe alcoholic
hepatitis (HA): Results of a randomized study. Journal of
Hepatology 1993;18(Suppl 1):S75.
Sainz 1992 {published data only}
Sainz S, Guarner C, Villanueva C, Ordonez J, Sancho EJ,
Enriquez J. Colchicine treatment in alcoholic liver disease.
A controlled and randomized study. Journal of Hepatology
1992;16(Suppl 1):S64.
Salvagnini 1985 {published data only}
Salvaqnini M, Martines D, Piccoli A, Sciarrone R, Rizzo
A, Campesato A, et al. Silymarin treatment in alcoholic
liver disease: a double blind randomized trial. Journal of
Hepatology 1985;1(Suppl 1):S124.
Serrano-Cancino 1981 {published data only}
Serrano-Cancino H, Botero R, Jeffers L, Mariani A,
Cowen G, Ravendhran N. Treatment of severe alcoholic
hepatitis with propythiouracil (PTU). American Journal of
Gastroenterology 1981;76:194.
Shumaker 1978 {published data only}
Shumaker JB, Resnick RH, Galambos JT. A controlled trial
of 6-methylprednisolone in acute alcoholic hepatitis. With
a note on published results in encephalopathic patients.
American Journal of Gastroenterology 1978;69:443–9.
Sidhu 2012a {published data only}
Sidhu SS, Goyal O, Singla P, Gupta D, Chhina RS, Sood
A. A prospective randomised trial to compare the efficacy
of corticosteroids plus pentoxifylline versus corticosteroids
alone in the treatment of severe alcoholic hepatitis. Journal
of Hepatology 2010;52:S306–S.
∗ Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina
RS, et al. Corticosteroid plus pentoxifylline is not better
than corticosteroid alone for improving survival in severe
alcoholic hepatitis (COPE trial). Digestive Diseases &
Sciences 2012;57:1664–71.
Sidhu 2012b {published data only}
Sidhu S, Singla M, Bhatia KL. Pentoxifylline reduces disease
severity and prevents renal impairment in severe acute
alcoholic hepatitis: a double blind, placebo controlled trial.
Hepatology 2006;44(4 (Suppl 1)):373a–4a.
∗ Sidhu SS, Goyal O, Singla M, Bhatia KL, Chhina RS,
Sood A. Pentoxifylline in severe alcoholic hepatitis: a
prospective, randomised trial. Journal of the Association of
Physicians of India 2012;60:20–2.
Singh 2014 {published data only}
∗ Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma
N, Sharma R. Granulocyte colony-stimulating factor
in severe alcoholic hepatitis: a randomized pilot study.
American Journal of Gastroenterology 2014;109:1417–23.
Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma
N, Sharma R. Granulocyte-colony stimulating factor (G-
CSF) in alcoholic hepatitis: a randomized controlled trial.
Gastroenterology 2013;144(5 suppl. 1):S1004.
Spahr 2002 {published data only}
Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E,
Rougemont AL, Pugin J, et al. Combination of steroids
with infliximab or placebo in severe alcoholic hepatitis: a
randomized controlled pilot study. Journal of Hepatology
2002;37:448–55.
58Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stenner 2000 {published data only}
Stenner J, Jazrawi R, Verma A, Ahmed H, Northfield T.
Effect of UDCA on fibrosis markers in alcoholic liver
disease. Clinical science 2000;98:17p.
Stewart 2007 {published data only}
∗ Stewart S, Prince M, Bassendine M, Hudson M, James O,
Jones D, et al. A randomized trial of antioxidant therapy
alone or with corticosteroids in acute alcoholic hepatitis.
Journal of Hepatology 2007;47:277–83.
Stewart S, Prince M, Bassendine M, Hudson M, James
O, Jones D, et al. A trial of antioxidant therapy alone or
with corticosteroids in acute alcoholic hepatitis. Journal of
Hepatology 2002;36(Suppl 1):16.
Stigliano 2005 {published data only}
Stigliano R, Marelli L, Pang K, Lowdell M, Rolles K,
Patch D, et al. G-CSF mobilization of bone marrow-
derived hepatocyte and haematopoietic progenitors in
acute alcoholic hepatitis - a randomised controlled trial.
Preliminary data. Hepatology 2005;42:741A.
Takase 1989 {published data only}
∗ Takase S, Matsuda Y, Yasuhara M, Takada A. Effects of
malotilate treatment on alcoholic liver disease. Alcohol
1989;6(3):219–22.
Takase S, Takada A, Yasuhara M, Sato H, Matsuda Y. Effects
of malotilate treatment on the serum markers of hepatic
fibrogenesis in liver cirrhosis. Gastroenterologia Japonica
1988 Dec;23(6):639–45.
Theodossi 1982 {published data only}
Theodossi A, Eddleston A L, Williams R. Controlled trial
of methylprednisolone therapy in severe acute alcoholic
hepatitis. Gut 1982;23:75–9.
Thursz 2015 {published data only}
Forrest E, Mellor J, Stanton L, Bowers M, Ryder P, Austin
A, et al. Steroids or pentoxifylline for alcoholic hepatitis
(STOPAH): study protocol for a randomised controlled
trial. Trials 2013;14:262.
Thursz M, Forrest E, Roderick P, Day C, Austin A, O’Grady
J, et al. The clinical effectiveness and cost-effectiveness of
steroids or pentoxifylline for alcoholic hepatitis (STOPAH):
a 2x2 factorial randomised controlled trial. Health
Technology Assessment 2015;19(102):1–104.
∗ Thursz MR, Richardson P, Allison M, Austin A, Bowers
M, Day CP, et al. Prednisolone or pentoxifylline for
alcoholic hepatitis. New England Journal of Medicine 2015;
372:1619–28.
Tkachenko 2016 {published data only}
Tkachenko P, Komkova I, Maevskaya M, Ivashkin V.
Prednisolone plus S-adenosylmethionine in severe alcoholic
hepatitis. Journal of Hepatology 2016;64(2 suppl. 1):S239.
∗ Tkachenko P, Maevskaya M, Pavlov A, Komkova I, Pavlov
C, Ivashkin V. Prednisolone plus S-adenosil-L-methionine
in severe alcoholic hepatitis. Hepatology International 2016;
10(6):983–7.
Trinchet 1989a {published data only}
∗ Trinchet JC, Beaugrand M, Callard P, Hartmann DJ,
Gotheil C, Nusgens BV, et al. Treatment of alcoholic
hepatitis with colchicine. Results of a randomized double
blind trial. Gastroenterologie Clinique et Biologique 1989;13:
551–5.
Trinchet JC, Beaugrand M, Ferrier JP, Galet B, Callard P,
Hartmann D, et al. Treatment of active alcoholic liver
disease (AADL) by colchicine: Results of a 6 months double
blind trial. Journal of Hepatology 1985;1(Suppl 1):S142.
Trinchet JC, Galet B, Beaugrand M, Callard P, Ferrier
JP. Treatment of alcoholic hepatitis with colchicine.
Preliminary results of a double blind study in 46 patients.
Gastroenterologie Clinique Et Biologique 1983;7(2):103a.
Trinchet 1989b {published data only}
Trinchet JC, Coste T, Levy VG, Grippon P, Vivet F,
Duchatelle V, et al. Treatment of alcoholic hepatitis
by silymarine, a double blind multicenter study in 116
patients. Gastroenterologie Clinique Et Biologique 1987;11(2
bis):167a.
∗ Trinchet JC, Coste T, Levy VG, Vivet F, Duchatelle
V, Legendre C, et al. A randomized double blind trial
of silymarin in 116 patients with alcoholic hepatitis.
Gastroenterologie Clinique Et Biologique 1989;13(2):120–4.
Trinchet 1992 {published data only}
Trinchet JC, Balkau B, Heintzmann F, Poupon RE, Callard
P, Gotheil C, et al. Treatment of severe alcoholic hepatitis
by infusion of insulin and glucagon a multicentre sequential
trial. Journal of Hepatology 1990;11(Suppl 2):S63.
∗ Trinchet JC, Balkau B, Poupon RE, Heintzmann F,
Callard P, Gotheil C, et al. Treatment of severe alcoholic
hepatitis by infusion of insulin and glucagon: a multicenter
sequential trial. Hepatology 1992;15:76–81.
Velussi 1997 {published data only}
∗ Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau
C, Zilli M. Long-term (12 months) treatment with an anti-
oxidant drug (silymarin) is effective on hyperinsulinemia,
exogenous insulin need and malondialdehyde levels in
cirrhotic diabetic patients. Journal of Hepatology 1997;26:
871–9.
Velussi M, Cernigoi AM, Viezzoli L, Dapas F, Caffau C, Zilli
M. Silymarin reduces hyperinsulinemia, malondialdehyde
levels, and daily insulin need in cirrhotic diabetic patients.
Current Therapeutic Research - Clinical and Experimental
1993;53(5):533–45.
References to studies excluded from this review
Achord 1987 {published data only}
Achord JL. A prospective randomized clinical trial of
peripheral amino acid-glucose supplementation in acute
alcoholic hepatitis. American Journal of Gastroenterology
1987;82:871–5.
Bunout 1989 {published data only}
Bunout D, Aicardi V, Hirsch S, Petermann M, Kelly M,
Silva G, et al. Nutritional support in hospitalized patients
with alcoholic liver disease. European Journal of Clinical
Nutrition 1989;43:615–21.
59Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cabre 2000 {published data only}
Cabre E, Rodriguez-Iglesias P, Caballeria J, Quer JC,
Sanchez-Lombrana JL, Pares A, et al. Short- and long-term
outcome of severe alcohol-induced hepatitis treated with
steroids or enteral nutrition: a multicenter randomized trial.
Hepatology 2000;32:36–42.
Calvey 1985 {published data only}
Calvey H, Davis M, Williams R. Controlled trial of
nutritional supplementation, with and without branched
chain amino acid enrichment, in treatment of acute
alcoholic hepatitis. Journal of Hepatology 1985;1:141–51.
Carithers 1990 {published data only}
Carithers R, Herlong HF, Diehl AM, Shaw EW, Combes
B, Fallon HJ, et al. Corticosteroid therapy of alcoholic
hepatitis: How many studies will it take?. Hepatology 1990;
12(3):619–20.
Conn 1978 {published data only}
Conn HO. Steroid treatment of alcoholic hepatitis. The
yeas and the nays. Gastroenterology 1978;74(2 Pt 1):319–22.
DiNubile 2015 {published data only}
DiNubile MJ. Prednisolone or pentoxifylline for alcoholic
hepatitis. New England Journal of Medicine 2015;373(3):
281–2.
Dupont 2012 {published data only}
Dupont B, Dao T, Joubert C, Dupont-Lucas C, Gloro R,
Nguyen-Khac E, et al. Randomised clinical trial: enteral
nutrition does not improve the long-term outcome of
alcoholic cirrhotic patients with jaundice. Alimentary
Pharmacology & Therapeutics 2012;35:1166–74.
Hendy 2016 {published data only}
Hendy P. Pentoxifylline is ineffective in treating severe
alcoholic hepatitis. Frontline Gastroenterology 2016;7(2):
80–1.
Hirsch 1993 {published data only}
Hirsch S, Bunout D, de la Maza P, Iturriaga H, Petermann
M, Icazar G, et al. Controlled trial on nutrition
supplementation in outpatients with symptomatic alcoholic
cirrhosis. JPEN. Journal of Parenteral and Enteral Nutrition
1993;17:119–24.
Kearns 1992 {published data only}
Kearns PJ, Young H, Garcia G, Blaschke T, O’Hanlon G,
Rinki M, et al. Accelerated improvement of alcoholic liver
disease with enteral nutrition. Gastroenterology 1992;102:
200–5.
Kolasani 2016 {published data only}
∗ Kolasani BP, Sasidharan P, Divyashanthi CM, Kumar A.
Vitamin e improves quality of life in patients with alcoholic
liver disease. National Journal of Physiology, Pharmacy and
Pharmacology 2016;6(4):269–75.
Kolasani BP, Sasidharan P, Kumar A. Efficacy of vitamin e
supplementation in patients with alcoholic liver disease:
an open-label, prospective, randomized comparative
study. International Journal of Nutrition, Pharmacology,
Neurological Diseases 2016;6(3):101–10.
Lesesne 1978 {published data only}
Lesesne HR, Bozymski EM, Fallon HJ. Treatment of
alcoholic hepatitis with encephalopathy. Comparison of
prednisolone with caloric supplements. Gastroenterology
1978;74:169–73.
Ma 2011 {published data only}
Ma AL, Guo XZ, Liu X, Xu Q, Wang TL.
Efficacy comparison between bicyclol and polyene
phosphatidylcholine treatments for alcoholic liver disease.
Chung Hua Kan Tsang Ping Tsa Chih 2011;19:471–2.
Mathurin 1996 {published data only}
Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa
P, Erlinger S, et al. Long term survival and prognostic factors
in patients with severe biopsy-proved alcoholic hepatitis
(ah) treated by prednisolone: Randomized trial, new cohort
and simulation. Hepatology 1994;20(4 (Pt 2)):319a.
∗ Mathurin P, Duchatelle V, Ramond MJ, Degott C,
Bedossa P, Erlinger S, et al. Survival and prognostic factors
in patients with severe alcoholic hepatitis treated with
prednisolone. Gastroenterology 1996;110(6):1847–53.
Mezey 1991 {published data only}
Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF,
Rodes J. Effect of parenteral amino acid supplementation
on short-term and long-term outcomes in severe alcoholic
hepatitis: a randomized controlled trial. Hepatology 1991;
14:1090–6.
Moreno 2014 {published data only}
Moreno C, Trépo E, Louvet A, Degré D, Bastens B,
Hittelet A, et al. Impact of intensive enteral nutrition in
association with corticosteroids in the treatment of severe
alcoholic hepatitis: a multicenter randomized controlled
trial. Hepatology 2014;60(Suppl 1):269A–70A.
Nasrallah 1980 {published data only}
Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic
hepatitis. Lancet 1980;2:1276–7.
Naveau 1986 {published data only}
Naveau S, Pelletier G, Poynard T, Attali P, Poitrine A, Buffet
C, et al. A randomized clinical trial of supplementary
parenteral nutrition in jaundiced alcoholic cirrhotic
patients. Hepatology 1986;6:270–4.
Panos 1990 {published data only}
Panos MZ, Polson R, Johnson R, Portmann B, Williams R.
Polyunsaturated phosphatidyl choline for acute alcoholic
hepatitis: a double-blind, randomized, placebo-controlled
trial. European Journal of Gastroenterology and Hepatology
1990;2:351–5.
Ramond 1992a {published data only}
Ramond MJ, Poynard T, Rueff B, Carey WD. Steroids in
alcoholic hepatitis: another salvo of data. American Journal
of Gastroenterology 1992;87(9):1219–20.
Sas 2011 {published data only}
Sas E, Grinevich V, Kravchuk U, Efimov O. Polyunsaturated
phosphatidylcholine reduces insulin resistance and hepatic
fibrosis in patients with alcoholic liver disease. results of
randomized blinded prospective clinical study. Journal of
Hepatology 2011;54:S207.
60Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Simon 1988 {published data only}
Simon D, Galambos JT. A randomized controlled study
of peripheral parenteral nutrition in moderate and severe
alcoholic hepatitis. Journal of Hepatology 1988;7:200–7.
Spahr 2008 {published data only}
Spahr L, Lambert JF, Rubbia-Brandt L, Chalandon
Y, Frossard JL, Giostra E, et al. Granulocyte-colony
stimulating factor induces proliferation of hepatic
progenitors in alcoholic steatohepatitis: a randomized trial.
Hepatology 2008;48(1):221–9.
Thursz 2015a {published data only}
Thursz MR, Forrest EH, Ryder S, STOPAH Investigators.
Prednisolone or pentoxifylline for alcoholic hepatitis. New
England Journal of Medicine 2015;373(3):282–3.
Verbeke 2015 {published data only}
Verbeke L, Laleman W, Nevens F. Prednisolone or
pentoxifylline for alcoholic hepatitis. New England Journal
of Medicine 2015;373(3):281.
Wenzel 1993 {published data only}
Wenzel G, Kuklinski B, Ruhlmann C, Ehrhardt D. Alcohol-
induced toxic hepatitis-a “free radical” associated disease.
Lowering fatality by adjuvant antioxidant therapy. Zeitschrift
für die gesamte Innere Medizin und ihre Grenzgebiete 1993;
48:490–6.
Additional references
Abenavoli 2010
Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in
liver diseases: past, present, future. Phytotherapy Research
2010;24(10):1423–32.
Anstee 2012
Anstee QM, Day CP. S-adenosylmethionine (SAMe)
therapy in liver disease: a review of current evidence and
clinical utility. Journal of Hepatology 2012;57(5):1097–109.
Blachier 2013
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC,
Roudot-Thoraval F. The burden of liver disease in Europe - a
review of available epidemiological data, 2013. www.easl.eu/
assets/application/files/54ae845caec619f˙file.pdf (accessed
23 October 2014).
BLT 2014
British Liver Trust. Alcohol, 2014.
www.britishlivertrust.org.uk/liver-information/liver-
conditions/alcohol/ (accessed 23 October 2014).
Chaimani 2012
Chaimani A, Salanti G. Using network meta-analysis to
evaluate the existence of small-study effects in a network
of interventions. Research Synthesis Methods 2012;3(2):
161–76.
Chaimani 2013
Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti
G. Graphical tools for network meta-analysis in STATA.
PloS One 2013;8(10):e76654.
Chan 2013
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche
PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining
standard protocol items for clinical trials. Annals of Internal
Medicine 2013;158(3):200–7.
D’Amico 2006
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and
prognostic indicators of survival in cirrhosis: a systematic
review of 118 studies. Journal of Hepatology 2006;44(1):
217–31.
Del Re 2013
Del Re AC, Spielmans GI, Flückiger C, Wampold BE.
Efficacy of new generation antidepressants: differences seem
illusory. PLoS One 2013;8(6):e63509.
DeMets 1987
DeMets DL. Methods for combining randomized clinical
trials: strengths and limitations. Statistics in Medicine 1987;
6(3):341–50.
DerSimonian 1986
DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7(3):177–88.
Dias 2010
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking
consistency in mixed treatment comparison meta-analysis.
Statistics in Medicine 2010;29(7-8):932–44.
Dias 2012a
Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU
Technical Support Document 3: heterogeneity: subgroups,
meta-regression, bias and bias-adjustment, September
2011 (last updated April 2012). www.nicedsu.org.uk/
TSD3%20Heterogeneity.final%20report.08.05.12.pdf
(accessed 27 March 2014).
Dias 2012b
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU
Technical Support Document 1: introduction to
evidence synthesis for decision making, April 2011
(last updated April 2012). www.nicedsu.org.uk/
TSD1%20Introduction.final.08.05.12.pdf (accessed 27
March 2014).
Dias 2014a
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU
technical support document 2: a generalised linear
modelling framework for pair wise and network meta-
analysis of randomised controlled trials, August 2011
(last updated April 2014). www.nicedsu.org.uk/
TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf
(accessed 8 October 2014).
Dias 2014b
Dias S, Welton NJ, Sutton AJ, Caldwell DM,
Lu G, Ades AE. NICE DSU Technical Support
Document 4: inconsistency in networks of evidence
based on randomised controlled trials, May 2011
(last updated April 2014). www.nicedsu.org.uk/
TSD4%20Inconsistency.final.15April2014.pdf (accessed 8
October 2014).
Duffy 2010
Duffy JP, Kao K, Ko CY, Farmer DG, McDiarmid SV,
Hong JC, et al. Long-term patient outcome and quality of
61Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
life after liver transplantation: analysis of 20-year survivors.
Annals of Surgery 2010;252(4):652–61.
EASL 2012
European Association for Study of Liver. EASL clinical
practical guidelines: management of alcoholic liver disease.
Journal of Hepatology 2012;57(2):399–420.
Egger 1997
Egger M, Davey Smith G, Schneider M, Minder C. Bias
in meta-analysis detected by a simple, graphical test. BMJ
(Clinical Research Ed.) 1997;315(7109):629–34.
EuroQol 2014
EuroQol. About EQ-5D. www.euroqol.org/about-eq-
5d.html (accessed 8 October 2014).
Fede 2011
Fede G, Germani G, Gluud C, Gurusamy KS, Burroughs
AK. Propylthiouracil for alcoholic liver disease. Cochrane
Database of Systematic Reviews 2011, Issue 6. [DOI:
10.1002/14651858.CD002800.pub3]
Ferri 2006
Ferri M, Amato L, Davoli M. Alcoholics Anonymous
and other 12-step programmes for alcohol dependence.
Cochrane Database of Systematic Reviews 2006, Issue 3.
[DOI: 10.1002/14651858.CD005032.pub2]
Gao 2011
Gao B, Bataller R. Alcoholic liver disease: pathogenesis and
new therapeutic targets. Gastroenterology 2011;141(5):
1572–85.
Gluud 1988
Gluud C. Testosterone and alcoholic cirrhosis.
Epidemiologic, pathophysiologic and therapeutic studies in
men. Danish Medical Bulletin 1988;35(6):564–75.
Gluud 2016
Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-
Biliary Group. About Cochrane (Cochrane Review Groups
(CRGs)) 2016, Issue 10. Art. No.: LIVER.
Guyatt 2011
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek
J, et al. GRADE guidelines: 1. Introduction - GRADE
evidence profiles and summary of findings tables. Journal of
Clinical Epidemiology 2011;64(4):383–94.
Hicks 1992
Hicks M, Wong LS, Day RO. Antioxidant activity of
propylthiouracil. Biochemical Pharmacology 1992;43(3):
439–44.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. Cochrane, 2011. Available from
www.cochrane-handbook.org.
Higgins 2012
Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE,
White IR. Consistency and inconsistency in network meta-
analysis: Concepts and models for multi-arm studies.
Research Synthesis Methods 2012;3(2):98–110.
ICH-GCP 1997
International Conference on Harmonisation Expert
Working Group. International conference on harmonisation
of technical requirements for registration of pharmaceuticals for
human use. ICH harmonised tripartite guideline. Guideline
for good clinical practice CFR & ICH Guidelines. Vol. 1,
Pennsylvania: Barnett International/PAREXEL, 1997.
Jakobsen 2014
Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud
C. Thresholds for statistical and clinical significance in
systematic reviews with meta-analytic methods. BMC
Medical Research Methodology 2014;14(1):120.
Kjaergard 2001
Kjaergard LL, Villumsen J, Gluud C. Reported
methodologic quality and discrepancies between large and
small randomized trials in meta-analyses. Annals of Internal
Medicine 2001;135(11):982–9.
Lu 2006
Lu G, Ades AE. Assessing evidence inconsistency in mixed
treatment comparisons. Journal of the American Statistical
Association 2006;101(474):447–59.
Lucey 2009
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis.
New England Journal of Medicine 2009;360(26):2758–69.
Lundh 2017
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L.
Industry sponsorship and research outcome. Cochrane
Database of Systematic Reviews 2017, Issue 2. [DOI:
10.1002/14651858.MR000033.pub3]
Macaskill 2001
Macaskill P, Walter SD, Irwig L. A comparison of methods
to detect publication bias in meta-analysis. Statistics in
Medicine 2001;20(4):641–54.
Mills 2012
Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ,
Puhan MA, Guyatt GH. How to use an article reporting a
multiple treatment comparison meta-analysis. JAMA 2012;
308(12):1246–53.
Moher 1998
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher
M, et al. Does quality of reports of randomised trials affect
estimates of intervention efficacy reported in meta-analyses?
. Lancet 1998;352(9128):609–13.
NCBI 2014a
NCBI. Liver diseases, alcoholic, 2014.
www.ncbi.nlm.nih.gov/mesh/68008108 (accessed 23
October 2014).
NCBI 2014b
NCBI. Fatty liver, 2014. www.ncbi.nlm.nih.gov/mesh/
68005234 (accessed 23 October 2014).
NCBI 2014c
NCBI. Hepatitis, alcoholic, 2014. www.ncbi.nlm.nih.gov/
mesh/68006519 (accessed 23 October 2014).
62Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Newell 1992
Newell DJ. Intention-to-treat analysis: implications for
quantitative and qualitative research. International Journal
of Epidemiology 1992;21(5):837–41.
NHS 2014
NHS Choices. Alcohol-related liver disease.
www.nhs.uk/conditions/liver˙disease˙(alcoholic)/Pages/
Introduction.aspx (accessed 23 October 2014).
O’Shea 2010
O’Shea RS, Dasarathy S, McCullough AJ, Practice
Guideline Committee of the American Association for the
Study of Liver Diseases, Practice Parameters Committee of
the American College of Gastroenterology. Alcoholic liver
disease. Hepatology 2010;51(1):307–28.
OpenBUGS 3.2.3 [Computer program]
Members of OpenBUGS Project Management Group.
OpenBUGS. Version 3.2.3. Members of OpenBUGS
Project Management Group, 2014.
Pavlov 2016
Pavlov CS, Tsochatzis E, Casazza G, Nikolova D, Volcek
E, Gluud C. Glucocorticosteroids for people with alcoholic
hepatitis. Cochrane Database of Systematic Reviews 2016,
Issue 6. [DOI: 10.1002/14651858.CD001511.pub2]
Puhan 2014
Puhan MA, Schünemann HJ, Murad MH, Li T,
Brignardello-Petersen R, Singh JA, et al. A GRADE
Working Group approach for rating the quality of treatment
effect estimates from network meta-analysis. BMJ (Clinical
Research Ed.) 2014;349:g5630.
Rambaldi 2006
Rambaldi A, Gluud C. Anabolic-androgenic steroids
for alcoholic liver disease. Cochrane Database of
Systematic Reviews 2006, Issue 4. [DOI: 10.1002/
14651858.CD003045.pub2]
Rambaldi 2008
Rambaldi A, Saconato HH, Christensen E, Thorlund
K, Wetterslev J, Gluud C. Systematic review:
glucocorticosteroids for alcoholic hepatitis--a Cochrane
Hepato-Biliary Group systematic review with meta-analyses
and trial sequential analyses of randomized clinical trials.
Alimentary Pharmacology & Therapeutics 2008;27(12):
1167–78.
Rambaldi 2015
Rambaldi A, Gluud C. S-adenosyl-L-methionine
for alcoholic liver diseases. Cochrane Database of
Systematic Reviews 2015, Issue 11. [DOI: 10.1002/
14651858.CD002235.pub3]
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Royle 2003
Royle P, Milne R. Literature searching for randomized
controlled trials used in Cochrane reviews: rapid versus
exhaustive searches. International Journal of Technology
Assessment in Health Care 2003;19(4):591–603.
Salanti 2011
Salanti G, Ades AE, Ioannidis JP. Graphical methods and
numerical summaries for presenting results from multiple-
treatment meta-analysis: an overview and tutorial. Journal
of Clinical Epidemiology 2011;64(2):163–71.
Salanti 2012
Salanti G. Indirect and mixed-treatment comparison,
network, or multiple-treatments meta-analysis: many
names, many benefits, many concerns for the next
generation evidence synthesis tool. Research Synthesis
Methods 2012;3(2):80–97.
Savovi 2012a
Savovi J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal
J, et al. Influence of reported study design characteristics on
intervention effect estimates from randomized controlled
trials: combined analysis of meta-epidemiological studies.
Health Technology Assessment 2012;16(35):1–82.
Savovi 2012b
Savovi J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal
J, et al. Influence of reported study design characteristics on
intervention effect estimates from randomized controlled
trials. Annals of Internal Medicine 2012;157(6):429–38.
Schoening 2013
Schoening WN, Buescher N, Rademacher S, Andreou
A, Kuehn S, Neuhaus R, et al. Twenty-year longitudinal
follow-up after orthotopic liver transplantation: a single-
center experience of 313 consecutive cases. American
Journal of Transplantation 2013;13(9):2384–94.
Schulz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. JAMA 1995;273(5):408–12.
Schulz 2010
Schulz KF, Altman DG, Moher D. CONSORT 2010
statement: updated guidelines for reporting parallel group
randomised trials. BMJ (Clinical Research Ed.) 2010;340:
c332.
Severini 1993
Severini TA. Bayesian interval estimates which are also
confidence intervals. Journal of the Royal Statistical Society.
Series B (Methodological) 1993;55(2):533–40.
Singh 2015
Singh S, Murad MH, Chandar AK, Bongiorno CM,
Singal AK, Atkinson SR, et al. Comparative effectiveness
of pharmacological interventions for severe alcoholic
hepatitis: a systematic review and network meta-analysis.
Gastroenterology 2015;149(4):958–70.e12.
SRTR 2012
Scientific Registry of Transplant Recipients. OPTN/
SRTR 2012 annual data report: liver, 2012.
srtr.transplant.hrsa.gov/annual˙reports/2012/pdf/
03˙liver˙13.pdf (accessed 8 October 2014).
63Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stata/SE 14.2 [Computer program]
StataCorp LP. Stata/SE 14.2 for Windows[64-bit x86-64].
Version 14. College Station: StataCorp LP, 2017.
Thorlund 2011
Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger
G, Gluud C. User manual for Trial Sequential Analysis
(TSA). Copenhagen Trial Unit, Centre for Clinical
Intervention Research, Copenhagen, Denmark. Available
from www.ctu.dk/tsa 2011:1–115.
Thorlund 2012
Thorlund K, Mills EJ. Sample size and power considerations
in network meta-analysis. Systematic Reviews 2012;1:41.
TSA 2011 [Computer program]
Copenhagen Trial Unit, Centre for Clinical Intervention
Research, Copenhagen. TSA version 0.9. Copenhagen
Trial Unit, Centre for Clinical Intervention Research,
Copenhagen, 2011.
Turner 2012
Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins
JP. Predicting the extent of heterogeneity in meta-analysis,
using empirical data from the Cochrane Database of
Systematic Reviews. International Journal of Epidemiology
2012;41(3):818–27.
van Valkenhoef 2012
van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE,
Welton NJ. Automating network meta-analysis. Research
synthesis methods 2012;3(4):285–99.
Ware 2014
Ware JE. SF-36® health survey update, 2014. www.sf-
36.org/tools/sf36.shtml (accessed 8 October 2014).
Wetterslev 2008
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial Sequential
Analysis may establish when firm evidence is reached in
cumulative meta-analysis. Journal of Clinical Epidemiology
2008;61(1):64–75.
Wetterslev 2017
Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential
Analysis in systematic reviews with meta-analysis. BMC
Medical Research Methodology 2017;17(1):39.
Whitfield 2009
Whitfield K, Rambaldi A, Wetterslev J, Gluud C.
Pentoxifylline for alcoholic hepatitis. Cochrane Database
of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/
14651858.CD007339.pub2]
WHO 2013
World Health Organization - Regional Office for Europe.
Status report on alcohol and health in 35 European
countries 2013. www.euro.who.int/˙˙data/assets/pdf˙file/
0017/190430/Status-Report-on-Alcohol-and-Health-in-
35-European-Countries.pdf?ua=1 (accessed 23 October
2014).
WHO 2014
World Health Organization. Global status report on alcohol
and health 2014. http://apps.who.int/iris/bitstream/10665/
112736/1/9789240692763˙eng.pdf 2014.
Wood 2008
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman
DG, et al. Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions
and outcomes: meta-epidemiological study. BMJ (Clinical
Research Ed.) 2008;336(7644):601–5.
Yang 2014
Yang LS, Shan LL, Saxena A, Morris DL. Liver
transplantation: a systematic review of long-term quality of
life. Liver International 2014;34(9):1298–313.
References to other published versions of this review
Gurusamy 2015
Gurusamy KS, Tsochatzis E, Thorburn D, Davidson BR.
Pharmacological interventions for alcoholic liver disease
(alcohol-related liver disease): a network meta-analysis.
Cochrane Database of Systematic Reviews 2015, Issue 4.
[DOI: 10.1002/14651858.CD011646]
∗ Indicates the major publication for the study
64Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akriviadis 1990
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 74.
Post-randomisation dropouts: 2 (2.7%).
Revised sample size: 72.
Average age: 41 years.
Females: 23 (31.9%).
Inclusion criteria: 1. Palpable hepatomegaly. 2. Serum bilirubin of 5 mg/dL or more. 3.
One ormore of the followings: hepatic tenderness, fever above 100 degrees F, leucocytosis
above 12,000/mm3.
Exclusion criteria: 1. Life-threatening bacterial infection. 2. Massive gastrointestinal
haemorrhage. 3. Renal insufficiency (serum creatinine greater than 2.5mg/dL). 4. Serum
positivity for hepatitis B surface antigen. 5. Rapidly improving liver tests. 6. Clinical
evidence of advanced alcoholic cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 36): colchicine (1 mg once daily).
Group 2 (n = 36): placebo.
Duration: 30 days
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Reasons for post-randomisation dropouts: 1 withdrew consent and 1 left the hospital,
not considered for analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “all patients who fulfilled the above criteria were
randomly placed into two treatment groups”.
Comment: Further details were not available.
Allocation concealment (selection bias) Low risk Quote: “a coordinator that was not an investigator randomly
selected sealed envelopes for treatment decision, drugs were
coded and distributed by the hospital pharmacy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The studywas double blinded…one group received
identical placebo”
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Akriviadis 1990 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “An ombudsman who was not an investigator was
appointed to resolve issues arising from possible life-threat-
ening complications of therapy”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “There were two drop-outs: one patient withdrew
his consent 1 day after randomization, and a second patient
left the hospital against medical advice on the third day of
hospitalization”.
Comment: There were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “funded by the Division of Research Resources of
the National Resources of the National Institutes of Health,
Grant No. MOl-RR-43”
Other bias Low risk Comment: there was no other bias.
Akriviadis 2000
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 102.
Post-randomisation dropouts: 1 (1%).
Revised sample size: 101.
Average age: 42 years.
Females: 26 (25.7%).
Inclusion criteria: 1. History of heavy ethanol abuse. 2. Admission diagnosis of acute
alcoholic hepatitis. 3. Jaundice 4. Discriminant Fraction higher or equal to 32. 5. One
or more of: palpable tender hepatomegaly, fever, leukocytosis (white blood cell count
higher than 12,000/mm3 with predominantly neutrophil differentiation), hepatic en-
cephalopathy, hepatic systolic bruit hepatomegaly.
Exclusion criteria: 1. Concomitant bacterial infections. 2. Active gastrointestinal haem-
orrhage. 3. Severe cardiovascular or pulmonary disease. 4. decreasing serum bilirubin
values or rapid improvement of other liver test results over the first post admission days.
5. Clinical evidence of advanced alcoholic cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 49): pentoxifylline (400 mg thrice daily).
Group 2 (n = 52): placebo.
Duration: 4 weeks
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Gastrointestinal bleeding included in the adverse events because not specified if upper,
variceal or lower.
Reasons for post-randomisation dropouts: there was 1 dropout: a patient from the PTX
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Akriviadis 2000 (Continued)
group left the hospital against medical advice 1 day after randomisation. He received
only 3 capsules of PTX and therefore was excluded from analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A coordinator who was not an investigator ran-
domly selected sealed envelopes for treatment decisions, and
drugs were coded and distributed by the hospital pharmacy”
Allocation concealment (selection bias) Low risk Quote: “Sealed envelopes for treatment decisions, drugs
were coded and distributed by the hospital pharmacy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “VitaminB12 tablets were chosen as placebo because
their size and appearance are similar to those of PTX tablets,
thus facilitating identical filling of the capsules. The study
was double-blinded. Drugs were coded and distributed by
the hospital pharmacy”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The study was double-blinded. An ombudsman
who was not an investigator was appointed to resolve po-
tential issues arising from possible life-threatening compli-
cations of therapy”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “There was 1 dropout: a patient from the PTXgroup
left the hospital against medical advice 1 day after randomi-
sation. He received only 3 capsules of PTX and therefore
was excluded from analysis. The 5 patients fromboth groups
whomissed follow-up appointments were later contacted by
phone or were seen at a later date in the clinic, and their sur-
vival status was ascertained. Survival status was also assessed
after discharge from the hospital, over a 6-month follow-up
period, for all patients from both groups who survived the
index hospitalisation”.
Comment: only one missing of 102.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Hoeschst-Roussel Pharmaceuticals Inc for TNF
measurements”
Other bias Low risk Comment: there was no other bias.
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Baker 1981
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 51.
Post-randomisation dropouts: 1 (2%).
Revised sample size: 50.
Average age: 42 years.
Females: 21 (42%).
Inclusion criteria: 1. History of excessive alcohol consumption, 120 mL or more per day
for more than 1 year, a history of multiple repetitive alcoholic binges for years, or family
substantiation of excessive alcohol consumption for years without specific quantitation.
2. A liver biopsy demonstrating the lesion of alcoholic hepatitis, or when prolongation of
the prothrombin time refractory to parenteral vitamin K precluded biopsy an abnormal
SGOT which was greater than the SGPT.
Exclusion criteria: 1. Presence of active infections. 2. Gastrointestinal haemorrhage. 3.
Pancreatitis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 25): regular insulin 2 U/hour plus glucagon 200 µg/hour in 200 mL 5 %
dextrose over 12 hours daily.
Group 2 (n = 25): placebo.
Duration: 3 weeks
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: one patient left the study against medical
advice on second day infusion therapy and was not included in the data analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…using computer-generated random numbers”.
Allocation concealment (selection bias) Low risk Quote: “Patients were assigned to insulin and glucagon or
control groups by sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients in the control group received 5 % dextrose
in an identical fashion. Two grams of human serum albumin
were added to the bottles containing insulin and glucagon
to prevent absorption of the hormones to the infusion ap-
paratus and to the control bottles to maintain identical ap-
pearance of the solutions”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “One patient left the hospital against medical advice
on the 2nd day of the infusion therapy and is not included
in the data analysis”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Novo Research Institute, Copenhagen, Denmark,
and by Clinical Research Center Grant ”
Other bias Low risk Comment: there was no other bias.
Basu 2015
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 30.
Post-randomisation dropouts: not stated.
Revised sample size: 30.
Average age: not stated.
Females: not stated.
Inclusion criteria: 1. Severe alcoholic hepatitis (Maddrey discriminant function > 32).
2. Age 25 to 60 years. 3. MELD > 26
Exclusion criteria: 1.Hepatitis A, B,C. 2.Gastrointestinal bleed. 3.Hepatic encephalopa-
thy. 4. Sepsis
Interventions Participants were randomly assigned to three groups.
Group 1 (n = not stated): mycophenolate (500 mg twice daily) plus pentoxifylline (400
mg once daily).
Group 2 (n = not stated): glucocorticosteroids (prednisolone 30 mg once daily) plus
pentoxifylline (400 mg once daily).
Group 3 (n = not stated): mycophenolate (500 mg twice daily) plus glucocorticosteroids
(prednisolone 30 mg once daily) plus pentoxifylline (400 mg once daily).
Duration: 30 days
Outcomes None of the outcomes of interest were reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a randomised-open label placebo control”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Basu 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “a randomised-open label placebo control”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “a randomised-open label placebo control”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: none of the outcomes of interest were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Bird 1991
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 90.
Post-randomisation dropouts: 4 (4.4%).
Revised sample size: 86.
Average age: 46 years.
Females: 37 (43%).
Inclusion criteria: 1. History of alcohol intake greater than 40 mg/day in women or
60 mg/day in men. 2. Diagnosis of acute alcoholic hepatitis confirmed by liver biopsy
(characteristic histological features) OR by the presence of two or more of: palpable
hepatomegaly, leukocytosis of more than 11 x 10ˆ9 cells/L and “wipe out” on liver and
spleen isotope scanning in the absence of any other known or suspected aetiological
factor
Exclusion criteria: 1. Pancreatitis. 2. Severe gastrointestinal haemorrhage. 3. Malignant
disease. 4. Seropositivity forHBsAg. 5. Established alcoholic cirrhotic primarily admitted
for the control of complications arising directly from cirrhosis (bleeding oesophageal
or gastric varices). 6. Previous admissions for the management of the complications of
cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 43): insulin 30 U plus glucagon 3 mg (in 250 mL of 5% dextrose plus 1%
human albumin solution , infused in 12 hours/day).
Group 2 (n = 43): placebo.
Duration: max 3 weeks
Outcomes mortality, adverse events, liver transplantation.
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Notes Reasons for post-randomisation dropouts: 2 malignancy, 2 histology compatible to non-
A, non-B hepatitis (post-randomisation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “ Patients were randomised using sealed envelopes
to receive either insulin and glucagon treatment or placebo
after stratification on the basis of severity of illness”
Allocation concealment (selection bias) Low risk Quote: “sealed envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “ The control group received the dextrose-and-albu-
min solution in identical fashion. The nursing staff admin-
istering the infusions was blinded as to the contents of the
bags”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Four patients were withdrawn after randomisation
because of the subsequent additional diagnosis of malignant
disease in two patients (one case of pancreatic carcinoma
and one of HCC) and histological changes that were finally
attributed by the pathologist to non-A, non-B hepatitis (al-
though these were negative on serological testing for hepati-
tis C virus in two other patients. In the treatment group 1
patient left the hospital against medical advice and 4 with-
drew consent for the trial before death or the completion of
the 21-day course. In the placebo group 2 patients left the
hospital on their own and 5 withdrew consent. Respectively
3 and 2 patients were lost to 6 months follow up”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Novo Nordisk Pharmaceutical (Crawley. UK) pro-
vided Glucagon Novo and funded the hormone assay”
Other bias Low risk Comment: there was no other bias.
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Bird 1998
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 64.
Post-randomisation dropouts: 2 (3.1%).
Revised sample size: 62.
Average age: 52 years.
Females: 26 (41.9%).
Inclusion criteria: 1. History of alcohol intake greater than 40 mg/day in women or
60 mg/day in men. 2. Diagnosis of acute alcoholic hepatitis confirmed by liver biopsy
(characteristic histological features) OR by the presence of two or more of: palpable
hepatomegaly, leukocytosis of more than 11 x 10ˆ9 cells/L and “wipe out” on liver and
spleen isotope scanning in the absence of any other known or suspected aetiological
factor
Exclusion criteria: 1. Pancreatitis. 2. Severe gastrointestinal haemorrhage. 3. Malignant
disease. 4. Seropositivity for viral infections such as HBsAg, anti-HCV or anti-HIV. 5.
Established alcoholic cirrhotic primarily admitted for the control of complications arising
directly from cirrhosis (Bleeding oesophageal or gastric varices, recurrent or chronic
hepatic encephalopathy, ascites or oedema). 6. Previous admissions for the complications
of portal hypertension
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 32): amlodipine 5 mg or 10 mg once daily
Group 2 (n = 30): placebo.
Duration: 4 weeks
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: 2 patients were excluded from the analysis (1
malignant disease, 1 haemochromatosis)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Consecutive patients were randomised in a double-
blind fashion using a ‘sets of four’ procedure after stratifica-
tion on the basis of the severity of illness”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind fashion. The control group received
placebo capsules, similar in appearance and taste to the am-
lodipine. The treated patients received amlodipine (Pfizer,
Sandwich, UK) 10 mg (two capsules) daily, or 5 mg (one
capsule) if the prothrombin time was more than 3 s pro-
longed.In subjects with a prolonged prothrombin time on
entry to the study, the daily dose of the trial medication was
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increased to 10 mg (i.e. two capsules) when the prothrom-
bin time improved to only 3 or fewer seconds prolonged”.
Comment: Were there patients treated with 2 capsules in
the placebo group as well?
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Two patients were subsequently excluded from the
analysis: one in whom a diagnosis of genetic haemochro-
matosis was made after liver biopsy and a second patient in
whom an adenocarcinoma of the large bowel was diagnosed
2 weeks after entering the study”
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Financial assistance from Greater Glasgow Health
Board”
Other bias Low risk Comment: there was no other bias.
Blitzer 1977
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 33.
Post-randomisation dropouts: 5 (15.2%).
Revised sample size: 28.
Average age: 48 years.
Females: 0 (0%).
Inclusion criteria: 1. Recent history of heavy alcohol consumption (more than one
pint of whisky per day or its alcoholic equivalent). 2. Hepatomegaly based on physical
examination (palpablemore than5 cmbelow the costalmargin) and/or liver scan. 3. Total
serum bilirubin greater than 5 mg/dL. 4. At least two of the following abnormalities:
SGOT greater than 100 Reitman-Frankel units per mL, serum albumin concentration
less than 3 g/dL, prothrombin time more than 2 seconds greater than control value.
Exclusion criteria: 1. Adrenocorticosteroids in the six months prior to admission. 2.
Evidence of psychotic behavior precluding their co-operation during the investigation
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 12): glucocorticosteroids (prednisolone 10 mg four times daily (total of
40 mg per day)).
Group 2 (n = 16): placebo.
Duration:14 days, then tapering (20 mg for 4 days , 10 mg for 4 days, 5 mg for 4 days)
Outcomes mortality, adverse events.
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Blitzer 1977 (Continued)
Notes Reasons for post-randomisation dropouts: group 1: 3 withdrawal, 2 GI (received 5 days
of treatment), excluded from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were assigned by random, sealed-envelope
technique to receive either placebo or steroid”.
Comment: Further details were not available.
Allocation concealment (selection bias) Low risk Quote: “ Sealed-envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-blind study; only the pharmacist was aware
of the type of therapy. The control group received placebo
tablets according to the same dosage schedule of the steroid
group”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Double-blind study; only the pharmacist was aware
of the type of therapy”.
Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Five patients, who had each received less than 5
days of therapy, were subsequently excluded from analysis.
Of these, three had left the hospital against medical advice or
withdrew from the study, and in two experimental therapy
had been stopped following gastrointestinal haemorrhage”.
Comment: there were post-randomisation dropouts and no
results were reported about them
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Both prednisolone and placebo tablets were sup-
plied by the Upjohn Co., Kalamazoo, Michigan”
Other bias Low risk Comment: there was no other bias.
Boetticher 2008
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 48.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 48.
Average age: 51 years.
Females: 13 (27.1%).
Inclusion criteria: 1. Patients older than 18 years of age at entry. 2. Clinical evaluation and
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testing supporting a diagnosis of alcoholic hepatitis including jaundice, hepatomegaly,
leukocytosis, fever, elevations in transaminase levels. 3. MELD higher than 15. 4. Exclu-
sion of other causes of hepatitis including viral (negative hepatitis B surface antigen and
antibody to hepatitis C virus), autoimmune (antinuclear antibody titre 1:40, negative
antimitochondrial antibody, and smooth muscle antibody), drugs, or metabolic disor-
ders (normal ceruloplasmin levels) in the setting of compatible alcohol consumption. 5.
Significant alcohol consumption ( higher than 40 g per day for a minimum of 6 months
and within the 3 months prior to study enrolment). 6. In women: negative pregnancy
test or proof of surgical sterility or postmenopausal.
Exclusion criteria: 1. Hypersensitivity to etanercept. 2. Presence of infection documented
by chest x-ray or blood, urine, or ascites cultures. 3. History of autoimmune disease. 4.
Treatment with corticosteroids, pentoxifylline, propylthiouracil, or thalidomide in the
preceding 4 weeks prior to evaluation. 5. Breast-feeding or pregnancy in women
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 26): anti-TNF (etanercept 25 mg/day)
Group 2 (n = 22): placebo.
Duration: administration at days 1,4,8,11,15,18
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was conducted through the use of
logbooks in the study pharmacy at each individual site, in
which randomly generated numbers (blocks of 4) for each
strata were recorded. Enrolled patients were entered sequen-
tially to receive the assigned treatment. Randomization was
conducted separately at each center in absence of a stratifi-
cation scheme”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patient, coordinator, and physician were blinded to
randomisation group. The placebo group received subcuta-
neous injections of placebo on days 1, 4, 8, 11, 15, and 18
( 2 days for each dosing date), whereas the etanercept group
received subcutaneous injections of etanercept (25 mg) at
identical time points”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “An independent data safety board reviewed interim
data and analyses, whichwere blinded to all co-investigators”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were post-randomisation dropouts, 2 for
group and they never received trial treatment but all patients
analysed
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Supported byNIH, theNIH fundedMayoClinical
Research Unit (CTSA), Amgen (to V.S.), for study drug and
part of cytokine analyses”
Other bias Low risk Comment: there was no other bias.
Bories 1987
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 45.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 45.
Average age: 43 years.
Females: 18 (40%).
Inclusion criteria
1. Patients with acute alcoholic steatosis, fibrosis, or cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 24): glucocorticosteroids (prednisolone 40 mg/day).
Group 2 (n = 21): placebo.
Duration: 30 days duration
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “by random number table (’une table de nombre de
hasard’)”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants were included for analysis.
Selective reporting (reporting bias) High risk Comment: adverse events were not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Caballeria 1998
Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 136.
Post-randomisation dropouts: not stated.
Revised sample size: 136.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Age between 20 and 70 years; (2) A well-documented history of
an average daily alcohol consumption exceeding 80 g/day and active drinking at the
time of the study. 3. Mild clinical and laboratory abnormalities suggestive of early-stage
alcoholic liver disease. 4. Ultrasonographic evidence of fatty liver.
Exclusion criteria: 1. Advanced alcoholic liver disease. 2. Non-alcoholic liver disease. 3.
Allergy to pyridoxine or derivatives. 4. Regular treatments during the month prior to
the study. 5. Renal failure. 6. Other severe associated disease
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 69): metadoxine 1500 mg/day.
Group 2 (n = 67): placebo.
Duration: 3 months treatment
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A random code was prepared by computer for each
participating centre”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The study was conducted in a randomised, double-
blind fashion”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The study was conducted in a randomised, double-
blind fashion”.
Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Twelve patients in the metadoxine group and 13
in the placebo group were excluded prematurely from the
trial, mainly because of patient refusal to continue and loss
to follow-up”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Campra 1973
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 50.
Post-randomisation dropouts: 5 (10%).
Revised sample size: 45.
Average age: 43 years.
Females: 28 (62.2%).
Inclusion criteria: 1. Patients with severe acute alcoholic hepatitis. 2. Randomisation
within 10 days of hospital admission. 3. No previous history of liver disease. 4. No
contraindication for steroid therapy. 5. Judged to be seriously ill. 6. Other known illness
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 20): glucocorticosteroids (methylprednisolone 40 mg/day).
Group 2 (n = 25): no intervention.
Duration: 6 weeks treatment
Outcomes mortality.
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised to one of the two groups”.
Allocation concealment (selection bias) Unclear risk Quote: “By using previously prepared sealed envelopes, pa-
tients were randomly allocated”.
Comment: Further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The trial was not double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The trial was not double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events were not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Carithers 1989
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 67.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 67.
Average age: 43 years.
Females: 26 (38.8%).
Inclusion criteria: 1. Spontaneous hepatic encephalopathy. 2. Discriminant function of
32 or greater
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 36): glucocorticosteroids (methylprednisolone 32 mg/day).
Group 2 (n = 31): placebo.
Duration: 28 days
Outcomes mortality.
Notes
Risk of bias
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Carithers 1989 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A random code was prepared for each of the four
participating institutions…”.
Comment: the method of preparing the random code was
not reported
Allocation concealment (selection bias) Low risk Quote: “The random code sequence was kept by an inde-
pendent source.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All patients were included for analysis..
Selective reporting (reporting bias) High risk Comment: Adverse events were not reported.
For-profit bias Low risk Quote: “Supported by a research grant from the National
Institute of Alcohol Abuse and Alcoholism”
Other bias Low risk Comment: There was no other bias.
Colman 1998
Methods Randomised clinical trial
Participants Country: Australia.
Number randomised: 129.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 129.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Alcoholic liver cirrhosis
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 63): colchicine 1 mg once daily.
Group 2 (n = 66): placebo.
Duration: mean 45 months
Outcomes None of the outcomes of interest were reported.
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Colman 1998 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients with alcoholic cirrhosis were entered into
a randomised. double blind, placebo controlled trial…”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Patients with alcoholic cirrhosis were entered into
a randomised, double blind, placebo controlled trial”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “41 patients had to be withdrawn from the study
during follow up: 26 for non compliance, 10 for adverse
events and 5 for geographic reasons”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: none of the outcomes of interest was not re-
ported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Cortez-Pinto 2002
Methods Randomised clinical trial
Participants Country: Portugal.
Number randomised: 62.
Post-randomisation dropouts: 7 (11.3%).
Revised sample size: 55.
Average age: 54 years.
Females: 6 (10.9%).
Inclusion criteria: 1. Age between 18 and 65 years. 2. Biopsy- proven liver cirrhosis. 3.
A well-documented history of previous daily alcohol intake exceeding 40 g of ethanol
in women and 60 g in men for more than 5 years. 4. Exclusion of other causes of liver
disease were excluded.
Exclusion criteria: 1. Haemochromatosis. 2. Wilson’s disease. 3. Alfa-1-antitrypsin defi-
ciency. 4. Autoimmune hepatitis. 5. Primary biliary cirrhosis. 6. Viral hepatitis. 7. Child-
Pugh class C. 8. Serum bilirubin greater than 10 mg/dL. 9. Gastrointestinal bleeding in
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Cortez-Pinto 2002 (Continued)
the previous 15 days. 10. Refractory ascites. 11. Rrenal failure (creatinine greater than
2.5 mg/dL). 12. Cardiac failure. 13. Neoplasia. 14. Other serious illness
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 29): colchicine 1 mg once daily.
Group 2 (n = 26): placebo.
Duration: 5 days per week for 6 months
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: post-randomisation: 2 (groupA) and 5 (group
B) lost to follow-up at 6months, at 3 years 9, at 5 years 14, at 10 years 33/ no information
on the number of dropouts in each group of patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-generated randomisation list (blocks of
four)”
Allocation concealment (selection bias) Low risk Quote: “Codeddrugs, similar in appearance, concealed from
the clinicians. Study drugs identical in appearance, prepared
at the hospital pharmacy, coded and distributed to the pa-
tient by the hospital pharmacy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double blind; therapy prepared by the pharmacist;
at no timewere the treatment codes disclosed for any patient,
attending physicians or investigators”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “At no time were the treatment codes disclosed for
any patient, attending physicians or investigators”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “7 patients not considered in the analysis because
did not present at the first follow up visit; other drop outs
during the following years”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “This study was supported in part by a grant from
the Center of Nutrition and Metabolism”
Other bias Low risk Comment: there was no other bias.
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De 2009
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 70.
Post-randomisation dropouts: 2 (2.9%).
Revised sample size: 68.
Average age: 47 years.
Females: 1 (1.5%).
Inclusion criteria: 1. History of chronic alcohol intake of more than 50 g/d. 2. Clinical
and biochemical features of severe alcoholic hepatitis [Maddrey Discriminant Function
of 32 or greater, aspartate aminotransferase- alanine aminotransferase ratio higher than
2 (with AST lower than 500 IU/L and ALT lower than 200 IU/L)].
Exclusion criteria: 1. Acute or chronic viral hepatitis. 2. Autoimmune liver disease. 3.
Wilson’s disease. 4. History of abstinence from alcohol in the last month. 5. Seropositiv-
ity for HIV. 6. Infection, sepsis or spontaneous bacterial peritonitis. 7. Gastrointestinal
bleeding. 8. Hepatorenal syndrome. 9. Acute pancreatitis. 10. Any other severe associ-
ated disease (uncontrolled diabetes, hypertension, heart failure, pulmonary disease or
malignancy) at the time of inclusion or in the previous 3 months
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 34): pentoxifylline (400 mg thrice daily ) plus placebo once daily.
Group 2 (n = 34): glucocorticosteroids (prednisolone 40 mg once daily) plus placebo.
Duration: 4 weeks
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Reasons for post-randomisation dropouts: 2 withdrawal of consent after randomisation,
excluded from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The included patients were divided into two groups
by a computer-generated randomisation table”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “After the initial 4 weeks, the study was opened and
the patients allocated to the different groups were revealed”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigators who allocated the patients to the
groups, administered the drugs and collected the clinical
and laboratory data, as well the statisticians, were all blinded
regarding the nature of the pharmacotherapy”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Two patients in group withdrew voluntarily from
the study and were excluded”
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De 2009 (Continued)
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
De 2014
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 62.
Post-randomisation dropouts: 2 (3.2%).
Revised sample size: 60.
Average age: 42 years.
Females: 0 (0%).
Inclusion criteria: 1. History of chronic alcohol intake of more than 50 g/day. 2.Maddrey
Discriminant Function of 32 or more. 3. AST:ALT ratio higher than 2 (with absolute
value of AST lower than 500 IU/L and ALT lower than 200 IU/L).
Exclusion criteria: 1. Acute or chronic viral hepatitis. 2. Autoimmune liver disease. 3.
Wilson’s disease. 4. HIV- positivity. 5. History of abstinence from alcohol in the last
month. 6. Infection. 7. Sepsis. 8. Spontaneous bacterial peritonitis. 9. Acute pancreatitis.
10. Gastro-intestinal bleeding. 11. Hepatorenal syndrome. 12. Uncontrolled diabetes
mellitus. 13. Systemic hypertension. 14. Heart failure. 15. Pulmonary disease. 16. Ma-
lignancy at the time of inclusion or in the previous 3 months
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 30): pentoxifylline 400 mg thrice daily plus glucocorticosteroids (pred-
nisolone 40 mg once daily).
Group 2 (n = 30): pentoxifylline 400 mg thrice daily.
Duration: 4 weeks
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Reasons for post-randomisation dropouts: one patient in Group 1 developed severe
vertigo within 7 days after starting PTX and one patient in Group 2withdrew voluntarily
from the study and hence they were excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The recruited patients were then divided into 2
groups by a computer generated randomisation table”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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De 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The investigator, who allocated the patients to the
groups, administered the drugs and collected the clinical
and laboratory data, as well as statisticians were all blinded
regarding the nature of the pharmacotherapy”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigator, who allocated the patients to the
groups, administered the drugs and collected the clinical
and laboratory data, as well as statisticians were all blinded
regarding the nature of the pharmacotherapy”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “One patient in Group 1 developed severe vertigo
within 7 days after starting PTX and one patient in Group
2 withdrew voluntarily from the study and hence they were
excluded”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
De la Maza 1995
Methods Randomised clinical trial
Participants Country: Chile.
Number randomised: 74.
Post-randomisation dropouts: 7 (9.5%).
Revised sample size: 67.
Average age: 50 years.
Females: 11 (16.4%).
Inclusion criteria: 1. Two or more of the following: jaundice, encephalopathy, ascites,
oedema, spider naevi, marked collateral circulation, bleeding disorders, oesophageal
varices on endoscopy. 2. A history of 5 years or more of heavy alcohol consumption
(daily alcohol intake greater 150 g). 3. Absence of hepatitis B surface antigen. 4. Ab-
sence of significant renal, pulmonary or cardiac disease. 5. Absence of clinical diabetes
or malignant tumours (including hepatoma).
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 33): antioxidants (vitamin E 500 mg once daily).
Group 2 (n = 34): placebo.
Duration: 1 years treatment
Outcomes mortality.
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De la Maza 1995 (Continued)
Notes Reasons for post-randomisation dropouts: group A: 4 lack of compliance, Group B: 3
lack of compliance (post-randomisation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were randomly and blindly as-
signed to an experimental or control group. Patients were
previously stratified according to their Clinical Combined
Laboratory Index ”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double blind”.
Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Four experimental subjects and three controls were
removed from the study due to lack of compliance”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Financing was provided by INTA-University of
Chile, Roche and Saval Laboratories”
Other bias Low risk Comment: there was no other bias.
De Silva 2003
Methods Randomised clinical trial
Participants Country: Sri Lanka.
Number randomised: 80.
Post-randomisation dropouts: not stated.
Revised sample size: 80.
Average age: 47 years.
Females: 0 (0%).
Inclusion criteria: clinical, biochemical, and where possible, histological evidence of
alcoholic liver disease.
Exclusion criteria: 1. Evidence of oesophageal varices. 2. Hepatic encephalopathy. 3.
Other chronic diseases requiring long-term drug therapy such as diabetes, malignancy,
hypertension and others
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De Silva 2003 (Continued)
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 40): Liv.52 (3 twice daily).
Group 2 (n = 40): placebo.
Duration: 6 months treatment
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization done in India by an individual not
associated with the care or assessment of patients, by means
of a table of random numbers”
Allocation concealment (selection bias) Unclear risk This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind, Identical characteristics of drug and
placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigators who performed blood analysis
and those who did clinical assessments were blind to the
intervention”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “A significant number of subjects dropped out at
various stages of the trial. Despite many attempts, none of
the dropouts could be contacted”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias High risk Quote: “Liv.52 and placebo tablets were supplied by Hi-
malaya Drug Co., Bombay, India”
Other bias Low risk Comment: there was no other bias.
Depew 1980
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 28.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 28.
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Depew 1980 (Continued)
Average age: 49 years.
Females: 12 (42.9%).
Inclusion criteria: 1. Alcohol abusers. 2. Clinical diagnosis of severe acute alcoholic
hepatitis manifested by hepatomegaly, leucocytosis and a serum bilirubin greater than
5 mg/dL. 3. Spontaneous hepatic encephalopathy in the absence of gastrointestinal
haemorrhage, sedation, diuretic usage, or major electrolyte disturbances.
Exclusion criteria: 1. Severe diabetes. 2. Active tuberculosis. 3. Serious bacterial infection
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 15): glucocorticosteroids (prednisolone 40 mg once daily).
Group 2 (n = 13): placebo.
Duration: 28 days followed by tapered withdrawal over the ensuing 14 days
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “all patients fulfilling the criteria who gave informed
consent were randomised into two treatment protocols”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither the principal investigator nor the physicians
attending the patients were aware of the identity of the coded
drugs”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Diaz Belmont 1996
Methods Randomised clinical trial
Participants Country: Mexico.
Number randomised: 45.
Post-randomisation dropouts: not stated.
Revised sample size: 45.
Average age: 41 years.
Females: 5 (11.1%).
Inclusion criteria: 1. ALD. 2. At least 3 months of active drinking before the beginning
of the study. 3. Signed consent form. 4. Negative viral hepatitis markers. 5. Maddrey
discriminant function higher of equal to 32.
Exclusion criteria: 1. Grade IV hepatic encephalopathy. 2. Other cause of liver disease.
3. Doubtful alcoholic aetiology. 4. Other chronic co-morbidities (TB, diabetes, active
gastrointestinal bleeding)
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 22): s-adenosyl-L-methionine (200 mg).
Group 2 (n = 23): placebo.
Duration: 15 days
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Feher 1989
Methods Randomised clinical trial
Participants Country: Hungary.
Number randomised: 36.
Post-randomisation dropouts: not stated.
Revised sample size: 36.
Average age: 46 years.
Females: 9 (25%).
Inclusion criteria: ALD
Exclusion criteria: other causes of liver disease
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 17): silymarin 140 mg thrice daily.
Group 2 (n = 19): placebo.
Duration: 6 months treatment
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Random code”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Fenster 1966
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 32.
Post-randomisation dropouts: 5 (15.6%)
Revised sample size: 27.
Average age: 49 years.
Females: 15 (55.6%).
Inclusion criteria: 1. Clinical and laboratory evidence of chronic alcoholic liver disease.
2. Evidence of liver parenchymal dysfunction (distinct from signs of portal hypertension)
. 3. No gross gastro-intestinal bleeding. 4. No evidence of prostatic carcinoma.
Exclusion criteria: not reported.
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 17): anabolic steroids (methenolone 100 mg once daily or testosterone
100 mg once daily given randomly)
Group 2 (n = 10): placebo.
Duration: 1 month treatment
Outcomes mortality.
Notes Reasons for post-randomisation dropouts: although they initiated treatment, they were
not included in the analysis because they did not complete treatment schedule
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised by coded names”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk This information was not available.
For-profit bias High risk Quote: “medications provided by Squibb & Sons”.
Other bias Low risk Comment: there was no other bias.
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Fernandez-Rodriguez 2008
Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 24.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 24.
Average age: 53 years.
Females: 4 (16.7%).
Inclusion criteria: cirrhosis of alcoholic origin.
Exclusion criteria: 1. Aetiology other than alcohol abuse (infection with B or C hepatitis
viruses). 2. Active or recent gastrointestinal bleeding (one week prior to inclusion). 3.
Grade III-IV hepatic encephalopathy. 4. Primary renal or cardiopulmonary disease. 5.
Insulin-requiring diabetes mellitus. 6. Ongoing bacterial infection. 7. Complete portal
vein thrombosis. 8. Receiving drugs with haemodynamic effects such as β-blockers,
nitrites or non-steroidal anti-inflammatory drugs
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 12): pentoxifylline 400 mg thrice daily.
Group 2 (n = 12): placebo.
Duration: 4 weeks
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-generated random series performed by
a member of the pharmacy”
Allocation concealment (selection bias) Low risk Quote: “The sequence was concealed until intervention was
assigned. An allocation code was kept in sealed envelopes in
the hospital’s pharmacy until data analysis”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients, aswell as researchers, were blinded to treat-
ment assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, aswell as researchers, were blinded to treat-
ment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
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Fernandez-Rodriguez 2008 (Continued)
For-profit bias High risk Quote: “Ferrer Pharmaceutical Company supplied the
placebo”.
Other bias Low risk Comment: there was no other bias.
Fleig 1997
Methods Randomised clinical trial
Participants Country: Germany/UK.
Number randomised: 188.
Post-randomisation dropouts: not stated.
Revised sample size: 188.
Average age: 52 years.
Females: 73 (38.8%).
Inclusion criteria: Biopsy-proven alcoholic cirrhosis
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 98): Liv.52 300 mg thrice daily.
Group 2 (n = 90): placebo.
Duration: 2 years
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised after stratification for disease severity”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double-blind”.
Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: not reported if loss to follow up or dropouts.
Selective reporting (reporting bias) High risk Comment: not clear adverse events.
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Fleig 1997 (Continued)
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Garrido Garcia 2012
Methods Randomised clinical trial
Participants Country: Mexico.
Number randomised: 60.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 60.
Average age: 43 years.
Females: 4 (6.7%).
Inclusion criteria: 1. Clinical and biochemical criteria for alcoholic hepatitis. 2. Maddrey
DF higher or equal than 32.
Exclusion criteria: 1. Pregnancy. 2. serious bacterial infections at inclusion. 3. Cancer.
4. Other chronic co-morbidities such as diabetes mellitus, hypertension, heart disease.
4. HIV-infection. 5. Use of potentially hepatotoxic drugs. 6. Previous use of steroids
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 30): pentoxifylline 400 mg thrice daily (total 1200 mg/day).
Group 2 (n = 30): glucocorticosteroids (prednisolone 40 mg once daily).
Duration: 28 days
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Different treatments.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
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Garrido Garcia 2012 (Continued)
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Geminiani 1979
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 20.
Post-randomisation dropouts: not stated.
Revised sample size: 20.
Average age: 42 years.
Females: 5 (25%).
Inclusion criteria: alcoholic for at least 2 years, relatively constant alcohol intake.
Exclusion criteria: not reported.
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 10): cycloxilic acid 240 mg/day.
Group 2 (n = 10): placebo.
Duration: 1 month treatment
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
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Geminiani 1979 (Continued)
Selective reporting (reporting bias) High risk Comment: adverse events were not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Gluud 1986
Methods Randomised clinical trial
Participants Country: Denmark.
Number randomised: 221.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 221.
Average age: 53 years.
Females: 0 (0%).
Inclusion criteria: 1. A daily ethanol consumption greater than 50 g for more than 2
years. 2. Cirrhosis diagnosed by biopsy within last 6 months. 3. Specific aetiology of
cirrhosis other than ethanol could be excluded
Exclusion criteria: 1. Patients unable to co-operate or who refused to give consent. 2.
HBsAg- positivity. 3. HCC or other malignancies. 4. Other significant diseases. 5. Other
non-disease-related causes (e.g., immigration). 6. Previous treatment with anabolic-an-
drogenic steroids
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 134): anabolic steroids (testosterone 100 mg once daily).
Group 2 (n = 87): placebo.
Duration: 8 to 62 months (median 28)
Outcomes mortality, hepatocellular carcinoma.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization by skewed randomisation 3:2 in
each hospital (series of 10 serially numbered boxes with 6
of test and 4 of placebo); then each patient allocated at the
lowest box number”
Allocation concealment (selection bias) Low risk Quote: “numbered boxes”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind; drugs and placebo of identical ap-
pearance, taste and smell”
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Gluud 1986 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Double-blind; physicians not allowed to know the
testosterone serum levels”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “There were drop-outs, but criteria well-explained at
the beginning of the study and all included in the analysis”
Selective reporting (reporting bias) High risk Quote: “Adverse events not quantified or clearly reported”.
Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias Low risk Quote: “ supported by medical research foundations”.
Other bias Low risk Comment: there was no other bias.
Halle 1982
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 71.
Post-randomisation dropouts: 4 (5.6%).
Revised sample size: 67.
Average age: 39 years.
Females: 6 (9%).
Inclusion criteria: 1. Recent, heavy alcohol ingestion. 2. Serum bilirubin of 5 mg/dL
or more. 3. At least one of the following: hepatic tenderness, fever above 100°F, or
leukocytosis above 12,000 mm3
Exclusion criteria: 1. Serious bacterial infection. 2. Massive gastrointestinal bleeding. 3.
Pre-existing renal failure (serum creatinine greater than 2.5 mg/dL). 4. A previous or
current thyroid disease
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 31): propylthiouracil 75 mg four times daily.
Group 2 (n = 36): placebo.
Duration: 6 weeks
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Reasons for post-randomisation dropouts: 2 refused treatment, 2 had bilirubin lower
than 5 g/dL
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “all patients fulfilling the criteria who gave informed
consent were randomised into two treatment groups”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “.identical placebo”. “The investigators were not
aware of which regimen the patient was receiving until the
study ended”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Two patients refused therapy on the first day; in 2
other patients treatment was discontinued as bilirubin was
<5 mg/dl at randomisation”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “This work was supported by the Hastings Founda-
tion, Los Angeles, California. Dr. Halle received a Fellow-
ship from theCanadian Liver Foundation andDr. Pare from
the Medical Research Council (Canada)”
Other bias Low risk Comment: there was no other bias.
Helman 1971
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 37.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 37.
Average age: 48 years.
Females: 25 (67.6%).
Inclusion criteria: 1. Alcoholic hepatitis confirmed by percutaneous needle biopsy before
inclusion in the study.
Exclusion criteria: 1. If a biopsy could not be obtained within the first week of hos-
pitalisation. 2. Gastrointestinal bleeding requiring transfusion. 3. The purified protein
derivative (PPD) test was positive
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 20): glucocorticosteroids (prednisolone 40 mg once daily).
Group 2 (n = 17): placebo.
Duration: 4 weeks
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Outcomes mortality, cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were selected by a random, double-blind
technique”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Quote: “drug treatment was randomly determined by the
hospital pharmacist”.
Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “..without informing physicians, nurses, or patients
until completion of the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “supported in part by grants ES00129 AM05503,
and AM090C0, U. S. Public Health Service”.
Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Higuera de la Tijera 2015
Methods Randomised clinical trial
Participants Country: Mexico.
Number randomised: 135.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 135.
Average age: 43 years.
Females: 11 (8.1%).
Inclusion criteria: 1. Age between 18 and 65 years old. 2. History of heavy and chronic
alcohol intake (more than 80 g per day within the previous 5 years). 3. Rapid onset
of jaundice in the absence of biliary tract obstruction by ultrasound. 4. Painful hep-
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atomegaly. 5. Ascites. 6. Transaminases increase more than two times above the normal
value. 7. An aspartate aminotransferase/alanine aminotransferase ratio greater than 2
times normal. 8. Leucocytosis with a predominance of neutrophils. 9. Total bilirubin of
more than 5 mg/dL. 10. Maddrey discriminant factor greater than 32.
Exclusion criteria: 1. Acquired immunodeficiency syndrome. 2. Neoplasms. 3. Autoim-
mune diseases. 4. Psychiatric disorders different from alcoholism. 5. History of atopy or
asthma. 6. Diabetes. 7. Pregnancy. 8. Hepatits B virus. 9. Hepatitis C virus. 10. Tuber-
culosis. 11. Intake of illicit drugs, herbal products, antioxidant supplements, or previous
treatment with steroids or pentoxifylline within the previous 2 years. 12. Patients without
family support or without access to telephone communication
Interventions Participants were randomly assigned to four groups.
Group 1 (n = 35): glucocorticosteroids (prednisolone 40 mg once daily) plus metadoxine
(500 mg thrice daily).
Group 2 (n = 35): glucocorticosteroids (prednisolone 40 mg once daily)
Group 3 (n = 32): pentoxifylline (400 mg thrice daily) plus metadoxine (500 mg thrice
daily).
Group 4 (n = 33): pentoxifylline (400 mg thrice daily).
Duration: 30 days
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For the randomization, we used the Epidat 3.1 sta-
tistical program to construct a table of random numbers
considering groups of equal size. For each patient, once ver-
ified if he or she met with the selection criteria, we assigned
to a group of treatment according to the table of random
numbers (author’s reply)”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The present study was a randomized, open-label
clinical study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The present study was a randomized, open-label
clinical study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all patients were included for analysis.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
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For-profit bias Low risk Quote: “This work was partially sypported by funds granted
to Higuera de la Tijera through the stimulus ”Angeles Es-
pinosa Yglesias 2010“ granting FUNSALUD AC, AM-
PARO Foundation and FUNDHEPA AC, Mexico. Euro-
drug laboratories de mexico s.a. donated metadoxine to
Mexico’ General Hospital for this study”
Other bias Low risk Comment: there was no other bias.
Keiding 1994
Methods Randomised clinical trial
Participants Country: UK/Denmark/Spain.
Number randomised: 407.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 407.
Average age: 49 years.
Females: not stated
Inclusion criteria: 1. A daily estimated alcohol intake of 80 g or more for the preceding
4 years. 2. A liver biopsy compatible with alcoholic liver disease taken within 6 months
before the entry to the study, unless biopsy was impossible because of bleeding tendency,
or the patient refused liver biopsy and the physicians of the liver unit had other evidence
confirming the diagnosis. 3. The patient gave informed consent. 4. Age between 20 and
80 years of old.
Exclusion criteria: 1. Advanced encephalopathy. 2. Other aetiology for chronic liver
disease. 3. Other drug with intended effects similar to those of malotilate had been
given during the preceding 6 months. 4. Other disease with expected survival less than
6 months was detectable. 5. Pregnancy
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 270): malotilate (750 mg/d or 1500 mg/d given randomly) thrice daily.
Group 2 (n = 134): placebo.
Duration: 3 years
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated randomly to the three treat-
ment groups within each centre in blocks of six patients ”
Allocation concealment (selection bias) Low risk Quote: “…using the sealed envelopes method”.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “In the present study the effect of malotilate on the
survival of patients with alcoholic liver disease was examined
in a multicenter, international, double-blind, randomised,
placebo-controlled clinical trial. The tablets had identical
appearance and taste (Zyma 15057)”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Sixty-eight patients were lost to follow-up (26, 23,
and 19 patients in the three above-mentioned treatment
groups, respectively)”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “supported by Zyma SA, Nyon, Switzerland, and
Nihon Nohyaku, Tokyo”
Other bias Low risk Comment: there was no other bias.
Kim 2012
Methods Randomised clinical trial
Participants Country: South Korea.
Number randomised: 95.
Post-randomisation dropouts: not stated.
Revised sample size: 95.
Average age: 51 years.
Females: 15 (15.8%).
Inclusion criteria: 1. Age between 18 and 70 years. 2. Chronic alcoholic liver diseases.
3. Discontinuation of alcohol intake for at least 6 months before starting the study.
Exclusion criteria: 1.Decompensated liver disease/ cirrhosis. 2.Hepatocellular carcinoma
or other malignancies. 3. Hepatitis B, hepatitis C infection. 4. Autoimmune liver disease.
5. Previous alcohol intake lower than 140 g/week
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 42): candesartan 8 mg plus ursodeoxycholic acid 600 mg/day.
Group 2 (n = 43): ursodeoxycholic acid 600 mg/day.
Duration: 6 months
Outcomes adverse events.
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were chronologically randomised into two
groups by the pharmacy at Wonju Christian Hospital using
serially numbered sealed envelopes in batches of 90 that
designated a patient to one of two treatments”
Allocation concealment (selection bias) Low risk Quote: “sealed envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Open to patients and investigators”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Open to patients and investigators”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “12 patients were withdrawn from the study during
the 6 months due to loss to follow up, low medical compli-
ance and ingestion of alcohol”.
Comment: ITT analysis for fibrosis stage and scores, not for
serum markers of fibrosis
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Low risk Quote: “This work was supported by Yonsei University
Wonju College of Medicine Research Fund of 2008 and
also by a grant from the Korea Healthcare technology R&D
Project, Ministry of Health and Welfare, Republic of Korea.
(A102065). No financial support from any pharmaceutical
companies producing Angiotensin II type 1 receptor block-
ing agent (ARB) related drugs”
Other bias Low risk Comment: there was no other bias.
Lebrec 2010
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 133.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 133.
Average age: 55 years.
Females: not stated
Inclusion criteria: 1. Child-Pugh class C biopsy proven cirrhosis (higher than 9 points)
2. Age higher than 18 years.
Exclusion criteria: 1. Pregnancy. 2. Anticoagulant treatment. 3. Noncorticosteroid im-
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munosuppressive drugs. 4. Treated arterial hypertension. 5. Severe coronary artery dis-
ease. 6. HIV infection. 7. Hypersensitivity to pentoxifylline. 8. Transplanted patients. 9.
Pentoxifylline treatment in the 3 months before the study. 10. Advanced hepatocellular
carcinoma. 11. Associated illnesses with a life expectancy of 1 month. 12. Patients who
could not be regularly followed up
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 71): pentoxifylline 400 mg thrice daily.
Group 2 (n = 62): placebo.
Duration: 6 months
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was computer-generated”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind. Pentoxifylline in opaque capsule
form or identical capsules containing the placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Events were recorded without knowing the ran-
domisation code”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: subanalysis on subgroup of patients with alco-
holic hepatitis, therewere dropouts, not clear if patients from
this group
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Quote: “Supported by a grant from the French Ministry
of Health. Pentoxifylline and placebo were purchased from
Sanofi-Aventis, Sanofi-Aventis did not participate in any
part of the study, including study design, data analysis, and
manuscript preparation”
Other bias Low risk Comment: there was no other bias.
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Methods Randomised clinical trial
Participants Country: Germany.
Number randomised: 12.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 12.
Average age: not stated.
Females: 4 (33.3%).
Inclusion criteria: 1. Biopsy proven alcoholic cirrhosis of the liver. 2. Consumption of
more than 60 g of alcohol daily for more than 10 years. 3. Abstinence for more than 8
weeks prior to initiation of treatment.
Exclusion criteria: 1. Other viral active hepatitis. 2. HCC.
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 6): Liv.52 four times daily.
Group 2 (n = 6): placebo.
Duration: 24 weeks
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, randomised, placebo-controlled, dou-
ble-blind and cross-over design ”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “prospective, randomised, placebo-controlled, dou-
ble-blind and cross-over design ”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There were no dropouts ”.
Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 60.
Post-randomisation dropouts: 11 (18.3%).
Revised sample size: 49.
Average age: 49 years.
Females: 1 (2%).
Inclusion criteria: 1. Age between 20 and 70 years. 2. Diagnosis of alcoholic cirrhosis
within 5 years previous to inclusion and based on clinical and laboratory data with
evidence of portal hypertension and ultrasound or upper gastrointestinal endoscopy. 3.
Daily alcohol intake of 60 g or more in men and 40 g or more in women over a period of
more than 5 years. 4. Histological diagnosis of cirrhosis within 6months before inclusion
if applicable (patient’s refusal or coagulation disorders).
Exclusion criteria: other causes of liver disease, HCC, anticipated need for LT within 1
year, age < 20 > 70 years, immunosuppression
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 24): silymarin 150 mg thrice daily.
Group 2 (n = 25): placebo.
Duration: 6 months
Outcomes None of the outcomes of interest were reported.
Notes 11 patients were withdrawn for different reasons, of these five because of hepatic de-
compensation, one of whom died, and 1 because of an adverse event. The authors have
therefore considered just 49 patients for the analysis. Of these patients none died or had
adverse events.
Reasons for post-randomisation dropouts: 11withdrawn although receiving treatment (6
vs 5), 3 + 2 for alcohol-consumption, 2 + 3 for hospital admission due to decompensation
(1 died), 1 adverse event (silymarin)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computerized sequence generation. The patients
were assigned according to a balanced, randomly-generated
allocation sequence”.
Comment: according to the author’s reply.
Allocation concealment (selection bias) Low risk Quote: “Sealed envelopes kept at the pharmacy depart-
ment”.
Comment: according to the author’s reply.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “…a placebo of identical appearance”.
Comment: according to the author’s reply.
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: according to the author’s reply.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Eleven patients, 6 in the silymarin groups and 5
in the placebo group did not complete the trial and were
withdrawn”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: none of the outcomes of interest were reported.
For-profit bias High risk Quote: “Silymarin and placebo were kindly supplied by
Madaus, Cerafarm, Barcelona, Spain”
Other bias Low risk Comment: there was no other bias.
Maddrey 1978
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 57.
Post-randomisation dropouts: 1 (1.8%).
Revised sample size: 56.
Average age: 41 years.
Females: 20 (35.7%).
Inclusion criteria: 1. History of long-standing and recent alcoholism. 2. Percutaneous
liver biopsy if coagulation parameters permitted.
Exclusion criteria: 1. Active gastrointestinal bleeding. 2. Pancreatitis. 3. History of peptic
ulcer disease. 4. Active infection. 5. Presence of hepatitis B antigen. 6. History of previous
viral hepatitis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 25): glucocorticosteroids (prednisolone 5 mg once daily).
Group 2 (n = 31): placebo.
Duration: 28-32 days
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: one patient who was randomised to the
placebo group bled from oesophageal varices before receiving the study drug. He subse-
quently stoppedbleeding and survived. Another patient had an episode of upper gastroin-
testinal haemorrhage presumably from oesophageal varices after receiving prednisolone
for 9 days and the drug was stopped. This patient subsequently survived but has not
been included in the analysis because the study drug was discontinued
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the study was conducted in a randomised double
blind fashion”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Quote: “Random drug sequences were arranged within each
group”.
Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study was conducted in a randomised double
blind fashion”. “The investigators were not aware of which
regimen the patient was receiving until the completion of
the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigators were not aware of which regimen
the patient was receiving until the completion of the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “One patient who was randomised to the placebo
group bled from oesophageal varices before receiving the
study drug. He subsequently stopped bleeding and survived.
Another patient had an episode of upper gastrointestinal
haemorrhage after receiving prednisolone for 9 days and the
drug was stopped. This patient subsequently survived but
has not been included in the analysis”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “This study was supported by Research Grant
AA00201 from the National Institute of Alcohol Abuse and
Alcoholism of the National Institutes of Health, and by
Grant RR-35 from the Clinical Research Centers Program,
United States Public Health Service. Prednisolone (5 mg)
and identical placebo tablets were provided by the Division
of Steroid Research, The Upjohn Company, Kalamazoo,
Mich.)”
Other bias Low risk Comment: there was no other bias.
Mathurin 2013
Methods Randomised clinical trial
Participants Country: Belgium and France.
Number randomised: 278.
Post-randomisation dropouts: 8 (2.9%).
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Revised sample size: 270.
Average age: 52 years.
Females: 107 (39.6%).
Inclusion criteria: 1. Age between 18 and 70. 2. Heavy drinkers (more than 40 g/d of
alcohol for women and more than 50 g/d for men). 3. Biopsy-proven alcoholic hepatitis.
4. Recent onset of jaundice within the past 3months. 5. A Maddrey score of at least 32.
Exclusion criteria: 1. Presence of hepatitis B surface antigen, hepatitis C virus or HIV
antibodies. 2. Pregnancy. 3. Breastfeeding. 4. Concomitant or previous history of hepa-
tocellular carcinoma. 5. Evolutive neoplasia likely to threaten 1-year outcome. 6. Uncon-
trolled bacterial infection within 7 days. 7. Concomitant or previous history of fungal,
viral, or parasitic infection. 8. Severe associated disease (cardiac failure, severe pulmonary
disease, neoplastic disease, severe psychiatric disorders). 9. Portal thrombosis. 10. Acute
pancreatitis. 11. Type 1 hepatorenal syndrome. 12. Serum creatinine at randomisation
of more than 2.5 mg/dL
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 133): glucocorticosteroids (prednisolone 40 mg) plus pentoxifylline (400
mg thrice daily).
Group 2: (n = 137): glucocorticosteroids (prednisolone 40 mg) plus placebo.
Duration: 28 days
Outcomes mortality, adverse events, decompensated cirrhosis, liver transplantation
Notes Reasons for post-randomisation dropouts: 7 did not meet the criteria for severe AAH, 1
withdrawal (post-randomisation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients were randomly assigned at a 1:1
ratio. Randomization was centralized and patients were as-
signed in blocks of 6 by a computerized procedure to achieve
a balance between the 2 groups, with stratification according
to center”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-blind. One patient was excluded for not
blinded administration of pentoxifylline by the general prac-
titioner during the treatment period”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “missing data did not exceed the 10%, two patients
with HRS were excluded from the analysis”.
Comment: there were post-randomisation dropouts.
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Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Supported by the Hospital-Based Clinical Research
Program. PTX and placebo provided by Sanofi-Aventis
Pharmaceuticals”
Other bias Low risk Comment: there was no other bias.
Mato 1999
Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 123.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 123.
Average age: 52 years.
Females: 17 (13.8%).
Inclusion criteria: 1. Age over 18 years. 2. History of ethanol consumption over 80 g
per day for women and over 120 g per day for men, for more that 5 years. 3. Physical
examination and biochemical tests compatible to alcoholic cirrhosis. 4. Confirmation
with liver biopsy when applicable.
Exclusion criteria: 1. Total serumbilirubin equal to or higher than 3mg/dL. 2. Refractory
ascites or gastrointestinal bleeding or encephalopathy within 1 week before entry into
the trial. 3. Hepatocellular carcinoma. 4. Other treatments such as colchicine, malotilate,
silymarin, penicillamine or corticosteroids. 5. Other aetiologies for liver cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 62): s-Adenosylmethionin 400 mg thrice daily.
Group 2 (n = 61): placebo.
Duration: 2 years
Outcomes mortality, adverse events, liver transplantation, hepatocellular carcinoma
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “According to centralized randomisation by a num-
ber table…”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “….or a placebo of identical appearance, smell and
taste, with the same schedule”.
Comment: this information was not available.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “There were pt lost to follow up, assumption not
specified. Ten patients (8%) were lost to follow-up (three pa-
tients in the placebo group and seven patients in the AdoMet
group), and their survival status was unknown at the close
of the study, although four of the ten patients (two in each
group) were alive in the months 23-24 of follow-up”.
Comment: presumably ITT.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Supported by the Laboratories Europharma, S.A.
group Boehringer Ingelheim Espafia, S.A., Madrid, Spain;
Laboratories Knoll Farmaceutici Spa, L&ate, Milan, Italy;
grant from theComisionAsesora de InvestigacionCientifica
y Tecnica (SAF 96/0108), and (SAF98/0 132), Ministerio
de Education y Ciencia, Spain; grant from the Fondo de
Investigaciones Sanitarias (FIS 94/0231), Spain”
Other bias Low risk Comment: there was no other bias.
McHutchinson 1991
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 22.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 22.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Bilirubin of 10 mg/dL or greater. 2. Prothrombin ratio of 40% or
lower. 3. White blood count of 12,000 mmˆ3 or greater. 4. Tender hepatomegaly. 5.
Fever of 100°F or greater.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 12): pentoxifylline 1200 mg.
Group 2 (n = 10): standard treatment.
Duration: 10 days
Outcomes mortality.
Notes Abstract
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Medici 2011
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 37.
Post-randomisation dropouts: not stated.
Revised sample size: 37.
Average age: 45 years.
Females: 12 (32.4%).
Inclusion criteria: 1. A positive history for chronic alcohol abuse according to World
Health Organization definition and the AUDIT screening test. 2. ALD
Exclusion criteria: 1. Child-Pugh score>10. 2. Positive laboratory tests for chronic hep-
atitis B or C. 3. Primary biliary cirrhosis. 4. Autoimmune hepatitis. 5. Wilson disease.
6. Haemochromatosis. 7. Hepatocellular carcinoma with alpha-fetoprotein >10 times
the upper limit of normal. 8. Cancer. 9. Congestive heart failure. 10. Renal insufficiency
with serum creatinine >1.2 mg/mL. 11. Use of antifolate drugs or corticosteroids. 12.
Infectious illness
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 18): s-adenosyl-L-methionine 1.2 g/day.
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Medici 2011 (Continued)
Group 2 (n = 19): placebo.
Duration: 24 weeks treatment
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Volunteer ALDpatients were randomly assigned by
an independent UC Davis Medical Center Investigational
Drug Service pharmacist in a 1:1 ratio to receive SAM or
matching placebo, using a computer-generated allocation
sequence”
Allocation concealment (selection bias) Low risk Quote: “A sealed, opaque envelope was used to conceal the
randomisation scheme and was kept by the independent
pharmacist”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study subjects, care providers, study coordina-
tor, and those assessing outcomes were all blinded to inter-
vention”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The study subjects, care providers, study coordina-
tor, and those assessing outcomes were all blinded to inter-
vention”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “11 patients were withdrawn from the study for re-
sumed active drinking”.
Comment: iTTanalysis for serumparameters, not for scores.
Selective reporting (reporting bias) High risk Comment: Comment: mortality was not reported.
For-profit bias High risk Quote:
“Supported by R01AA14562 (CHH), R01AG09834 (S.P.
S.), P50 011999 (SWF), R01DK072398 (JFG), and UL1
RR024146 from theNational Center for ResearchResources
(NCRR), a component of the National Institutes of Health
(NIH), and NIH Roadmap for Medical Research. S-adeno-
syl-L-methionine was provided as a generous gift from Ab-
bott Laboratories. The funding agencies had no role in the
study design, data analysis and interpretation, nor in draft-
ing the manuscript”
Other bias Low risk Comment: there was no other bias.
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Mendenhall 1984
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 178.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 178.
Average age: 51 years.
Females: 0 (0%).
Inclusion criteria: Diagnosis of moderate or severe alcoholic hepatitis based on conven-
tional clinical and laboratory changes.
Exclusion criteria: 1. Positive test for HBsAg. 2. Clinical or historical evidence of recent
parenteral drug abuse. 3. Intractable congestive heart failure. 4. Neoplasms that com-
monly metastasise to the liver. 5. NAFLD. 6. Severe infections. 7. Active peptic ulcer
disease. 8. Insulin-dependent diabetes mellitus. 9. Corticosteroids within the preceding
3 months
Interventions Participants were randomly assigned to three groups.
Group 1 (n = 90): glucocorticosteroids (prednisolone 60 mg tapered to 5mg in 1month)
.
Group 2 (n = 88): placebo.
Group 3 (n=85): anabolic steroids (oxandrolone 80 mg).
Duration: 30 days treatment
Outcomes mortality.
Notes 3 groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Treatment assignments were made by the Coordi-
nating Center. The random assignment of tretment was bal-
anced within each hospital, as well as according to disease
severity”
Allocation concealment (selection bias) Unclear risk Comment: Further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patient, physician and the local hospital phar-
macy had no knowledge of the specific medication in use”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “ Ten patients withdrew from the study before com-
pleting treatment, however they were included in the out-
come analysis. If patients were lost to follow up after hos-
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pital-discharge the VABIRL System was used to determine
their status and the date of death”
Comment: presumably ITT analysis.
Selective reporting (reporting bias) Low risk Quote: “Not precisely specified”.
Comment: all important outcomes were reported.
For-profit bias Unclear risk Quote: “Supported by Cooperative Studies program of
VAMRS.Matching placebos were prepared for each of these
medications by Upjohn Company and G.D. Searle and
Company”
Other bias Low risk Comment: there was no other bias.
Mezey 2004
Methods Randomised clinical trial
Participants Country: Spain and USA.
Number randomised: 51.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 51.
Average age: 48 years.
Females: 17 (33.3%).
Inclusion criteria: 1. Age between 18-70 years. 2. Recent history of heavy alcohol in-
gestion. 3. Moderate elevation of AST (lower than 10 times above normal. 4. AST/
ALT ratio greater than 1. 5. No evidence of viral hepatitis, autoimmune liver disease,
haemochromatosis, Wilson’s disease, drug-induced hepatitis.
Exclusion criteria: 1. Pregnancy. 2. Breast feeding. 3. Cardiovascular, pulmonary, kidney
disease. 4. Pancreatitis. 5. Type I diabetes. 6. Recent (within 1 month) gastrointestinal
bleeding. 7. Peptic ulcer disease. 8. Concurrent infection. 9.History of thrombophlebitis.
10. HIV positivity. 11. History of ingestion of more than 100 I.U. vitamin for the prior
month
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 25): antioxidants (vitamin E 1000 UI).
Group 2 (n = 26): placebo.
Duration: 3 months
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Mezey 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Generation of the allocation sequence was done on
a computer in blocks of 4”
Allocation concealment (selection bias) Low risk Quote: “For each patient entered into the trial the investi-
gators opened a consecutive sealed container which had a 3
month supply of capsules”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The investigators and participants were blinded,
The vitamin E capsules and placebo capsules, which were
prepared and labeled by the hospital pharmacies, were iden-
tical in looks, smell, and taste”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigators were blinded ”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there were patients lost to follow-up: data con-
sidered?
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk This information was not available.
Other bias Low risk Comment: there was no other bias.
Mirouze 1982
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 26.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 26.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Jaundice. 2. Fever. 3. Hepatomegaly. 4. Transaminases elevation.
5. At least 2 of the following: total bilirubin greater than 5 mg/dL, prothrombin time
lower than 50 %, leukocytosis higher than 12,000/mm3.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 14): insulin (36 U) plus 4 mg glucagon.
Group 2 (n = 12): no active treatment.
Duration: 2 weeks
Outcomes mortality.
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The aim of this randomised clinical trial is ”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Moreno 2010
Methods Randomised clinical trial
Participants Country: Belgium.
Number randomised: 44.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 44.
Average age: 49 years.
Females: 12 (27.3%).
Inclusion criteria: 1. Biopsy proven AAH. 2. Maddrey Discriminant Function of 32 or
more
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 25): N-acetyl-cysteine 300 mg/kg intravenously.
Group 2 (n = 19): placebo.
Duration: 14 days
Outcomes mortality, adverse events.
Notes
117Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Moreno 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Morgan 2005
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 549.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 549.
Average age: 55 years.
Females: 11 (2%).
Inclusion criteria: 1. Clinical diagnosis of alcoholic cirrhosis (based on a long history of
alcohol use and the exclusion of other causes of liver disease. 2. A modified Pugh score of
7 or greater. 3. Liver biopsy demonstrating cirrhosis unless contraindications to biopsy
were present.
Exclusion criteria: 1. Gastrointestinal bleeding within the prior 28 days requiring trans-
fusion. 2. Illicit drug use in the prior 12 months. 3. HIV infection. 4. Cancer in the prior
10 years. 5. Serum creatinine greater than 1.5 mg/dL. 6. Total white blood cell count
less than 3500/mL. 7. Age 70 years or greater. 8. Serious chronic disease interfering with
adherence to the protocol follow-up schedule. 9. No home telephone. 10. Refusal
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Interventions Participants were randomly assigned to two groups.
Group 1 (n = 274): colchicine 0.6 mg twice daily.
Group 2 (n = 275): placebo.
Duration: 24 months to 72 months
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patient enrollment and randomassignment to treat-
ment was by telephone call to the data-coordinating centre
(CSPCC, Perry Point, MD)”
Allocation concealment (selection bias) Low risk Quote: “Studymedicationswere dispensed by eachVAPhar-
macy from prepackaged kits matched to the treatment ID
number. The treatment randomisation schemewas based on
permuted blocks of random length separately for each study
centre”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither the patients, the nurses administering the
treatment, nor the physicians assessing the outcomes were
aware of the treatment group assignment until all data anal-
ysis was complete”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither the patients, the nurses administering the
treatment, nor the physicians assessing the outcomes were
aware of the treatment group assignment until all data anal-
ysis was complete”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All analysed as assigned”.
Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Naveau 2004
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 36.
Post-randomisation dropouts: 1 (2.8%).
Revised sample size: 35.
Average age: 52 years.
Females: 11 (31.4%).
Inclusion criteria: 1. Age between 18 and 70 years old. 2. Chronic alcoholism (alcohol
intake of more than 50 g per day over the previous year). 3. Severe alcoholic hepatitis
(serum aspartate aminotransferase level of 1.5 N and a Maddrey score of 32). 4. Biopsy-
proven alcoholic hepatitis.
Exclusion criteria: 1. Presence of hepatitis B surface antigen. 2. Hepatitis C virus or
HIV antibodies. 3. Hepatocellular carcinoma. 4. Ethanol abstinence for more than 1
month. 5. Concomitant symptomatic or asymptomatic bacterial infection. 6. Severe
bacterial infection within the previous 3 months (septicaemia, spontaneous bacterial
peritonitis). 7. Concomitant or previous history of tuberculosis. 8. Severe associated
disease (cardiac failure, severe pulmonary disease, neoplastic disease, severe psychiatric
disorders). 9. Acute pancreatitis. 10. Gastrointestinal bleeding over the previous month.
11. Hepatorenal syndrome. 12. Acanthocytosis. 13. Patients in whom corticosteroids
were contraindicated. 14. Patients who had taken infliximab or corticosteroids during
the 3 months before inclusion. 15. Treatment with immunosuppressants, budesonide,
and thalidomide during the 3 months before enrollment. 16. Suspected noncompliance.
17. Pregnancy
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 18): glucocorticosteroids (prednisolone 40 mg) plus anit-TNF (infliximab
10 mg/Kg).
Group 2 (n = 17): glucocorticosteroids (prednisolone 40 mg) plus placebo.
Duration: 28 days
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Reasons for post-randomisation dropouts: one patient from group 2 was found not to
have satisfied the inclusion criteria before treatmentwas started (bacterial urine infection)
and did not receive the allocated treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was carried out by computer-gen-
erated allocation”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “This study was a randomised, double blind,
placebo-controlled trial in two parallel groups. The placebo
was identical in appearance to the infliximab solution”
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Naveau 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Infliximab and placebo treatments were donated by
Schering-Plough”.
Comment: the trial was funded by a party with vested in-
terest in the results
Other bias Low risk Comment: there was no other bias.
Nguyen-Khac 2011
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 180.
Post-randomisation dropouts: 6 (3.3%).
Revised sample size: 174.
Average age: 52 years.
Females: 69 (39.7%).
Inclusion criteria: 1. Age of 18 years or older. 2. Average alcohol intake of more than 50
g per day during the 3 months before enrollment. 3. A Maddrey’s discriminant function
of 32 or more. 4. Liver histologic findings consistent with alcoholic hepatitis.
Exclusion criteria: 1. Hepatorenal syndrome. 2. Hepatocellular carcinoma. 3. Uncon-
trolled bacterial infection. 4. Gastrointestinal haemorrhage in the previous 4 day. 5.
Infection with HCV, HBV, HIV. 6. Auto immune hepatitis. 7. Haemochromatosis. 8.
Wilson’s disease. 9. Alpha1-antitrypsin deficiency. 10. Acetaminophen-induced hepati-
tis. 11. Cancer. 12. N-acetyl-cysteine allergy. 13. Serious cardiac, respiratory, neurologic
disease
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 85): glucocorticosteroids (prednisolone 40 mg) plus N-acetylcysteine (150
first day then 100 mg/kg from days 2 to 5).
Group 2 (n = 89): glucocorticosteroids (prednisolone 40 mg).
Duration: steroids 28 days treatment, N-acetylcysteine 5 days
Outcomes mortality, adverse events, decompensated cirrhosis, liver transplantation
Notes Reasons for post-randomisation dropouts: 3 were found to meet the exclusion criteria,
3 other reason
Risk of bias
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Nguyen-Khac 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed centrally in blocks
of four by means of a computerized procedure, with strati-
fication according to centre”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The treatment assignments were not concealed
from the investigators or the patients”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The treatment assignments were not concealed
from the investigators or the patients”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “see table, 6 post-randomisation drop-outs, not con-
sidered in the analysis”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Quote: “Supported by ProgrammeHospitalier de Recherche
Clinique plus Novartis?”
Other bias Low risk Comment: there was no other bias.
Orrego 1979
Methods Randomised clinical trial
Participants Country: Canada.
Number randomised: 143.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 143.
Average age: 49 years.
Females: 18 (12.6%).
Inclusion criteria: 1. One or more of the following clinical findings: hepatomegaly (liver
palpablemore than3 cmbelow the costalmargin), tender liver, jaundice, ascites, collateral
circulation, spider nevi, and splenomegaly. 2. At least two of the following abnormal
laboratory tests were required: SGOT more than 20 IU/L; serum gamma glutamyl
transpeptidase more than 29 IU/L; serum alkaline phosphatase more than 36 IU/L; total
serum bilirubin more than 1.5 mg/100 mL. 3. No more than 6 days of abstinence from
alcohol.
Exclusion criteria: 1. A known history of hypothyroidism. 2. A known history of diabetes
or requirement of other therapies that contraindicated the use of Propylthiouracil. 3.
Congestive heart failure
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Interventions Participants were randomly assigned to two groups.
Group 1 (n = 63): propylthiouracil 300 mg once daily.
Group 2 (n = 50): placebo.
Duration: not clear. One or 2 months
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned sequential numbers on ad-
mission to the different hospitals; the numbers had been
previously distributed by a computerized random number
generator between the lists of patients to receive PTU or
placebo”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Only the pharmacist at the ARF.CI had the in-
formation on the type of therapy (PTU or placebo) that
any individual patient was receiving. Sixty-three patients
received identical placebo capsules according to the same
dosage schedule”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Eight patients (5 PTU, 3 placebo) who discharged
themselves from the hospital against medical advice within
3 days of admission were excluded from the study. One PTU
patient was excluded when found to have HBsAg-positive
infectious hepatitis. One placebo patient was excluded be-
cause after 10 days of treatment he had an episode of severe
acute pancreatitis”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “PTU was obtained from Charles E. Frosst and Co.
, Montreal, Quebec, Canada”.
Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Orrego 1987
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 360.
Post-randomisation dropouts: 50 (13.9%).
Revised sample size: 310.
Average age: 49 years.
Females: 69 (22.3%).
Inclusion criteria: 1. Alcoholism defined as excessive drinking resulting in several emer-
gency room visits, hospitalisations, or important social problems related to drinking, a
well-documented history of an average daily consumption exceeding 80 g of ethanol, or
spree drinking consisting of repeated prolonged inebriations. 2. Clinical or laboratory
evidence of liver disease.
Exclusion criteria: 1. Hepatoma. 2. The presence of hepatitis B surface antigen. 3. Con-
traindications to propylthiouracil therapy
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 157): propylthiouracil 300 mg twice daily.
Group 2 (n = 153): placebo.
Duration: 2 years
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: non-compliance: 25 Group A, 25 Group B,
dropouts at 2 years: 104 Group A,
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Upon entering the study, patients were randomly
assigned to receive either propylthiouracil or placebo, with
use of a computerized random-assignment method”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Propylthiouracil was given in a double-blind man-
ner… Capsules contained 75 mg of propylthiouracil or
placebo…The physician in the liver clinic when confronted
with a possible side effect of propylthiouracil, referred the
patient to the consulting physician, who had access to the
drug or placebo code. In all cases in which a patient was seen
by the consulting physician, the code numbers were changed
and the drug adjustment was kept confidential from the staff
conducting the trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The code was not broken until the analyses were
completed”
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “.and to W.D. Dorian of Merck Frosst Canada Inc
for providing propylthiouracil”
Other bias Low risk Comment: there was no other bias.
Paladugu 2006
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 30.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 30.
Average age: 47 years.
Females: not stated
Inclusion criteria: 1. Discriminant factor of 32 or greater. 2. Hepatic encephalopathy.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 14): pentoxifylline 400 mg thrice daily.
Group 2 (n = 16): placebo.
Duration: 4 weeks
Outcomes mortality, decompensated cirrhosis.
Notes Abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were included and randomised”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Pares 1998
Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 200.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 200.
Average age: 50 years.
Females: 42 (21%).
Inclusion criteria: 1. A daily alcohol intake of more than 80 g in men and 60 g in women
for a period longer than 5 years. 2. Liver cirrhosis supported by histology within the 3
months before inclusion in the trial or by laparoscopic examination in those with very
low prothrombin index or platelet count in whom percutaneous liver biopsy could not
be performed.
Exclusion criteria: 1. Previous treatment with colchicine, malotilate, penicillamine or
corticosteroids. 2. Life expectancy less than 6 months. 3. Drug-addicted patients. 4.
Pregnancy. 5. Other known etiologies for liver cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 103): silymarin 150 mg thrice daily.
Group 2 (n = 97): placebo.
Duration: 2 years
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomizationwas carried out for all patients strat-
ified by sex using a random-number sequence table in the
Hospital Clinic of Barcelona, which served as the coordinat-
ing centre”
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Allocation concealment (selection bias) Low risk Quote: “When a patient was included in the study, the as-
signed treatment was obtained from the coordinating centre
by telephone; the packs were coded with’x’ or’y’ by the coor-
dinating centre; treatment and placebo drugs were identical
in appearance”.
Comment: according to the author’s reply.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients were randomly assigned to receive either
450 mg of silymarin (150 mg three times/day orally) or a
placebo with identical appearance, smell and taste…”.
Comment: according to the author’s reply.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: according to the author’s reply.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Fifteen patients (seven in the silymarin group and
eight in the placebo group) did not reappear after their first
visit, so that further information was not available”.
Comment: Not clear what kind of assumption if ITT anal-
ysis. There were post-randomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Patients were randomly assigned to receive either
450 mg of silymarin (150 mg three times/day orally) or a
placebo with identical appearance, smell and taste, kindly
supplied by Madaus Cerafarm (Barcelona, Spain)”
Other bias Low risk Comment: there was no other bias.
Park 2014
Methods Randomised clinical trial
Participants Country: Korea.
Number randomised: 124.
Post-randomisation dropouts: 3 (2.4%).
Revised sample size: 121.
Average age: 49 years.
Females: 30 (24.8%).
Inclusion criteria: 1. Age range of 20-75 years. 2. Average alcohol intake of more than 40
g per day during the 3 months before enrolment. 3. Recent onset of jaundice in the prior
3 months plus one or more of: hepatic encephalopathy, ascites, tender hepatomegaly,
leukocytosis with predominantly neutrophil differentiation, fever, elevated liver enzymes.
4. Maddrey’s discriminant function of 32 or more.
Exclusion criteria: 1. Bacterial infection. 2. Gastrointestinal bleeding. 3. Concomitant
viral hepatitis. 4. Renal impairment. 5. Pancreatitis. 6. Hepatocellular carcinoma. 7.
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Autoimmune liver disease. 8.Wilson’s disease. 9. Haemochromatosis,. 10. Drug-induced
liver injury
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 62): pentoxifylline 400 mg thrice daily.
Group 2 (n = 59): glucocorticosteroids (prednisolone 40 mg once daily).
Duration: 28 days
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: 3 patients not included in the analysis, not
meeting inclusion criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation was centralised and balanced
by centre. The allocation sequence was generated with a
computer list of random set numbers stratified by centre”
Allocation concealment (selection bias) Unclear risk Quote: “open trial”.
Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The study was a randomised, open label, parallel
group clinical trial”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The study was a randomised, open label, parallel
group clinical trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “3 patients were excluded from the analysis because
did not receive the allocated intervention. 1 patients in pen-
toxifylline group and 3 patients in prednisolone group were
lost to follow-up, but we assessed the status (alive or dead)
of patients lost to follow-up by calling a family member”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Research Supporting Program of the Korean Asso-
ciation for the Study of the Liver”
Other bias Low risk Comment: there was no other bias.
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Pelletier 2003
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 226.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 226.
Average age: 50 years.
Females: 87 (38.5%).
Inclusion criteria: 1. Biopsy-proven alcohol-induced cirrhosis within 2 months before
entry into the trial. 2. Serum bilirubin higher than 50 mol/L.
Exclusion criteria: 1. A life-threatening complicationof cirrhosiswithin 1week (bleeding,
encephalopathy, sepsis, hepatorenal syndrome). 2. Evidence of hepatocellular carcinoma
at sonography and serum a-fetoprotein. 3. Associated hepatitis B or C viral infection. 4.
Severe psychiatric disorders. 5. Alcoholic abstinence for more than 2 months. 6. Patients
receiving ursodeoxycholic acid within 3 months from the study entry. 7. Patients with
HIV antibodies
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 113): ursodeoxycholic acid (13 to 15 mg/kg per day).
Group 2 (n = 113): placebo.
Duration: 6 months
Outcomes mortality, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random assignment to eitherUDCA or placebo
was done in random blocks of 4”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Consecutive patients with alcohol-induced cirrho-
sis and a serum bilirubin level higher than 50 mol/L and
who agreed to participate were included in this multicenter,
double-blind trial comparing the effects of UDCA and a
placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Twenty patients presented deviations to the pro-
tocol: 6 from the AUDC group and 14 from the placebo
group”.
Comment: iTT analysis, assumption was not specified.
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Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Supported by the Synthelabo-Recherche labora-
tory, France”
Other bias Low risk Comment: there was no other bias.
Phillips 2006
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 101.
Post-randomisation dropouts: 2 (2%).
Revised sample size: 99.
Average age: 44 years.
Females: 41 (41.4%).
Inclusion criteria: 1. History of heavy alcohol consumption defined as greater than 80 g
alcohol per day formen, or greater than 60 g alcohol per day for women, prior to the onset
of illness of at least 1-month duration. 2. Absence of alternative aetiology of liver disease.
3. Serum bilirubin greater than 100 micromol/L. 4. Serum AST lower than 300 IU/L. 5.
Serum IgA greater than 5 g/L. 6.White cell count greater than 20x10ˆ9/L. 7. Ultrasound
evidence of hepatic fatty infiltration. 8. Hepatomegaly (clinical or radiological).
Exclusion criteria: 1. Active sepsis (defined as positive microbiological culture, ascitic
white cell count greater than 500 cells/mL or ascitic neutrophil count greater than 250
cells/mL, or radiological appearances consistent with pneumonia ), not treated with
appropriate antibiotics for at least 48 h prior to randomisation. 2. Active significant
gastrointestinal haemorrhage within the previous 48 h. 3. Shock necessitating inotropic
support. 4. Evidence of co-existing non-alcoholic liver disease. 5. Pregnant or lactating
women. 6. Patients with a history of allergy to any component of the regimen
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 46): antioxidants plus intralipid solution.
Group 2 (n = 53): glucocorticosteroids (oral prednisolone 30 mg once daily or methyl-
prednisolone 24 mg intravenously).
Duration: 28 days (+ 2 weeks tapering steroid).
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: 2 from group 2 withdrew immediately post-
randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients randomised using consecutive envelopes
produced by computer-generated randomisation”
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Not possible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “ITT analysis”.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Pierri 1985
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 40.
Post-randomisation dropouts: not stated.
Revised sample size: 40.
Average age: 48 years.
Females: 8 (20%).
Inclusion criteria: 1. A positive history for chronic alcohol for at least 2 years and con-
suming at least 80 g of alcohol daily. 2. Negative viral hepatitis markers. 3. Absence of
other factors causing secondary steatosis.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 20): epomediol 600 mg/day.
Group 2 (n = 20): placebo.
Duration: 90 days
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “At random”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: Not reported data about safety.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Plevris 1991
Methods Cross-over randomised clinical trial
Participants Country: UK.
Number randomised: 12.
Post-randomisation dropouts: 1 (8.3%).
Revised sample size: 11.
Average age: 56 years.
Females: 1 (9.1%).
Inclusion criteria: ALD (alcoholic liver disease)
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 6): ursodeoxycholic acid (15 mg/kg/day).
Group 2 (n = 5): placebo.
Duration: 4 weeks
Outcomes adverse events.
Notes Reasons for post-randomisation dropouts: 1 withdrawn for diarrhoea
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Single-blind study”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Single-blind”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “1 patient withdrew for collateral effect”.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Popescu 2009
Methods Randomised clinical trial
Participants Country: Romania.
Number randomised: 68.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 68.
Average age: not stated
Females: not stated
Inclusion criteria: acute alcoholic hepatitis
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 34): glucocorticosteroids (prednisolone 40 mg) plus ursodeoxycholic acid
(600 mg) plus rifaximin (1200 mg/day for 28 days, then 800 mg/day for 10 days/month)
.
Group 2 (n = 34): glucocorticosteroids (prednisolone 40 mg) plus ursodeoxycholic acid
(600 mg).
Duration: 28 days for prednisolone and ursodeoxycholic acid and then rifaximin alone
in group 1 for 10 days per month for 1 year
Outcomes mortality, adverse events.
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Equally randomised”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Porter 1971
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 23.
Post-randomisation dropouts: 3 (13%).
Revised sample size: 20.
Average age: 47 years.
Females: 7 (35%).
Inclusion criteria: For admission to the study all three absolute criteria should be fulfilled.
Also, two or more major criteria or one major and four or more minor criteria. Absolute
criteria: 1. History of recent, heavy alcohol ingestion. 2. Serum total bilirubin of 5 mg
per 100 mL or more. 3. Clinical and laboratory deterioration over the first 5 hospital
days, a striking lack of improvement in the patient’s clinical and biochemical status over
this same period, or rapid, marked deterioration in less than 24 hours. Major criteria:
1. Liver biopsy showing alcoholic hepatitis. 2. Hepatic encephalopathy, persistent or
progressive azotaemia unexplained by another process, with either a blood urea nitrogen
over 20 mg or a creatinine over 1.5 mg per 100 mL (or both). 3. Total bilirubin over
20 mg per 100 mL. Minor criteria: 1. Fever not obviously secondary to another process.
2. Anorexia or nausea or vomiting. 3. Palpable hepatomegaly. 4. Palpable splenomegaly.
5. Oesophageal varices. 6. A prothrombin time prolonged three or more seconds over
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control.
Exclusion criteria: 1. Active gastrointestinal bleeding. 2. Pancreatitis. 3. Radiologic ev-
idence of peptic ulcer disease. 4. Active or questionably active pulmonary tuberculosis.
5. Life-threatening bacterial infections
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 11): glucocorticosteroids (6-methylprednisolone 40 mg thrice daily par-
enterally).
Group 2 (n = 9): placebo.
Duration: if clinical improvement: for 10 days, then given orally and the dose gradually
tapered. If no clinical improvement: 40 mg parenterally till improvement or death
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: 3 died.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was achieved by a number drawn
from a pool”
Allocation concealment (selection bias) Unclear risk Quote: “both the steroid and the placebo were packaged and
coded by number in both parenteral and oral forms”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither patients nor physicians knew which form
of treatment was used until the study had been completed”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “3 patients died within 36 hours of the start of ther-
apy and were excluded from analysis before the code was
broken”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “gastroenterology-research training grant from the
National Institute of Arthritis and Metabolic Diseases and
a grant from the National Institutes of Health”
Other bias Low risk Comment: there was no other bias.
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Radvan 1983
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 35.
Post-randomisation dropouts: 4 (11.4%).
Revised sample size: 31.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Fever, jaundice and tender hepatomegaly following alcohol inges-
tion. 2. Serum bilirubin higher than 5 mg %, SGOT higher than SGPT, prothrombin
time lower than 50 % and leucocytosis higher than 12,000
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 16): insulin 2 U/hour glucagon 0.2 mg/hr at 40 mL/h.
Group 2 (n = 15): no intervention.
Duration: 2 weeks
Outcomes mortality.
Notes Reasons for post-randomisation dropouts: two patients in each group failed to complete
the protocol and their results were excluded from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised clinical trial”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Two patients in each group failed to complete the
protocol and their results were excluded from the analysis”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Ramond 1992
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 65.
Post-randomisation dropouts: 4 (6.2%).
Revised sample size: 61.
Average age: 48 years.
Females: 42 (68.9%).
Inclusion criteria: 1. Biopsy-proven alcoholic hepatitis. 2. Spontaneous hepatic en-
cephalopathy or a discriminant function value higher than 32 (or both).
Exclusion criteria: 1. Gastointestinal bleeding. 2. Bacterial infections
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 32): glucocorticosteroids (prednisolone 40 mg once daily).
Group 2 (n = 29): placebo.
Duration: 28 days
Outcomes mortality.
Notes Reasons for post-randomisation dropouts: 4 met exclusion criteria, infection
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a random code was prepared by computer”.
Allocation concealment (selection bias) Unclear risk Quote: “random sequences of drug or placebowere prepared
by the pharmacist”.
Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The principal investigators and their associates were
not aware of the randomisation procedure or of the medi-
cation that the patients were receiving throughout the trial.
The pharmacist was the only person who knew which regi-
men the patient had received”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The principal investigators and their associates were
not aware of the randomisation procedure or of the medi-
cation that the patients were receiving throughout the trial”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Four patients were excluded from the analysis after
randomisation. These four patients were alive at the end of
the study”.
Comment: there were post-randomisation dropouts.
137Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ramond 1992 (Continued)
Selective reporting (reporting bias) High risk Quote: “adverse events were not reported”.
Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias Low risk Quote: “Prednisolone and identical placebo tabletswere pro-
vided by Laboratoire Houde (Paris)”
Other bias Low risk Comment: there was no other bias.
Resnick 1974
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 43.
Post-randomisation dropouts: 3 (7%).
Revised sample size: 40.
Average age: 47 years.
Females: 14 (35%).
Inclusion criteria: 1. Hepatic decompensation accompanied by a history of heavy alcohol
intake without other established aetiology of liver injury. 2. Serum bilirubin more than
2 mg %. 3. Albumin less than 3.5 mg %. 4. Prothrombin prolongation more than 2.5
seconds. 5. SGOT higher than SGPT (with SGOT lower than 500 U).
Exclusion criteria: 1. Biopsy evidence of cirrhosis prior to the present hospitalisation.
2. Gastroesophageal varices. 3. Gastrointestinal bleeding. 4. Hepatic encephalopathy. 5.
Renal insufficiency. 6. Penicillin hypersensitivity
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 19): penicillamine 250 mg four times daily.
Group 2 (n = 21): placebo.
Duration: 8 weeks
Outcomes mortality.
Notes Reasons for post-randomisation dropouts: 3 post-randomisation due to carcinoma, lack
of compliance (2 in placebo group, one in penicillamine)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “by random assignment”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “a capsule physically identical to the active drug”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “three additional randomised patients were subse-
quently excluded”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “MercK, Sharp and Dohme supplied penicillamine
and a similarly appearing placebo”
Other bias Low risk Comment: there was no other bias.
Richardet 1993
Methods Cross-over randomised clinical trial
Participants Country: France.
Number randomised: 23.
Post-randomisation dropouts: not stated.
Revised sample size: 23.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Patients with severe acute alcoholic hepatitis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 12): glucocorticosteroids (prednisolone 40 mg/day).
Group 2 (n = 11): no intervention.
Duration: 8 days
Outcomes None of the outcomes of interest were reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Results of a randomised study”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: Neither mortality nor adverse events
were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Sainz 1992
Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 54.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 54.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Alcoholic liver disease.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 28): colchicine 1 mg once daily for 5 d/week.
Group 2 (n = 26): no intervention.
Duration: treatment duration not reported.
Outcomes None of the outcomes of interest were reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Cirrhotic and non-cirrhotic patients were ran-
domised in 2 groups”.
Comment: Further details were not available.
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “….treatment (T) received colchicine 1 mg/d for 5
d a week. and control (C) without anti-fibrotic treatment”.
Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “14 patients were lost during the follow-up”.
Comment: Few details.
Selective reporting (reporting bias) High risk Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Salvagnini 1985
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 122.
Post-randomisation dropouts: not stated.
Revised sample size: 122.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Alcohol abusers consecutively hospitalised in 5 clinical units because
of liver disease.
Exclusion criteria: 1. HBs Ag positive. 2. Decompensated cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 60): silymarin 420 mg/day.
Group 2 (n = 62): placebo.
Duration: 45 days treatment
Outcomes None of the outcomes of interest were reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “RCT”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”.
Comment: Further details were not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: None of the outcomes of interest were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Serrano-Cancino 1981
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 41.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 41.
Average age: not stated
Females: not stated
Inclusion criteria: severe alcoholic hepatitis.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 21): propylthiouracil 100 mg thrice daily.
Group 2 (n = 20): placebo.
Duration: 17 days (mean)
Outcomes mortality.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomised in a double-blinded
manner”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The patients were randomised in a double-blinded
manner”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Shumaker 1978
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 27.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 27.
Average age: 45 years.
Females: 11 (40.7%).
Inclusion criteria: minimal criteria: 1. A recent heavy alcoholic ingestion. 2. Bilirubin
grater than 5 mg %. 3. Hospitalisation for at least 5 days without improvement in liver
tests. 4. Rapid deterioration of the clinical condition during a 24-hour period while un-
der observation. Major criteria: 1. Liver biopsy showing alcoholic hepatitis. 2. Hepatic
encephalopathy. 3. Azotemia unexplained by another process. 4. Hyperbilirubinemia.
5. Prothrombin time prolonged more than 4 seconds over control and unresponsive
to parenteral administration of Vitamin K. Minor criteria: 1. Fever not obviously sec-
ondary to other conditions. 2. Leucocytes more than than 12,000. 3. Hepatomegaly. 4.
Splenomegaly. 5. Liver stigmas. A patient should have all minimal criteria and a mini-
mum of two major criteria or one major and two minor criteria.
Exclusion criteria: 1. Active gastrointestinal bleeding. 2. Pancreatitis. 3. X-ray evidence
of peptic ulcer disease. 4. Active or questionably active tuberculosis. 5. Acute infection.
6. Sever psychiatric disorder. 7. SGOT greater than 500
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Interventions Participants were randomly assigned to two groups.
Group 1 (n = 12): glucocorticosteroids (6-methylprednisolone 80 mg).
Group 2 (n = 15): placebo.
Duration: 4 to 7 days; the medication was then tapered on a flexible schedule with
cessation of therapy planned for 4 weeks
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patient was then randomised into a predeter-
mined code provided by the drug manufacturer”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “”Clinical evaluation was carried out by junior staff
physicians blinded to treatment status of the patients“.
”Following randomisation patients were placed on 80mg
of 6-methylprednisolone or equivalent number of placebo
tablets“”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which will generally
be assessed were not reported
For-profit bias High risk Quote: “Upjohn Co, Kalamazoo, prepared and supplied the
medications and placebo”
Other bias Low risk Comment: there was no other bias.
Sidhu 2012a
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 70.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 70.
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Average age: 41 years.
Females: 0 (0%).
Inclusion criteria: 1. Clinical and laboratory results suggestive of alcoholic hepatitis. 2.
Presence of severe alcoholic hepatitis defined by discriminant function of 32 or more. 3.
Severe alcoholic hepatitis presenting as the first liver decompensating event.
Exclusion criteria: 1. Chronic jaundice for over 3 months due to end-stage liver disease.
2. Pre-existing renal dysfunction including hepatorenal syndrome. 3. Acute pancreatitis.
4. Positive viral serology. 5. Severe cardiovascular or pulmonary diseases. 6. Neoplastic
and other inflammatory conditions. 7. Spontaneous decline in discriminant function to
less than 32 with symptomatic treatment after 5-7 days of admission
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 36): pentoxifylline 400 mg thrice daily plus glucocorticosteroids (pred-
nisolone 40 mg once daily).
Group 2 (n = 34): glucocorticosteroids (prednisolone 40 mg once daily).
Duration: 28 days. Prednisolone was gradually tapered after the first 28 days, for 2
additional weeks
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated random numbers”.
Allocation concealment (selection bias) Low risk Quote: “sequentially numbered, sealed, opaque envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Group A received tablet PTX 400 mg thrice daily
along with prednisolone 40 mg once a day per oral, and
group B patients received prednisolone 40 mg once a day
for 28 days”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the randomisation sequence was concealed from
the investigators until the intervention was assigned”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Department of Gastroenterology, Dayanand Med-
ical College and Hospital, Ludhiana, Punjab”
Other bias Low risk Comment: there was no other bias.
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Sidhu 2012b
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 50.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 50.
Average age: 43 years.
Females: 0 (0%).
Inclusion criteria: 1. Clinical and laboratory features suggestive of alcoholic hepatitis. 2.
Patients with discriminant function greater than 32.
Exclusion criteria: 1. Positive viral serology. 2. Concomitant infections. 3. Active gas-
trointestinal bleeding. 4. Severe cardiovascular or pulmonary diseases. 5. A decline in
discriminant function lower than 32 with symptomatic treatment for 5-7 days
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 25): pentoxifylline 400 mg thrice daily.
Group 2 (n = 25): placebo.
Duration: 28 days
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised”.
Allocation concealment (selection bias) Low risk Quote: “sequentially numbered (table of random numbers)
, sealed, opaque envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
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Singh 2014
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 46.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 46.
Average age: 43 years.
Females: 0 (0%).
Inclusion criteria: 1. Age 18-75 years. 2. Average alcohol intake of more than 100 g/day
during the 3 months before enrolment. 3. Modified discriminant factor higher than 32.
Exclusion criteria: 1. Presence of hepatocellular carcinoma or portal vein thrombosis. 2.
Refusal to participate in the study. 3. Prior treatment with steroids. 4. Any significant
co-morbidity including hepatorenal syndrome, grade 3 or 4 hepatic encephalopathy,
upper gastrointestinal bleeding within the preceding. 5. Uncontrolled bacterial infection.
6. HIV infection. 7. Hepatitis B virus infection. 8. Hepatitis C virus seropositivity.
9. Autoimmune hepatitis. 10. Haemochromatosis. 11. Wilson’s disease. 12. Alpha-1-
antitrypsin deficiency. 13. Pregnancy. 14. Any previous known hypersensitivity to G-
CSF
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 23): G-CSF (5 µg/Kg SC twice daily) plus pentoxifylline (400 mg thrice
daily).
Group 2 (n = 23): pentoxifylline (400 mg thrice daily).
Duration: 5 days
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “This was an open-label, randomised pilot study. A
randomisation code was generated”
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed with sequentially
numbered envelopes”.
Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This was an open-label, randomised pilot study”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This was an open-label, randomised pilot study”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
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Singh 2014 (Continued)
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Spahr 2002
Methods Randomised clinical trial
Participants Country: Switzerland.
Number randomised: 20.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 20.
Average age: 53 years.
Females: 5 (25%).
Inclusion criteria: 1. History of excessive alcohol intake (higher than 100-150 g/day). 2.
A liver chemistry profile suggestive of alcoholic hepatitis. 3. Maddrey’s score between 32
and 55. 4. Written informed consent.
Exclusion criteria: 1. Positive serology for hepatitis B, C and HIV. 2. Severe renal failure
(serum creatinine less than 170 µmol/L). 3. Uncontrolled infection. 4. Recent (in the
last 15 days) gastrointestinal bleeding. 5. Maddrey score greater than 55
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 11): anti-TNF (infliximab 5 mg/kg intravenous single dose) plus gluco-
corticosteroids (prednisolone (40 mg once daily).
Group 2 (n = 9): placebo plus glucocorticosteroids (prednisolone 40 mg once daily).
Duration: one day for infliximab or placebo, 28 days for prednisolone
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated list”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “patients and heath care providers were blinded”.
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Spahr 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the assessment of results was performed while
blinded to treatment allocated”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Essex Chemie AG”.
Other bias Low risk Comment: there was no other bias.
Stenner 2000
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 48.
Post-randomisation dropouts: 10 (20.8%).
Revised sample size: 38.
Average age: not stated
Females: not stated
Inclusion criteria: Biopsy confirmed ALD
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1: ursodeoxycholic acid (I0 to 15 mg/kg/day).
Group 2: placebo.
Duration: 3 months
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Stenner 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: None of the outcomes of interest were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Stewart 2007
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 77.
Post-randomisation dropouts: 7 (9.1%).
Revised sample size: 70.
Average age: 44 years.
Females: 32 (45.7%).
Inclusion criteria: 1. Recent, heavy (higher than 40 g/day for women or 60 g/day for
men) alcohol intake. 2. Age between 18 and 65. 3. A diagnostic liver biopsy or two of
the following: hepatomegaly, leucocytosis higher than 11 x 109 cells/L, “white out” on
liver and spleen isotope scanning.
Exclusion criteria: 1. Evidence of malignancy. 2. Positive HBV or HCV serology. 3.
Pregnant or lactating women. 4. Cirrhotic patients admitted primarily for control of the
complications arising from portal hypertension. 5. Active infection. 6. Gastrointestinal
bleeding
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 36): N-acetylcysteine (loading dose of 150 mg/kg followed by 100 mg/
kg/day) for one week then other antioxidants for 6 months.
Group 2 (n = 34): placebo.
Duration: 1 week plus 6 months
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: in total, 7 patients were lost to follow-up; 3
from the active group and 4 from the placebo group, 7 patients were excluded from the
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “computer-derived randomisation schedule”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the trial was blinded and control patients received
identical placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Our pharmacy provided identical active or placebo
infusions and tablets to the patients. The outcomes were
determined after the event (primary outcome was mortality)
with no knowledge of the allocation”.
Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “In total, 7 patients were lost to follow-up; 3 from
the active group and 4 from the placebo group”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “The authors who have taken part in this study de-
clared that they have no relationship with the manufactur-
ers of the drugs involved either in the past or present and
did not receive funding from the manufacturers to carry out
their research”
Other bias Low risk Comment: there was no other bias.
Stigliano 2005
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 12.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 12.
Average age: 49 years.
Females: 4 (33.3%).
Inclusion criteria: acute alcoholic hepatitis.
Exclusion criteria: not reported
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 6): G-CSF (2 cycles of 10 g/kg/day).
Group 2 (n = 6): glucocorticosteroids (further details not available).
Duration: 5 days
Outcomes mortality.
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: no comment on adverse events.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Takase 1989
Methods Randomised clinical trial
Participants Country: Japan.
Number randomised: 55.
Post-randomisation dropouts: not stated.
Revised sample size: 55.
Average age: 64 years.
Females: 1 (1.8%).
Inclusion criteria: ALD.
Exclusion criteria: not reported.
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 25): malotilate 600 mg/day.
Group 2 (n = 30): no intervention.
Duration: 9 weeks treatment
Outcomes adverse events.
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Takase 1989 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomly assigned”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: “Controls, no placebo”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Theodossi 1982
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 60.
Post-randomisation dropouts: 5 (8.3%).
Revised sample size: 55.
Average age: not stated
Females: 24 (43.6%).
Inclusion criteria: 1. History of alcohol intake of 80 g or more daily for at least 5 years. 2.
Serum bilirubin concentration greater than 80 µmol/L. 3. Serum aspartate transferase
at least twice the upper limit of normal. 4. Prothrombin time prolonged by at least nine
seconds.
Exclusion criteria: 1.Hepatoma. 2. Recentmyocardial infarction. 3. Accompanying cere-
brovascular accident including evidence of subdural haematoma. 4. Active tuberculosis
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 27): glucocorticosteroids (methylprednisolone 1 g intravenous daily).
Group 2 (n = 28): no intervention.
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Theodossi 1982 (Continued)
Duration: 3 days
Outcomes mortality, adverse events.
Notes Reasons for post-randomisation dropouts: group 1: 1, Group 2: 4 (previous steroids,
doubtful diagnosis)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were allocated by random sealed envelope”.
Comment: Further details were not available.
Allocation concealment (selection bias) Low risk Quote: “random sealed envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “patients were allocated to a control or treatment
group”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “5 patients were not included in the analysis”.
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Thursz 2015
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 1103.
Post-randomisation dropouts: 11 (0.99%).
Revised sample size: 1092.
Average age: 49 years.
Females: 407 (37.2%).
Inclusion criteria: 1. Clinical diagnosis of alcoholic hepatitis (history of recent excess
alcohol consumption and the absence of other causes of liver disease). 2. Age of 18 years
or older. 3. An average alcohol consumption of more than 80 g per day for men and
more than 60 g per day for women. 4. A serum bilirubin level greater than 80 µmol per
litre (4.7 mg per dL). 5. A discriminant function of 32 or higher.
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Thursz 2015 (Continued)
Exclusion criteria: 1. Jaundice for more than 3 months. 2. Cessation of alcohol con-
sumption for more than 2 months before randomisation. 3. The presence of other causes
of liver disease. 4. A serum aspartate aminotransferase level greater than 500 IU per litre
or serum alanine transaminase level greater than 300 IU per litre. 5. Previous entry into
the study within the preceding 6 months
Interventions Participants were randomly assigned to four groups.
Group 1 (n = 273): glucocorticosteroids (prednisolone 40 mg once daily) plus pentoxi-
fylline 400 mg thrice daily.
Group 2 (n = 272): placebo plus placebo.
Group 3 (n = 274): glucocorticosteroids (prednisolone 40 mg one daily) plus placebo.
Group 4 (n = 273): pentoxifylline 400 thrice daily plus placebo.
Duration: 28 days
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes Reasons for post-randomisation dropouts: group 1 (Combination group): 1 (incorrect
randomisation). Group 2 (placebo-placebo): 4 (incorrect randomisation)
Group 3 (prednisolone/placebo): 3 (1 incorrect randomisation, 2 no usage of data).
Group 4 (Pentoxifylline/placebo): 3 (1 incorrect randomisation, 2 no usage of data)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A Web-based computer system (Tenalea, Forms-
Vision) was used to enrol eligible patients and randomly
assign them to study groups”
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed with a block size
of four, with stratification according to geographic area and
risk category”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “STOPAH was a multicenter, randomised, double-
blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts. 5 not
considered for the analysis
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Supported by a grant (08 14 44) from the National
Institute for Health Research (NIHR) Health Technology
Assessment program”
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Other bias Low risk Comment: there was no other bias.
Tkachenko 2016
Methods Randomised clinical trial
Participants Country: Russia.
Number randomised: 40.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 40.
Average age: 46 years.
Females: 13 (32.5%).
Inclusion criteria: 1. 18 years or older. 2. Maddrey’s discriminant function of 32 or more.
3. Average alcohol intake of more than 50 g/day during the 3 months before enrolment.
4. Screening-tests results
Exclusion criteria: 1. Cessation of alcohol consumption for more than 2 months before
randomisation. 2. SAMe, UDCA, or pentoxifylline administration prior to hospitalisa-
tion. 3. Presence of other causes of liver disease. 4. Uncontrolled bacterial infection or
gastrointestinal haemorrhage in the previous 4 days. 5. Cancer. 6. Psychiatric disease.
7. Drug abuse. 8. Serious cardiac, respiratory, or neurologic disease, and previous entry
into the study within the preceding 6 months
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 20): glucocorticosteroids (prednisolone 40 mg/day for 28 days) plus SAMe
(started as 800 mg intravenously daily converted to 1200 mg/day for 3 months).
Group 2 (n = 20): glucocorticosteroids (prednisolone 40 mg/day for 28 days)
Duration: 28 days (prednisolone) and 90 days (for SAMe)
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was performed with sequentially
numbered envelopes”
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed with sequentially
numbered envelopes”.
Comment: Further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “a multicenter, open-label, randomized controlled
study”
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Tkachenko 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “a multicenter, open-label, randomized controlled
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Trinchet 1989a
Methods Randomised clinical trial
Participants Country: Belgium.
Number randomised: 67.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 67.
Average age: 52 years.
Females: 29 (43.3%).
Inclusion criteria: Histologically proven acute alcoholic hepatitis assessed by percuta-
neous liver biopsy.
Exclusion criteria: 1. Hepatic encephalopathy. 2. Presence of ascites. 3. Prothrombin
activity below 50%. 4. Platelet count below 100,000/µL. 5. Hepatocellular carcinoma.
6. Evident lack of compliance. 7. Refusal to participate in the study
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 33): colchicine 1 mg once daily.
Group 2 (n = 34): placebo.
Duration: 6 months
Outcomes mortality, adverse events, decompensated cirrhosis.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly allocated into two groups”.
Comment: Further details were not available.
Allocation concealment (selection bias) Low risk Quote: “…using sealed envelopes with a stratification ac-
cording to the presence or absence of cirrhosis”
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Trinchet 1989a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Drugs ans placebo were administered in a double
blind fashion. Control patients received placebo in a iden-
tical presentation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Not clear if ITT, there were patients who did not
complete the trial, not clear if outcome assessed
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “Houde Pharmaceutical Laboratories, Paris, France
supplied colchicine and placebo”
Other bias Low risk Comment: there was no other bias.
Trinchet 1989b
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 116.
Post-randomisation dropouts: not stated.
Revised sample size: 116.
Average age: not stated
Females: not stated
Inclusion criteria: 1. Histologically proven alcoholic hepatitis.
Exclusion criteria: 1. Hepatic encephalopathy. 2. Contraindication to percutaneous liver
biopsy. 3. Hepatocellular carcinoma. 4. Evident lack of discipline. 5. Refusal to enter the
trial
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 57): silymarin (420 mg/day oral).
Group 2 (n = 59): placebo.
Duration: 3 months treatment
Outcomes mortality, adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random number table”.
158Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Trinchet 1989b (Continued)
Allocation concealment (selection bias) Low risk Quote: “….using numbered sealed envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a randomised double blind trial”.
Comment: identical placebo was used to achieve double-
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a randomised double blind trial”.
Comment: identical placebo was used to achieve double-
blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “The authors thank Dr De Peufeilhoux and Dr
Piquemal of Roger Bellon Laboratories for their assistance.”
Other bias Low risk Comment: there was no other bias.
Trinchet 1992
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 82.
Post-randomisation dropouts: 10 (12.2%).
Revised sample size: 72.
Average age: 49 years.
Females: 36 (50%).
Inclusion criteria: 1. Age higher than 18 years. 2. Hospitalised chronic alcoholics (alcohol
intake more than 100 g/day in men and 80 g/day in women). 3. Liver biopsy (at least two
of the following three lesions of alcoholic hepatitis: polymorphonuclear inflammatory
infiltration, Mallory bodies and hepatocellular damage).
Exclusion criteria: 1. Hepatocellular carcinoma. 2. Insulin-dependent diabetes. 3. An
extrahepatic disorder involving poor short-term prognosis. 4. any treatment that could
potentially influence the course pf alcoholic hepatitis such as corticosteroids, anabolic
steroids, propylthiouracil
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 37): 30 IU of insulin plus 3 mg of glucagon.
Group 2 (n = 35): placebo.
Duration: 3 weeks
Outcomes mortality.
Notes Reasons for post-randomisation dropouts: 10 not compatible biopsy (post-randomisa-
tion)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “treatment was randomised by centre”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Clinical Research Contract from the Assistance
Publique, Hospitaux de Paris”
Other bias Low risk Comment: there was no other bias.
Velussi 1997
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 60.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 60.
Average age: 63 years.
Females: not stated
Inclusion criteria: 1. Age 45 to 70 years. 2. Non-insulin dependent diabetes mellitus with
alcoholic liver cirrhosis. 3. Body mass index less than 29 kg/m2. 4. Ascertained diabetes
for a period of at least 5 years and treated with insulin only. 5. Undergoing stable insulin
therapy for a period of at least 2 years. 6. Presenting raised endogenous insulin secretion.
7. Fasting insulin levels and basal and stimulated Cpeptide levels above normal range
(above 15 mU/ml for insulin; above 1 ng/mL for basal C-peptide levels and 3 ng/mL
stimulated C-peptide levels). 8. Liver biopsy, performed no more than 4 years prior to
enrolment, demonstrating liver cirrhosis.
Exclusion criteria: 1. Negative for markers of hepatitis A, B and C. 2. No bleeding from
oesophageal varices. 3. Not addicted to alcohol for a period of at least 2 years prior to
the start of the study
160Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Velussi 1997 (Continued)
Interventions Participants were randomly assigned to two groups.
Group 1 (n = 30): silymarin 600 mg thrice daily.
Group 2 (n = 30): no intervention.
Duration: 12 months
Outcomes adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “On inclusion into the study, the patients were ran-
domly assigned to one of two groups”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The control group (30 patients), were not treated
with silymarin”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
ALD = alcoholic liver disease
ALT = alanine transaminase
AST = aspartate transaminase
G-CSF = granulocyte-colony stimulating factor
HCC = hepatocellular carcinoma
ITT = intention-to-treat
IU = international unit
LT = liver transplant
MELD = model for end-stage liver disease
NAFLD = non-alcoholic fatty liver disease
PTX = pentoxifylline
SAMe = s-adenosyl-L-methionine
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SC = subcutaneous
SGOT = serum glutamic oxaloacetic transaminase (currently called aspartate transaminase)
SGPT = serum glutamic pyruvic transaminase (currently called alanine transaminase)
TNF = tumour necrosis factor
UDCA = ursodeoxycholic acid
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Achord 1987 One group received nutritional supplements as treatment.
Bunout 1989 One group received nutritional support as treatment.
Cabre 2000 One group received nutritional support as treatment.
Calvey 1985 Groups received different nutritional supports as treatment.
Carithers 1990 Comment on Carithers 1989.
Conn 1978 Editorial.
DiNubile 2015 Comment on Thursz 2015.
Dupont 2012 Groups received different nutritional supports as treatment.
Hendy 2016 Comment on Thursz 2015.
Hirsch 1993 One group received nutritional support as treatment.
Kearns 1992 One group received nutritional support as treatment.
Kolasani 2016 The intervention and control groups did not receive a standardised drug treatment regime
Lesesne 1978 One group received nutritional supplements as treatment.
Ma 2011 One group received nutritional supplements as treatment.
Mathurin 1996 Long-term follow-up of Ramond 1992, but patients in the placebo group received prednisolone routinely, breaking
the randomisation
Mezey 1991 One group received nutritional supplements as treatment.
Moreno 2014 Both groups received corticosteroids plus a different type of nutrition
Nasrallah 1980 One group received nutritional supplements as treatment.
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(Continued)
Naveau 1986 Groups received different nutritional supports as treatment.
Panos 1990 One group received nutritional supplements as treatment.
Ramond 1992a Comment on Ramond 1992.
Sas 2011 One group received nutritional supplements as treatment.
Simon 1988 One group received nutritional supplements as treatment.
Spahr 2008 The intervention and control group did not have fixed drug regimens
Thursz 2015a Comment on Thursz 2015.
Verbeke 2015 Comment on Thursz 2015.
Wenzel 1993 Quasi-randomised study (randomisation by date of birth).
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D A T A A N D A N A L Y S E S
Comparison 1. Alcoholic hepatitis (all)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 48 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Amlodipine versus no
intervention
1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.22, 2.58]
1.2 Anabolic steroids versus
no intervention
1 173 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.43, 1.42]
1.3 Antioxidants versus no
intervention
1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.8 [0.19, 3.40]
1.4 Anti-TNF versus no
intervention
1 48 Odds Ratio (M-H, Fixed, 95% CI) 4.64 [1.31, 16.42]
1.5 Colchicine versus no
intervention
2 139 Odds Ratio (M-H, Fixed, 95% CI) 1.31 [0.47, 3.64]
1.6 Glucocorticosteroids
versus no intervention
12 1147 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.67, 1.08]
1.7 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.64, 1.28]
1.8 Insulin plus glucagon
versus no intervention
5 265 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.69, 1.90]
1.9 N-acetyl cysteine versus
no intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.34, 4.32]
1.10 N-acetyl cysteine
plus antioxidants versus no
intervention
1 70 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [0.44, 2.91]
1.11 Penicillamine versus no
intervention
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.15, 4.13]
1.12 Pentoxifylline versus no
intervention
6 881 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.58, 1.02]
1.13 Propylthiouracil versus
no intervention
2 108 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.50, 2.72]
1.14 Silymarin versus no
intervention
1 116 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.30]
1.15 Anabolic steroids versus
glucocorticosteroids
1 175 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.36, 1.19]
1.16 Antioxidants versus
glucocorticosteroids
1 99 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [0.63, 3.16]
1.17 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 55 Odds Ratio (M-H, Fixed, 95% CI) 2.37 [0.67, 8.42]
1.18 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.04, 0.34]
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1.19 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 174 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.32, 1.14]
1.20 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 887 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.67, 1.16]
1.21 SAMe plus
glucocorticosteroids versus
glucocorticosteroids
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.06, 1.97]
1.22 GSF versus
glucocorticosteroids
1 12 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.05, 20.83]
1.23 Pentoxifylline versus
glucocorticosteroids
5 864 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.65, 1.13]
1.24 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.06, 0.51]
1.25 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.08, 0.63]
1.26 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 1.49 [0.55, 4.07]
1.27 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 606 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.63, 1.22]
1.28 Rifaximin plus UDCA
plus glucocorticosteroids
versus UDCA plus
glucocorticosteroids
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.20, 1.89]
1.29 GSF plus pentoxifylline
versus pentoxifylline
1 46 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.31]
1.30 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 65 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.12, 0.94]
2 Mortality (30-days) 38 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Amlodipine versus no
intervention
1 62 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.22, 2.58]
2.2 Anti-TNF versus no
intervention
1 48 Odds Ratio (M-H, Random, 95% CI) 1.8 [0.50, 6.50]
2.3 Colchicine versus no
intervention
2 139 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.36, 4.02]
2.4 Glucocorticosteroids
versus no intervention
9 887 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.34, 1.03]
2.5 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 545 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.46, 1.20]
2.6 Insulin plus glucagon
versus no intervention
5 265 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.46, 1.63]
2.7 N-acetyl cysteine versus
no intervention
1 44 Odds Ratio (M-H, Random, 95% CI) 2.07 [0.46, 9.40]
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2.8 Pentoxifylline versus no
intervention
4 647 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.33, 1.41]
2.9 Propylthiouracil versus no
intervention
2 108 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.50, 2.72]
2.10 Antioxidants versus
glucocorticosteroids
1 99 Odds Ratio (M-H, Random, 95% CI) 2.12 [0.93, 4.83]
2.11 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 55 Odds Ratio (M-H, Random, 95% CI) 4.74 [0.73, 30.85]
2.12 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 70 Odds Ratio (M-H, Random, 95% CI) 0.29 [0.11, 0.80]
2.13 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 174 Odds Ratio (M-H, Random, 95% CI) 0.29 [0.12, 0.73]
2.14 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 887 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.62, 1.34]
2.15 SAMe plus
glucocorticosteroids versus
glucocorticosteroids
1 40 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.01, 4.01]
2.16 GSF versus
glucocorticosteroids
1 12 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.05, 20.83]
2.17 Pentoxifylline versus
glucocorticosteroids
5 864 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.57, 1.83]
2.18 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 67 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.16, 1.18]
2.19 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 68 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.12, 0.90]
2.20 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 67 Odds Ratio (M-H, Random, 95% CI) 1.51 [0.53, 4.33]
2.21 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 606 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.25, 3.58]
2.22 Rifaximin plus UDCA
plus glucocorticosteroids
versus UDCA plus
glucocorticosteroids
1 68 Odds Ratio (M-H, Random, 95% CI) 0.29 [0.05, 1.56]
2.23 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 65 Odds Ratio (M-H, Random, 95% CI) 0.49 [0.18, 1.34]
3 Mortality (90-days) 14 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Antioxidants versus no
intervention
1 51 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.14, 8.04]
3.2 Colchicine versus no
intervention
1 67 Odds Ratio (M-H, Fixed, 95% CI) 3.18 [0.13, 81.01]
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3.3 Glucocorticosteroids
versus no intervention
4 672 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.71, 1.39]
3.4 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.64, 1.42]
3.5 Insulin plus glucagon
versus no intervention
1 72 Odds Ratio (M-H, Fixed, 95% CI) 2.57 [0.92, 7.15]
3.6 Pentoxifylline versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.81, 1.74]
3.7 Silymarin versus no
intervention
1 116 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.30]
3.8 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
1 20 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [0.13, 23.52]
3.9 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.04, 0.34]
3.10 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 174 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.29, 1.11]
3.11 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
1 547 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.51, 1.09]
3.12 Pentoxifylline versus
glucocorticosteroids
3 683 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.56, 1.10]
3.13 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.08, 0.63]
3.14 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 67 Odds Ratio (M-H, Fixed, 95% CI) 1.49 [0.55, 4.07]
3.15 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 65 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.12, 0.94]
3.16 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 606 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.53, 1.11]
3.17 GSF plus pentoxifylline
versus pentoxifylline
1 46 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.31]
3.18 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.06, 0.51]
4 Serious adverse events
(proportion)
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Anti-TNF versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Glucocorticosteroids
versus no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4.3 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Pentoxifylline versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Pentoxifylline versus
glucocorticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Serious adverse events (number) 2 Rate Ratio (Fixed, 95% CI) Totals not selected
5.1 Anti-TNF versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Liver transplantation 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Insulin plus glucagon
versus no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Decompensated cirrhosis 17 Rate Ratio (Fixed, 95% CI) Subtotals only
7.1 Anti-TNF versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.27 [0.45, 3.57]
7.2 Colchicine versus no
intervention
2 Rate Ratio (Fixed, 95% CI) 1.38 [0.56, 3.45]
7.3 Glucocorticosteroids
versus no intervention
3 Rate Ratio (Fixed, 95% CI) 1.03 [0.70, 1.53]
7.4 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.95 [0.63, 1.45]
7.5 Pentoxifylline versus no
intervention
3 Rate Ratio (Fixed, 95% CI) 0.77 [0.55, 1.08]
7.6 Propylthiouracil versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.95 [0.47, 1.93]
7.7 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 1.42 [0.24, 8.48]
7.8 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.56 [0.36, 0.88]
7.9 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.77 [0.46, 1.29]
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7.10 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 Rate Ratio (Fixed, 95% CI) 0.81 [0.57, 1.14]
7.11 Pentoxifylline versus
glucocorticosteroids
4 Rate Ratio (Fixed, 95% CI) 0.93 [0.73, 1.18]
7.12 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.74 [0.49, 1.12]
7.13 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.58 [0.37, 0.90]
7.14 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 1.31 [0.81, 2.12]
7.15 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 Rate Ratio (Fixed, 95% CI) 0.88 [0.59, 1.33]
7.16 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.76 [0.50, 1.16]
8 Cirrhosis 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Glucocorticosteroids
versus no intervention
1 37 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.19, 9.02]
9 Adverse events (proportion) 21 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Amlodipine versus no
intervention
1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.12, 7.08]
9.2 Anti-TNF versus no
intervention
1 48 Odds Ratio (M-H, Fixed, 95% CI) 3.25 [0.99, 10.68]
9.3 Colchicine versus no
intervention
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Glucocorticosteroids
versus no intervention
4 159 Odds Ratio (M-H, Fixed, 95% CI) 4.00 [1.80, 8.88]
9.5 Insulin plus glucagon
versus no intervention
2 136 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [0.75, 4.12]
9.6 N-acetyl cysteine versus
no intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [0.51, 6.83]
9.7 N-acetyl cysteine plus
antioxidants versus no
intervention
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.8 Pentoxifylline versus no
intervention
2 151 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [1.10, 4.46]
9.9 Propylthiouracil versus no
intervention
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.36, 2.50]
9.10 Silymarin versus no
intervention
1 116 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.11 Antioxidants versus
glucocorticosteroids
1 99 Odds Ratio (M-H, Fixed, 95% CI) 6.29 [2.14, 18.43]
9.12 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 55 Odds Ratio (M-H, Fixed, 95% CI) 4.44 [1.33, 14.80]
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9.13 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 270 Odds Ratio (M-H, Fixed, 95% CI) 1.47 [0.85, 2.54]
9.14 Rifaximin plus UDCA
plus glucocorticosteroids
versus UDCA plus
glucocorticosteroids
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.04, 0.54]
9.15 GSF plus pentoxifylline
versus pentoxifylline
1 46 Odds Ratio (M-H, Fixed, 95% CI) 13.97 [0.73, 269.23]
10 Adverse events (number) 32 Rate Ratio (Random, 95% CI) Subtotals only
10.1 Amlodipine versus no
intervention
1 Rate Ratio (Random, 95% CI) 0.93 [0.13, 6.57]
10.2 Anti-TNF versus no
intervention
1 Rate Ratio (Random, 95% CI) 2.26 [1.05, 4.85]
10.3 Colchicine versus no
intervention
2 Rate Ratio (Random, 95% CI) 1.53 [0.86, 2.72]
10.4 Glucocorticosteroids
versus no intervention
7 Rate Ratio (Random, 95% CI) 1.43 [1.10, 1.87]
10.5 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 Rate Ratio (Random, 95% CI) 1.19 [0.85, 1.68]
10.6 Insulin plus glucagon
versus no intervention
2 Rate Ratio (Random, 95% CI) 1.21 [0.81, 1.81]
10.7 N-acetyl cysteine versus
no intervention
1 Rate Ratio (Random, 95% CI) 1.52 [0.52, 4.45]
10.8 N-acetyl cysteine
plus antioxidants versus no
intervention
1 Rate Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
10.9 Pentoxifylline versus no
intervention
3 Rate Ratio (Random, 95% CI) 1.43 [0.92, 2.23]
10.10 Propylthiouracil versus
no intervention
1 Rate Ratio (Random, 95% CI) 1.10 [0.62, 1.98]
10.11 Antioxidants versus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 1.15 [0.79, 1.68]
10.12 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 Rate Ratio (Random, 95% CI) 1.42 [0.77, 2.62]
10.13 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 0.63 [0.44, 0.89]
10.14 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 0.59 [0.37, 0.96]
10.15 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 Rate Ratio (Random, 95% CI) 1.26 [0.78, 2.04]
10.16 SAMe plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 0.75 [0.35, 1.59]
10.17 Pentoxifylline versus
glucocorticosteroids
5 Rate Ratio (Random, 95% CI) 0.89 [0.75, 1.06]
170Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10.18 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 0.76 [0.54, 1.07]
10.19 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 Rate Ratio (Random, 95% CI) 0.67 [0.47, 0.96]
10.20 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 1.21 [0.83, 1.77]
10.21 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 Rate Ratio (Random, 95% CI) 1.01 [0.78, 1.30]
10.22 Rifaximin plus UDCA
plus glucocorticosteroids
versus UDCA plus
glucocorticosteroids
1 Rate Ratio (Random, 95% CI) 0.21 [0.06, 0.75]
10.23 GSF plus pentoxifylline
versus pentoxifylline
1 Rate Ratio (Random, 95% CI) 11.00 [0.61, 198.93]
10.24 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 Rate Ratio (Random, 95% CI) 0.81 [0.57, 1.15]
Comparison 2. Severe alcoholic hepatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 18 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Glucocorticosteroids
versus no intervention
2 607 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.63, 1.21]
1.2 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.64, 1.28]
1.3 N-acetyl cysteine versus
no intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.34, 4.32]
1.4 Pentoxifylline versus no
intervention
4 726 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.59, 1.07]
1.5 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 55 Odds Ratio (M-H, Fixed, 95% CI) 2.37 [0.67, 8.42]
1.6 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.04, 0.34]
1.7 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 174 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.32, 1.14]
171Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.8 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 887 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.67, 1.16]
1.9 SAMe plus
glucocorticosteroids versus
glucocorticosteroids
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.06, 1.97]
1.10 Pentoxifylline versus
glucocorticosteroids
5 864 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.65, 1.13]
1.11 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.06, 0.51]
1.12 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.11, 0.80]
1.13 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 1.49 [0.55, 4.07]
1.14 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 606 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.63, 1.22]
1.15 GSF plus pentoxifylline
versus pentoxifylline
1 46 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.31]
1.16 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 65 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.12, 0.94]
2 Mortality (30 days) 16 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Glucocorticosteroids
versus no intervention
2 607 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.45, 1.07]
2.2 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.46, 1.20]
2.3 N-acetyl cysteine versus
no intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 2.07 [0.46, 9.40]
2.4 Pentoxifylline versus no
intervention
3 625 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.64, 1.42]
2.5 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 55 Odds Ratio (M-H, Fixed, 95% CI) 4.81 [0.75, 30.87]
2.6 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.11, 0.80]
2.7 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 174 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.12, 0.73]
2.8 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 887 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.62, 1.34]
2.9 SAMe plus
glucocorticosteroids versus
glucocorticosteroids
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.01]
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2.10 Pentoxifylline versus
glucocorticosteroids
5 864 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.82, 1.63]
2.11 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.16, 1.18]
2.12 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.12, 0.90]
2.13 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.53, 4.33]
2.14 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 606 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.45, 1.12]
2.15 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 65 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.18, 1.34]
3 Mortality (90 days) 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Glucocorticosteroids
versus no intervention
2 607 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.71, 1.43]
3.2 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.64, 1.42]
3.3 Pentoxifylline versus no
intervention
1 545 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.81, 1.74]
3.4 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
1 20 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [0.13, 23.52]
3.5 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.04, 0.34]
3.6 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 174 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.29, 1.11]
3.7 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
1 547 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.51, 1.09]
3.8 Pentoxifylline versus
glucocorticosteroids
3 683 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.56, 1.10]
3.9 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.06, 0.51]
3.10 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.08, 0.63]
3.11 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 67 Odds Ratio (M-H, Fixed, 95% CI) 1.49 [0.55, 4.07]
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3.12 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 606 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.53, 1.11]
3.13 GSF plus pentoxifylline
versus pentoxifylline
1 46 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.31]
3.14 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 65 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.12, 0.94]
4 Serious adverse events
(proportion)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Glucocorticosteroids
versus no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Pentoxifylline versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Pentoxifylline versus
glucocorticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Serious adverse events (number) 1 Rate Ratio (Fixed, 95% CI) Totals not selected
5.1 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Liver transplantation 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Decompensated cirrhosis 11 Rate Ratio (Fixed, 95% CI) Subtotals only
7.1 Glucocorticosteroids
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.97 [0.64, 1.47]
7.2 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.95 [0.63, 1.45]
7.3 Pentoxifylline versus no
intervention
3 Rate Ratio (Fixed, 95% CI) 0.77 [0.55, 1.08]
7.4 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 1.42 [0.24, 8.48]
7.5 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.56 [0.36, 0.88]
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7.6 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.77 [0.46, 1.29]
7.7 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 Rate Ratio (Fixed, 95% CI) 0.81 [0.57, 1.14]
7.8 Pentoxifylline versus
glucocorticosteroids
4 Rate Ratio (Fixed, 95% CI) 0.93 [0.73, 1.18]
7.9 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.74 [0.49, 1.12]
7.10 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.58 [0.37, 0.90]
7.11 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 1.31 [0.81, 2.12]
7.12 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 Rate Ratio (Fixed, 95% CI) 0.88 [0.59, 1.33]
7.13 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.76 [0.50, 1.16]
8 Adverse events (proportion) 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 N-acetyl cysteine versus
no intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [0.51, 6.83]
8.2 Pentoxifylline versus no
intervention
2 151 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [1.10, 4.46]
8.3 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 55 Odds Ratio (M-H, Fixed, 95% CI) 4.44 [1.33, 14.80]
8.4 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
1 270 Odds Ratio (M-H, Fixed, 95% CI) 1.47 [0.85, 2.54]
8.5 GSF plus pentoxifylline
versus pentoxifylline
1 46 Odds Ratio (M-H, Fixed, 95% CI) 13.97 [0.73, 269.23]
9 Adverse events (number) 16 Rate Ratio (Fixed, 95% CI) Subtotals only
9.1 Glucocorticosteroids
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 1.37 [0.98, 1.90]
9.2 Pentoxifylline plus
glucocorticosteroids versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.19 [0.85, 1.68]
9.3 N-acetyl cysteine versus
no intervention
1 Rate Ratio (Fixed, 95% CI) 1.52 [0.52, 4.45]
9.4 Pentoxifylline versus no
intervention
3 Rate Ratio (Fixed, 95% CI) 1.33 [1.01, 1.75]
9.5 Anti-TNF plus
glucocorticosteroids versus
glucocorticosteroids
2 Rate Ratio (Fixed, 95% CI) 1.42 [0.77, 2.62]
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9.6 Metadoxine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.63 [0.44, 0.89]
9.7 N-acetyl cysteine plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.59 [0.37, 0.96]
9.8 Pentoxifylline plus
glucocorticosteroids versus
glucocorticosteroids
3 Rate Ratio (Fixed, 95% CI) 1.10 [0.86, 1.40]
9.9 SAMe plus
glucocorticosteroids versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.75 [0.35, 1.59]
9.10 Pentoxifylline versus
glucocorticosteroids
5 Rate Ratio (Fixed, 95% CI) 0.89 [0.75, 1.06]
9.11 Metadoxine plus
pentoxifylline versus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.76 [0.54, 1.07]
9.12 Metadoxine plus
glucocorticosteroids versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.67 [0.47, 0.96]
9.13 Metadoxine
plus pentoxifylline
versus metadoxine plus
glucocorticosteroids
1 Rate Ratio (Fixed, 95% CI) 1.21 [0.83, 1.77]
9.14 Pentoxifylline plus
glucocorticosteroids versus
pentoxifylline
2 Rate Ratio (Fixed, 95% CI) 1.01 [0.78, 1.30]
9.15 GSF plus pentoxifylline
versus pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 11.00 [0.61, 198.93]
9.16 Metadoxine plus
pentoxifylline versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.81 [0.57, 1.15]
Comparison 3. Alcohol-related liver disease (others)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 16 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Anabolic steroids versus
no intervention
2 248 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.70, 2.39]
1.2 Antioxidants versus no
intervention
2 255 Odds Ratio (M-H, Fixed, 95% CI) 1.96 [0.99, 3.89]
1.3 Colchicine versus no
intervention
2 604 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.80, 1.53]
1.4 Cycloxilic acid versus no
intervention
1 20 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Epomediol versus no
intervention
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.6 Glucocorticosteroids
versus no intervention
1 45 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.15, 2.78]
1.7 Malotilate versus no
intervention
1 407 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.52, 1.41]
1.8 Metadoxine versus no
intervention
1 136 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Propylthiouracil versus no
intervention
2 423 Odds Ratio (M-H, Fixed, 95% CI) 0.45 [0.26, 0.78]
1.10 SAMe versus no
intervention
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.21, 1.30]
1.11 Silymarin versus no
intervention
1 200 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.46, 2.22]
1.12 Ursodeoxycholic acid
versus no intervention
1 226 Odds Ratio (M-H, Fixed, 95% CI) 2.09 [1.12, 3.90]
2 Mortality (30 days) 6 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Cycloxilic acid versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Epomediol versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Glucocorticosteroids
versus no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Metadoxine versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Propylthiouracil versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Ursodeoxycholic acid
versus no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mortality (90 days) 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Epomediol versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Glucocorticosteroids
versus no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 SAMe versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Serious adverse events
(proportion)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 SAMe versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Liver transplantation 1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.13]
5.1 SAMe versus no
intervention
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.13]
6 Decompensated cirrhosis 3 Rate Ratio (Fixed, 95% CI) Totals not selected
6.1 Colchicine versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Malotilate versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Ursodeoxycholic acid
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Hepatocellular carcinoma 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Anabolic steroids versus
no intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.2 SAMe versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events (proportion) 18 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Antioxidants versus no
intervention
2 92 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Colchicine versus no
intervention
2 604 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.66, 1.28]
8.3 Malotilate versus no
intervention
2 462 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.45, 1.79]
8.4 Metadoxine versus no
intervention
1 136 Odds Ratio (M-H, Fixed, 95% CI) 2.96 [0.12, 73.86]
8.5 Pentoxifylline versus no
intervention
1 24 Odds Ratio (M-H, Fixed, 95% CI) 7.86 [0.75, 82.13]
8.6 Propylthiouracil versus no
intervention
2 423 Odds Ratio (M-H, Fixed, 95% CI) 1.59 [0.73, 3.46]
8.7 SAMe versus no
intervention
3 205 Odds Ratio (M-H, Fixed, 95% CI) 1.86 [0.65, 5.33]
8.8 Silymarin versus no
intervention
3 296 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.48, 5.98]
8.9 Ursodeoxycholic acid
versus no intervention
1 11 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 7.05]
8.10 Candesartan plus
ursodeoxycholic acid versus
ursodeoxycholic acid
1 85 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (number) 11 Rate Ratio (Fixed, 95% CI) Subtotals only
9.1 Colchicine versus no
intervention
2 Rate Ratio (Fixed, 95% CI) 0.89 [0.75, 1.05]
9.2 Malotilate versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.91 [0.48, 1.75]
9.3 Metadoxine versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 2.91 [0.12, 71.48]
9.4 Pentoxifylline versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 7.00 [0.86, 56.89]
9.5 Propylthiouracil versus no
intervention
2 Rate Ratio (Fixed, 95% CI) 1.17 [0.58, 2.33]
9.6 SAMe versus no
intervention
2 Rate Ratio (Fixed, 95% CI) 1.52 [0.69, 3.31]
9.7 Silymarin versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.65 [0.48, 5.63]
9.8 Ursodeoxycholic acid
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.29 [0.01, 7.20]
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WH A T ’ S N E W
Last assessed as up-to-date: 28 February 2017.
Date Event Description
12 April 2017 Amended TheCochraneCentral Editorial Unit requested removal of the ’attempted networkmeta-analysis’ phrase
from the end of the review title, as this further description of the review might create confusion in the
reader. Although we followed the planned methodology for network meta-analysis and we performed
network meta-analyses, we decided not to report the obtained results because there was evidence of
inconsistency by one or more methods of assessment of inconsistency. Therefore, we did not report
the results of the network meta-analysis and reported the comparative benefits and harms of different
interventions using standard Cochrane methodology
C O N T R I B U T I O N S O F A U T H O R S
Elena Buzzetti, Maria Kalafateli identified trials and extracted the data. Elena Buzetti also wrote the first draft of the review.
Kurinchi Gurusamy wrote the protocol, performed the analysis, and wrote parts of the review.
Douglas Thorburn, Emmanuel Tsochatzis, and Brian Davidson critically commented on the protocol and the review.
Maja Thiele, Lise Lotte Gluud, Cinzia Del Giovane, Gro Askgaard, and Aleksander Krag critically commented on the review.
D E C L A R A T I O N S O F I N T E R E S T
This report is independent research funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/
89/03 - Evidence-based diagnosis and management of upper digestive, hepato-biliary, and pancreatic disorders). The views expressed in
this publication are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR, or the Department
of Health.
Kurinchi Gurusamy, Emmanuel Tsochatzis, and Brian Davidson have no financial disclosures.
Astellas funded Douglas Thorburn for his attendance at the International Liver Transplantation Society meeting in 2014. Douglas
Thorburn has also received GBP 25,000 from Boston Scientific to fund a clinical research fellow in 2013. There are no other financial
disclosures to report.
S O U R C E S O F S U P P O R T
Internal sources
• University College London, UK.
179Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease) (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• National Institute for Health Research, UK.
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure, Cochrane
Programme Grant, or Cochrane Incentive funding to the Cochrane Hepato-Biliary and Upper Gastrointestinal and Pancreatic
Diseases Groups. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, the National Health Service, or the Department of Health. The funding covered salary,
equipment, and other resources to complete this review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We used both the fixed-effect model and random-effects model, and used the more conservative model to arrive at conclusions,
rather than using the model with the best fit as defined by deviance information criteria.
• We also revised the network meta-analysis extensively to ensure that these reflect recent developments in this field.
• We analysed most outcomes as time-to-event outcomes since the length of follow-up between the trials was very variable.
Ignoring this difference in length of follow-up in a network meta-analysis means a major (and probably incorrect) assumption that
the frequency of events was not dependent upon the length of follow-up in the trials.
N O T E S
Considerable overlap is evident in the methods sections of this protocol and those of several other reviews written by the same group
of authors.
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